Role of CD15 and CD15s in the cellular mechanisms of cancer cell metastasis from lung to the brain by Jassam, Samah Ali
1 
 
 
 
 
Role of CD15 and CD15s in the Cellular 
Mechanisms of Cancer Cell Metastasis 
from Lung to the Brain  
 
 
 
 
 
 
 
 
 
Samah Ali Jassam 
 
 
 
 
 
This thesis is submitted in partial fulfilment of the requirements 
for the award of Doctor of Philosophy of the University of 
Portsmouth 
 
 
January 2016 
 
2 
 
 
Copyright 
Copyright © 2016 Samah Ali Jassam.  All rights reserved. 
The copyright of this thesis rests with the Author.  Copies (by any means) either in full, or 
of extracts, may not be made without prior written consent from the Author. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
 
DECLARATION 
Whilst registered as a candidate for the above degree, I have not been registered for any 
other research award. The results and conclusions embodied in this thesis are the work of 
the named candidate and have not submitted for any other academic award. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 
 
TABLE OF CONTENT 
Abstract                     I 
Abbreviations         III 
Dissemination         VI 
Publications         IX 
Acknowledgement         XIII 
Dedication          XIV 
1 Chapter one: Introduction  28 
1.1 Lewis antigens    29 
1.2 CD15  30 
1.3 CD15s (sialyl-CD15)   31 
1.4 Biosynthesis of CD15 and CD15s 33 
1.5 Structure of CD62E     34 
1.6 Role of CD15, CD15s and CD62E in brain metastasis  38 
1.7 Cell-cell adhesion 39 
1.8 Cell transendothelial migration (TEEM) (diapedesis) 42 
1.8.1 Paracellular and transcellular transendothelial migration   43 
1.9 Non-small cell lung cancer (NSCLC)   45 
1.10 Brain metastasis  50 
1.10.1 Diagnosis of brain metastases   53 
1.10.2 Treatment approaches of brain metastases  54 
1.10.2.1 Surgery   54 
1.10.2.2 Radiotherapy   54 
1.10.2.3 Radiosurgery  55 
1.10.2.4 Chemotherapy 56 
1.10.2.5 Molecular targeted therapy  57 
1.11 Metastasis mechanism and pathways 59 
1.11.1 Initial steps of metastasis  61 
1.11.2 Metastasis steps within the circulation and at entry site of 64 
5 
 
secondary tumour   
1.11.3 Seeding of cancer cells into the brain  67 
1.12 Structure and function of the blood brain barrier (BBB) 68 
 Plan of Investigation 74 
 Hypothesis  75 
 Aims 76 
 Objectives  77 
2 Chapter two: Materials and Methods  79 
2.1 Cell culture and cell lines 80 
2.1.2 Establishment of Primary cultures  80 
2.1.3 Cryopreservation of the cell lines  82 
2.1.4 Resurrection of cells from liquid nitrogen stores 82 
2.1.5 Cell counting  83 
2.1.6 Growth curves and cell population doubling time 84 
2.1.6.1 Cell population doubling time (PDT) 85 
2.2 Mycoplasma test  85 
2.3 Flow cytometry (FC) 86 
2.3.1 Statistical analyses of flow cytometry results   87 
2.4 Immunocytochemistry (ICC)  88 
2.5 Immunoblotting                                                       90 
2.5.1 Preparing cell membrane lysate  90 
2.5.2 Bicinchoninic Acid Protein Assay (BCA)   90 
2.5.3 Western blotting (WB)  91 
2.6 Immunohistochemistry (IHC)  93 
2.7 Confocal Microscopy 94 
2.8 Live cell imaging (Real-time Kinetic Microscopy) 94 
2.9 Genetic modification of FUT4 and FUT7 (stable transfection)  95 
6 
 
2.9.1 Up-regulation of CD15/FUT4 and CD15s/FUT7  95 
2.9.1.1 Transfection with cDNA of FUT4 and FUT7  96 
2.9.1.2 cDNA vectors and constructs  97 
2.9.2 Knockdown of FUT4 and FUT7  97 
2.9.2.1 shRNA vectors and constructs  98 
2.9.3 Determining the optimal concentration of selection marker 
(G418)    
99 
2.9.4 Selection of stable transfected cells   99 
2.10 Cell viability assay (MTS)   100 
2.10.1 Statistical analyses for viability  100 
2.11.1 Quantitative adhesion assay (under static conditions)  101 
 2.11.2 (under static conditions)Qualitative adhesion assays  101 
2.11.3 Cancer cell adhesion assay (under shear stress)  103 
2.11.4 Statistical analyses for adhesion assays  103 
2.12 Transendothelial migration assays  104 
2.12.1 Endothelial Voltohmmeter (EVOM)    104 
2.12.2 Electric cell-substrate impedance sensing system (ECIS
®
)  106 
2.12.3 Impedance spectroscopy (CellZscope
®
) 107 
2.13 Synchronization of cell cultures 109 
2.14 Detection of cell cycle stage 110 
2.15 Immunocytochemistry using Premo™ (FUCCI) Cell cycle 
Sensor (BacMam 2.0) 
110 
3 Chapter three: The role of both CD15 and CD15s in 
adhesion of NSCLC cells to brain endothelium 
111 
 Cellular morphology of cell cultures  112 
 Cell population-doubling time (PDT) 114 
3.1 CD15 expression in brain endothelial and NSCLC cell lines 117 
3.2 TNF-α increases CD62E expression in human brain 
endothelial cells and NSCLC cell lines 
119 
 
7 
 
3.3 CD15 and CD62E mediate adhesion of NSCLC to 
hCMEC/D3 monolayer under static conditions 
123 
3.4 CD15 mAb-blocking decreases adhesion of NSCLC cells 
under shear stress 
127 
3.5 CD15 and CD62E expression in human biopsy of lung to 
brain metastasis 
130 
3.6 CD15s-CD62E interaction mediates the adhesion of non-
small cell lung cancer cells on brain endothelial cells during 
metastasis to the brain. 
132 
3.7 Characterisation of CD15s in brain endothelium and NSCLC 
cultured cells 
133 
3.8 Interrupting CD15s-CD62E interaction reduces the adhesion 
of cancer cell-brain endothelium   
135 
3.9 Immunoblocking of CD15s reduced the adhesion of cancer 
cell-brain endothelium under static conditions 
137 
3.10 CD15s mAb blocking decreases adhesion of NSCLC cells 
under shear stress condition 
140 
3.11 CD15s expression was localised at the adhesion sites of 
cancer cell-brain endothelium 
142 
3.12 CD15s expression in human biopsy of lung to brain 
metastasis  
144 
3.13 Discussion 146 
3.13.1 Role of CD15-CD62E interaction in adhesion of NSCLC-
brain endothelium  
146 
3.13.2 Role of CD15s-CD62E interaction in adhesion of NSCLC-
brain endothelium  
149 
4 Chapter Four: The role of CD15 and CD15s in trans-
endothelial migration of non-small cell lung cancer cells 
through the blood brain barrier during metastasis from 
lung to the brain 
152 
4.1 The role of CD15 and CD15s on transendothelial migration of 
NSCLC cancer cells  
153 
4.2 A strong correlation between genetic manipulation of FUT4 
regulation and CD15 expression 
155 
4.3 A strong correlation between genetic manipulation of FUT7 159 
8 
 
regulation and CD15s expression 
4.4 CD15 expression correlates with cancer cell adhesion 163 
4.5 CD15s expression correlates with cancer cell adhesion 165 
4.6 Different transendothelial migration ability among different 
cancer cells 
167 
4.7 Cancer cell transendothelial migration was increased by 
overexpression of FUT4/CD15 and inhibited by FUT4/CD15 
knockdown  
170 
4.8 Increase in transendothelial migration of cancer cells was 
induced by overexpression of FUT7/CD15s and blocked by 
FUT7/CD15s knockdown. 
182 
4.9 Discussion  194 
5 Chapter Five: The expression of CD15 and CD15s during 
different stages of cell cycle in cancer cells 
199 
5.1 Expression of CD15 and CD15s is correlated with cell cycle 
arrest at G1 phase in primary and metastatic brain tumour 
cells 
200 
5.2 Expression of CD15 in non-synchronised brain cancer cells 201 
5.3 Expression of CD15s in non-synchronised brain cancer cells 202 
5.4 Synchronisation of cell cultures 205 
5.5 Expression of CD15 at different cell cycle stages 207 
5.6 Expression of CD15s at different cell cycle stages 209 
5.7 Discussion  210 
6 Chapter six: Conclusions  214 
 References  220 
 Appendices  252 
 Appendix 1 253 
 Appendix 2 255 
 Appendix 3 256 
 Form UPR16 257 
 
9 
 
LIST OF TABLES 
 
1 The TNM staging system of NSCLC  48 
2 The clinical TNM subsets staging of NSCLC 49 
3 Primary cell cultures and cell lines 80 
4 Primary and Secondary Antibodies used for Flow cytometry 86 
5 Primary and secondary antibodies used with their 
corresponding blocking buffers for ICC. 
88 
6 Primary and secondary antibodies used with Western blot  91 
7 Primary, secondary antibodies and blocking buffers used for 
IHC. 
92 
8 Population doubling times  114 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10 
 
LIST OF FIGURES 
 
1 Structure of CD15 (Lewis X) 31 
2 Structure of CD15s (sialyl-Lewis X) 31 
3 Biosynthesis of CD15 and CD15s 33 
4 Structure of CD62E 34 
5 Regulation of CD62E expression 35 
6 Heterophilic interaction of CD62E 37 
7 Role of CD15, CD15s and CD62E in trans-endothelial 
migration to the brain 
38 
8 Metastasis steps at the site of primary tumour 62 
9 Metastasis steps at circulation and entry to the site of 
secondary tumour. 
65 
10 Cellular structure of the BBB 68 
11 Metastasis from lung to brain 74 
12 Growth curve for cell culture 83 
13 Mechanism of action of MTS 99 
14 Cancer cell-brain endothelium adhesion assay 101 
15 Measurement of resistance of hCMEC/D3 monolayer 
using Endothelial Voltohmmeter (EVOM) 
104 
16 Measurement of resistance of adherent cells by ECIS 106 
17 Measurement of resistance of adherent cells by Cell-
Zscope 
107 
18 Cellular morphology of studied cell lines   112 
19 Extracellular expression of CD15 in brain endothelial and 117 
11 
 
 lung cancer cell lines
20 TNF-α and TNF-β effect on hCMEC/D3 viability 119 
21  CD62E expression in TNF-α treated endothelial cells 120 
22  CD62E expression in TNF-α treated NSCLC cell lines. 121 
23 NSCLC adhesion to TNF-α treated brain endothelial cells 
and the effect CD15 immunoblocking 
124 
24 CD15 mAb blocking effect on cell viability 125 
25 CD15 mAb-blocking reduces adhesion of NSCLC cells 
under dynamic conditions 
127 
26 CD15 and CD62E immunohistochemistry in human 
derived biopsy tissue 
132 
27 Expression of CD15s in brain endothelial and lung cancer 
cell lines 
133 
28 Role of CD62E in adhesion of NSCLC cells-brain 
endothelium 
135 
29A CD15s immunoblocking reduced the adhesion of lung 
cancer cells under static conditions 
137 
29B Blocking with CD15s mAb significantly reduced the 
adhesion of NSCLC to brain endothelium 
138 
30 Immunoblocking with CD15s mAb significantly 
decreased the adhesion ability of NSCLC under dynamic 
conditions (2.5 dyn/cm
2
). 
140 
31 Localisation of CD15s on the surface of adherent SEBTA-
001 cells at the site of adhesion. 
142 
32 CD15 expression in FUT4-(cDNA and shRNA) 
transfected cells 
155-
157 
33 CD15s expression in FUT7-(cDNA and shRNA) 
transfected cells. 
159-
161 
34A Quantitative adhesion of cancer cells following the genetic 
manipulation of FUT4/CD15 
163 
34B Quantitative adhesion of cancer cells following the genetic 165 
12 
 
manipulation of FUT7/CD15s 
35A,B Changes in transendothelial electrical resistance (TEER) 
in the presence of cancer cells measured by EVOM 
167 
35C Changes in transendothelial electrical resistance (TEER) 
in the presence of cancer cells measured by ECIS. 
168 
36A Effect of overexpression and knockdown of FUT4/CD15 
on cancer cells transendothelial migration 
171-
172 
36B Effect of overexpression and knockdown of FUT4/CD15 
on cancer cells transendothelial migration by ECIS 
173-
176 
36C Effect of FUT4/CD15 genetic manipulation on cancer 
cells transendothelial migration by CellZscope 
177-
180 
37A Effect of overexpression and knockdown of FUT7/CD15s 
on cancer cell  transendothelial migration by EVOM 
183-
184 
37B Effect of overexpression and knockdown of FUT7/CD15s 
on SEBTA-001 cells transendothelial migration by ECIS 
185-
188 
37C Effect of FUT7/CD15s genetic manipulation on SEBTA-001 
cells transendothelial migration by CellZscope. 
189-
190 
38 Expression and localization of CD15 in non-synchronised 
cells 
201 
39 Expression and localization of CD15s in non-
synchronised cells. 
203 
40 Synchronisation of cell cultures 205 
41 Expression and localisation of CD15 during different 
stages of the cell cycle. 
207 
42 Expression and localisation of CD15s during different 
stages of the cell cycle 
209 
 
 
 
 
13 
 
ABSTRACT  
Non-small cell lung cancer is one of the most common primary tumours to metastasise to 
the brain in adults. The underlining molecular mechanisms of brain metastasis are still not 
fully understood. Interactions between brain endothelial cells and cancer cells play key 
roles in brain metastasis. CD15 and CD15s are cell-cell adhesion molecules which interact 
with E-selectin which is expressed on endothelial cells and known to be involved in the 
leukocyte homing process as well as being implicated in metastasis with many non-CNS 
neoplasms. The aim of this project was to investigate the role of CD15 and CD15s in 
cancer cell adhesion to brain endothelial cells and transendothelial migration of lung 
cancer cells during brain metastasis. Expression of CD15, CD15s and CD62E was 
characterised in human primary and brain metastatic lung cancer cells using 
immunocytochemistry, flow cytometry, Western blot and immunohistochemistry in human 
tissue sections. Effects of CD15 and CD15s expression on NSCLC metastatic to brain were 
assessed using genetic manipulation (overexpression and knockdown) followed by 
functional assays. Both CD15 and CD15s were overexpressed and knockdowned and cell-
cell adhesion was then examined using qualitative and quantitative adhesion assays, under 
both static and flow physiological conditions. Transendothelial migration potential was 
also assessed using a voltometer, Electric Cell-Substrate Impedance sensing system and 
cell-monitoring system CellZscope™. Findings showed that CD15 and CD15s were 
prominently expressed on metastatic lung cancer cells (SEBTA-001, SEBTA-005 and 
NCI-H1299) and weakly expressed on both primary lung cancer cells (COR-L105 and 
A549) and brain endothelium (hCMEC/D3). The highest expression of CD62E was 
observed on brain endothelium stimulated with TNF-α (25pg/ml) (p<0.001). CD15, CD15s 
and CD62E expression was detected in human metastatic tissues. The absence of CD62E 
and immunoblocking and knockdown of CD15 and CD15s significantly reduced the 
adhesion of cancer cells under both static and shear stress conditions (p<0.0001).  
I 
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Overexpression of CD15 and CD15s significantly increased their adhesion on an 
endothelial monolayer (p<0.001). Metastatic cancer cells were able to transmigrate through 
a brain endothelial monolayer compared to primary and glioblastoma multiforme (GBM) 
cells. Knockdown of CD15 and CD15s decreased the transendothelial migration potential 
of cancer cells while even primary lung cancer cells and GBM cells transmigrated 
following overexpression of CD15 and CD15s. These results confirmed the correlation 
between CD15 and CD15s in adhesion as well as transendothelial migration of cancer cells 
during cerebral metastasis.  
 
Keywords: Metastasis, CD15, CD15s, E-selectin, adhesion, transendothelial migration 
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1.1 Lewis Antigens   
Lewis antigens are cell membrane carbohydrates. They can be categorised into two major 
types depending on their chemical structure. Lewis antigens-Type1 include Lewis a 
(Galβ1,3(Fucα1,4)GlcNAc)(Lea) and Lewis b (Fucα1,2Galβ1,3 (Fucα1,4)GlcNAc)(Leb) 
(Cummings 2008). The antibodies against these carbohydrate epitopes are used in clinical 
detection of blood groups. Both Lewis a and Lewis b are expressed on the surface of red 
blood corpuscles  (RBCs), Reed-Sternberg cells (Zukerberg et al.,1991) and many types of 
endothelial cells. Both are secreted in body fluids such as blood serum and saliva (Kabat, 
1956). Lewis a 
 
is centrally involved in microbial adhesion and it is expressed on many 
types of pathogenic bacteria (Greenwell 1997, Peek and Blaser 2002, Holgersson and 
Lofling 2006 and Liu et al., 2009). Lewis b 
 
is expressed in many types of pathogenic 
bacteria but interestingly it does not play a role in microbial cell attachment (Zheng et al., 
2003). Overexpression of Lewis “a” has been reported to be correlated with the 
malignancy of colorectal cancer cells (Narimatsu et al., 1996 and Muinelo-Romay et al., 
2010). Lewis antigens-Type 2 include Lewis x (CD15) which will be discussed in section 
(1.4), and Lewis y (CD174) (Fucα1,2Galβ1,4(Fucα1,3)GlcNAc)(Ley) (Muinelo-Romay et 
al., 2010). Many studies refer to the correlation of Lewis y and cell apoptosis (Baldus et 
al., 2006 and Wang et al., 2003). There is a positive correlation between Lewis y and cell 
dysplasia in colorectal adenomas and most adenocarcinomas (Abe et al, 1986, Kim et al, 
1986, Waldock, et al., 1989, Baldus et al., 1995, 2002 and 2006). 
 
 
 
 
 
 
29 
 
1.2 CD15  
CD15, Lewis x (Le
x
) antigen is also known as stage specific embryonic antigen-1 (SSEA-
1) (Figure 1). It is a trisaccharide, cell-cell adhesion molecule (Gooi et al., 1981 and Elola 
et al., 2007). It is expressed on diffrant types of glycoconjugates at the surface of different 
cells. CD15 plays a key role in cell-cell intraction and comunication during specific 
developmental stages as in the 8-cell to blastocyst stages, primordial germ cells, non-
diffrantiated embryonic stem cells and embryonic carcinoma cells in mouse embryos 
(Kudo et al., 2004). Also, CD15-CD15 homophilic interaction is involved in cell 
diffrantiation and developmental process (Eggens et al., 1989). Morover, its 
overexpression is associated with human polymorphonuclear granulocytes and various 
tumour cells such as lung, colon and breast carcinomas (Spooncer et al., 1984 and Mordoh 
et al., 1994). In the CNS, it is expressed in cortical neuroepithelial cells as well as in the 
radial glia cells of human embryonic brain (Hennen et al., 2011). It is reported that CD15 
is not generally expressed on human glioblastoma multiforme (GBM) cells and anaplastic 
astrocytes (Martin et al., 1995). However, some studies revealed that CD15 is expressed on 
specific cancer cell population (Pruszak et al., 2007 and Pruszak et al., 2009).  
Furthermore, CD15 is localised on stem cell-like cells in human glioma and tumour 
spheres derived from murine astrocytoma and ependymoma (Mao et al., 2009). Recently,  
CD15 is considred a distinictive marker of cancer stem cells (CSCs) in medulloblastoma 
cells (Gate et al., 2015). It is also reported that CD15/CD24/CD29 represents “a marker 
profile that defines the linage development of neural stem cell” (Pruszak et al., 2007 and 
Pruszak et al., 2009). It is also reported that CD15 is may be considered as a marker of 
tumour-propagating cell (TPC) (Read et al., 2009). In cancer metastasis, elevated 
expression of CD15 is correlated with the adhesion of some cancer cells during the 
metastasis process since CD15 has the ability to bind by homophilic interaction with CD15 
expressed on endothelial cells and it initiates a heterophilic interaction with other cell 
adhesion molecules such as the selectins (Brooks and Leathem, 1995).  
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1.3 CD15s (Sialyl-CD15) 
CD15s (SLe
x
) also called Sialyl Lewis x, is a tetra-polysaccharide molecule (Figure 2), 
expressed on the terminus of glycolipids of different cells. CD15s is also a ligand for E-
selectin and P-selectin (Polley et al., 1991) and is involved in adhesion of cancer cells to 
endothelial cells (Vestweber and Blanks 1998, Giavazzi et al., 1993, Kitayama et al., 2000; 
Burdick et al., 2003). It mediates the initial steps of tethering and rolling of white blood 
cells during WBC homing process. The circulating cells head to the site of injury by initial 
binding between CD15s and E-selectin (Munro 1993; Aruffo and Glycosci 1994). Burdick 
et al.,(2003) highlighted that metastatic colon adenocarcinoma cells adhere to human 
umbilical vein endothelial cells (HUVEC), through CD15s-glycolipids and CD15s-
glycoproteins which bind to E-selectin. Wang et al., (2003) reported that CD15, CD15s 
and Sialyl dimeric CD15 (SDLe
x
) expression is associated with malignancy and reported 
their overexpression in human non-small pulmonary cancer (NSCPC) and human primary 
liver cancer (PLC) tissue while they are not expressed in the adjacent non-malignant tissue. 
Moreover, Ikeda et al.,(1996) showed that CD15s is expressed in 60% of patients with 
primary lesions of gastric cancer and in 51% of patients with advanced primary gastric 
tumour and metastatic lymph nodes. It is further reported that expression of CD15s may be 
used as a marker for the early diagnosis of cervical cancer (Nakagoe et al., 2002). Very 
little is however, known about CD15s in the CNS but we have  recently reported that 
overexpression of CD15s is seen to be correlated with cell arrest in G1 phase of cell cycle 
in GBM and metastatic lung to brain cancer cells (Jassam et al., 2015b).       
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Figure 1: CD15 (Lewis X) 3-fucosyl-N-acetyl-lactosamine 
 
Figure 1: Structure of CD15 (Lewis X) 3-fucosyl-N-acetyl-
lactosamine. CD15 is a tri-saccharide molecule consisting of 
three fucoses bound to N-acetyl-lactosamine by α1, 3 bonds. 
Figure adopted from  Moore and Auzanneau 2012.  
  
Figure 2: CD15s (sialyl-Lewis X) 3-fucosyl-N-acetyl-lactosamine 
 
Figure 2: Structure of CD15s (sialyl-Lewis X) sialic acid–
α (2–3)-Gal-β (1–4)-[Fuc-α (1–3)]-GlcNAc. CD15s is 
tetra-saccharide molecule consisting of three fucoses 
bound to N-acetyl-lactosamine molecule by α1,3 bond. 
Figure obtained from  Moore and Auzanneau 2012. 
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1.4 Biosynthesis of CD15 and CD15s  
Lewis antigens are encoded by the FUT gene family. These genes are distributed on the 
short and long arms of chromosome 19 and encode for fucosyltransferases enzymes (FUT) 
(Vries et  al., 2001). FUT enzymes have the ability to transfer fucose sugar molecules in 
α1,2, α1,3/4 and α1,6 linkages close O-peptidic and N-peptidic sites on a wide range of 
glycan molecules (Javaud et al., 2003). Up to date, eleven FUTs are known, all are 
involved diractally or indiractally in the synthesis of lewis antigens (Easton et al., 1993, 
Ikeda et al.,1996) as shown in Figure 3. The molecular mecanisms that regulate 
glycosylation process are not fully resolved; however, it has been shown that FUTs 
expression can be influenced by some cytokines as TNF-α which is shown to increase the 
expression of FUT3 and FUT4 but not FUT2.  Also, IL-6 and IL-8 induction significantly 
increased the expression of FUT3 and FUT11 in bronchial mucins from patients with 
cyctic fibrosis (Groux-Degroote et al., 2008). The molecular mechanisms that regulate the 
expression of CD15 and CD15s are still not fully understood and many mechanismis were 
proposed in different types of cells. Most studies focus on the synthesis of the 
fucosyltransferase that is located within the endoplasmic reticulum and Golgi apparatus 
which affect the expression of CD15 and CD15s (Kannagi 2001). The extracellular 
exposure of these epitopes is often attributed to the upregulation of these specific 
transferases (Nakayama et al., 2001). Groux-Degroote et al., (2008) revealed that 
expression levels of FUT3, FUT11 and CD15s are correlated in human bronchial mucins. 
In another study, CD15 and CD15s expression is seen to be regulated by Sialidase activity 
in human myloid cells (Gadhoum and Sackstein, 2008).  
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Figure 3: Biosynthesis of CD15 and CD15s   
Figure 3: Schematic diagram shows the possible pathways of  biosynthesis 
of CD15 and CD15s. The process occurs in the Golgi apparatus. Fucose 
molecules are added to a proteoglycan (O-glycan) molecule by 
fucosyltransferases (FUTs) and sialidase enzymes.  
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1.5 CD62E (E-selectin) 
CD62E or E-selectin (E-LE) is a glycoprotein and cell-cell adhesion molecule (CAM), it is 
also named as an leukocyte-endothelial cell adhesion molecule 2 (LEAM-2) or endothelial-
leukocyte adhesion molecule 1( ELAM-1). It is a member of selectins family, which 
includes other two members: CD62P and CD62L. All selectiens are classified as a type 1-
membran protein and C-type cell surface lectiens.  CD62E is expressed on the cell surface 
of activated endothelial cells, in response to specific cytokines stimuli (Zukerberg et al., 
1991 and Read et al., 2009). CD62E is composed of an N-terminal, a C-type lectin domain, 
an epidermal-growth factor like domain (EGP), 6 Sushi domains, a transmembrane domain 
and a cytoplasmic tail (Figure 4) (Graves et al., 1994). CD62E in human cells is encoded 
and regulated by the SELE gene that is located on the chromosom 1; each domain of 
CD62E is encoded by one independent exon, however the cytosolic domain is derived 
from two exons (Cumming et al., 2008).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Structure of CD62E. A Ribbon representation of 
CD62E structure showing CD62E protein chanes (gray), 
the bounded calcium ions (Ca
2+
) represented by red 
sphere, fucose (green), galactose (yellow), N-
acetyleuraminic acid (violet) and β-methyl-N-acetyl-D-
glucosamine(blue).  Modified figure obtained from Graves 
et al., 1994 and Protien Data Bank ID:1G1T. 
Figure 4: Structure of CD62E     
Lectin 
domain 
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CD62E extracellular expression is stimulated with specific cytokines such as: interleukin-1 
(IL-1β) (Huang RB and Eniola-Adefeso 2012), lipopolysaccharide (LPS) (Dixon et al., 
2004) and tumour necrosis factor (TNF-α). Also, it is suggested that CD62E formation can 
be activated in response to shear stress (Yoshizumi et al., 2003). The expression of CD62E 
is controled by the activity of transcription factor NF-KB, which regulates the transcription 
process of SELE gene that encoding CD62E as in Figure 5 (Cernuda-Morollon and Ridley, 
2006).  
 
 
Figure 5: Regulation of CD62E extracellular expression  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Schematic of regulation of CD62E expression. TNF-α, 
one of the important extracellular stimuli of CD62E expression, 
induces the activation of Rho GTPases which, in turn, promotes 
the transcription and translation of CD62E glycoprotein. Modified 
illustration adapted from Cernuda-Morollon and Ridley, 2006.      
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The molecular bases of CD62DE interactions are not fully unvield. However, the discovery 
of CD62E crystal structure lectin/EGF explaines the binding between CD62E and sialyl 
Lewis x (SLe x)-type glycans (Graves et al., 1994). Previuos studies showed that, CD62E 
has the ability to bind with specific fucosylated and sialylated carbohydrate epitopes which 
are present on glycan arms such as; CD15, CD15s and Lewis a which are expressed on 
neutrophils, monocytes, eosinophils and natural killer cells (NK) during inflammation and 
on many c ancer cells types (Graves et al., 1994 and Somers et al., 2000). CD44, CD107a 
and CD107b are considered as CD62E ligands related to the sialylated carbohydrate 
epitope as sialyl Lewis x,  y and a (Tomlinson et al., 2000, Gout et al., 2006, Napier et al., 
2007).  
CD62E plays an important role in the leukocyte tethering and rolling process through 
sugar-sugar interaction (Figure 6). Crystallography studies of  CD62E and its interaction 
with the different ligands show there is a high affinity between CD62E and CD15s 
(Somers et al, 2000). CD62E was also shown to play an important role in the neutrophil 
rolling process both in vivo using a mouse model and in vitro using flow chambers. It has 
also been hypothesised that CD62P (P-selectin) and CD62E interactions with 
glycoconjugates expressed by leukocytes mediate the tethering process during 
inflammation (Zarbock et al, 2011).  CD15/CD15s and CD62E interaction plays an 
important role in cancer cell metastasis, specifically during the intravasation and 
extravasation process of circulating cancer cells (Figure 6) (Laferriere et al., 2001). It is 
reported that CD62E is over-expressed on endothelial cells that are involved in homing the 
circulating cancer cells during formation of secondary discrete lesions in the lung 
(Hiratsukaa et al., 2011). Moreover, a neutralising CD62E via monoclonal anti-CD62E 
reduced the transendothelial migration in vivo of spontaneous murine glioma (SMA-560) 
cells.  
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Figure 6: Stereo view of CD62E (green) bound with fucosilated ligand 
(CD15s) epitop (purpal). (A) The image is showing the intraction of fucose. 
(B) The image shows the intraction between galgtose and NeuNAc. A yellow 
sphere represents Ca
2+
, H2O bound molecules represented by red spheare and 
dashed lines are showing the hydrogen bonds and Ca
2+ 
ligation. The figures 
are obtained from Somers et al., 2000.   
Figure 6: Heterophilic interaction of CD62E  
A 
B 
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1.6 Role of CD15, CD15s and CD62E in brain metastasis 
Distant secondary tumours originate from a single metastatic cell, which then migrate via 
vascular circulation (Al-Mehdi et al., 2000 and Narimatsu, et al., 2005). The mechanism of 
how metastatic cancer cells transmigrate through the vessels to target tissue is not fully 
understood. Both CD15 and CD15s have been  regarded as tumour-associated markers as 
well as natural ligands of CD62E (Martin et al., 1995 and Soejim & Koda, 2005). Some 
cancer cells tend to use the same mechanism as leukocytes during extravasation suggesting 
that CD15/CD15s expressed on the surface of metastatic cells homophilicly interact with 
CD62E exposed on endothelial cells (Figure 7). It was therefore speculated that this 
process may explain why some cancer cells are more metastatic than others (Jassam et al., 
2015). However, our knowledge about the role of CD15/ CD15s and CD62E interaction 
and its ability of cells to cross the intact endothelial cells monolayer is still in its infancy 
and the molecular mechanisms underlying transmigration through the BBB remains 
unexplored.  
 
 
 
 
 
 
 
 
 
 
Figure 7: Role of CD15, CD15s and CD62E in transendothelial migration   
Figure 7: Schematic diagram depicting the potential role of CD15, 
CD15s and CD62E in trans-endothelial migration to the brain. 
Circulating cancer cells expressing CD15 or CD15s are able to adhere to 
activated endothelial cells expressing CD62E, induced by TNF-α or IL-
1β, IL-6.   
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1.7 Cell-Cell adhesion   
Cell-cell adhesion is an important process in cell coordination, communication and 
migration in multicellular organisms. It is a selective process achieved by interaction 
between specific cell adhesion molecules. There are several types of cell-cell adhesion 
molecules, which are classified into many major sub-groups according to their structural 
and functional characteristics such as selectins which include three highly specialised 
lectins (carbohydrate-binding proteins): P-selectin (CD62P), L-selectin (CD62L) and E-
selectin (CD62E). All selectins are able to bind selectively with oligosaccharides, each of 
the selectins has a N-terminal domain (Ca
2+
-dependent, C-type), an epidermal growth 
factor like motif, a transmembrane domain and a cytoplasmic tail (Bathel et al., 2007). The 
results of molecular modelling studies revealed that P and L-selectins have a similar 
structure while, E-selectin differs (Mcever 2001). Selectins play a key role in the homing 
process of circulating leukocytes to endothelial cells. The formation of weak and transient 
bonds is a key step called tethering. This is followed by rolling in which leukocytes form 
stronger bonds on their leading edge. In both tethering and rolling the binding is transient 
and a rolling cell may return to the circulation at any time or fully adhere to the endothelial 
cell. Selectins are reported to be involved in all the three steps (tethering, rolling and 
adhesion) (Schon and Ludwig, 2005). Other important cell-cell adhesion molecules are 
within the immunoglobulin superfamily (IgCAMs); these molecules function as cell 
adhesion molecules and signalling receptors. They play important roles in signal 
transduction from the extracellular to the intracellular compartment (Brummendorf and 
Rathjen 1995). It is revealed that IgCAMs are expressed in different tissues and play 
important roles in cell-cell and cell-ECM communication. IgCAMs are also involved in 
cell migration, induction of the neurite, plasticity and path finding processes during neural 
wiring at the embryonic stages (Walsh and Doherty, 1997). The IgCAMs Ig-like domain is 
considered to be the major structural feature of all IgCAMs and the wide range of diversity 
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in IgCAMs is reported to be related to the post-transitional modification or alternative 
splicing (Walsh and Doherty, 1997). The intracellular domain of IgCAMs interacts with 
many cytoplasmic functions and it has been suggested that it is involved in cell motility as 
it connects between the IgCAM cytoplasmic domain and the cortical cytoskeleton like 
ankyrins. IgCAMs potentially bind with other IgCAMs as well as binding with a variety of 
different proteins, forming important functional complexes such as, the interactions of 
axon-ECM, axon-axon and axon-glia (Volkmer 2001). It has also been demonstrated that 
IgCAMs are involved in signal transduction pathways and are associated with receptor and 
non-receptor tyrosine kinases, serine/threonine kinases and receptor tyrosine phosphatase 
(RPTP) (Volkmer 2001). Cadherins are integral transmembrane glycoproteins, calcium-
dependent cell-cell adhesion molecules (approximately 350 cadherins) (Hulpiau and Van-
roy, 2009). This superfamily is categorised into four major sub-groups, which are: classical 
cadherins, protocadherins, desmosomal cadherins and cadherin-related proteins. All 
cadherins have a distinctive common structural feature in their extracellular compartment 
becoming multiple cadherin-specific repeats (CR) (Hulpiau and Van-roy, 2009). The main 
function of cadherins is to initiate a strong cell-cell adhesion such as the establishment of 
tight junctions between endothelial cells (Kishikawa et al., 2008). Cadherins are also 
involved in determining the selectivity and connectivity of neurons during the development 
of the central nervous system (CNS) (Radice and Takeichi, 2001). Other important cell-cell 
adhesion proteins are the integrin family which are transmembrane glycoproteins and cell-
ECM adhesion molecules. They act as receptors for specific proteins in the ECM and have 
an important role in communication between the cell and the extracellular 
microenvironment. All integrins are heterodimer molecules composed of two glycoprotein 
units (α and β), each unit of which has the ability to interact with a wide range of 
cytoplasmic (intracellular) and microenvironment (extracellular) proteins (Dzamba et al., 
2001). It is also reported that integrins are involved in cell cycle progression (Moreno-
Layseca and Streuli 2014), cell survival (Vachon 2011), cell migration (Hood and Cheresh, 
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2002) and cytoskeletal organization (Wang et al., 1999). Heparan sulfate proteoglycans 
(HSPGs) are also cell adhesion glycoproteins which are categorized according to their 
location and are classified into three subgroups: the first subgroup includes the cell 
membrane HSPGs, glypicans and syndecans, the second subgroup includes secreted HSPG 
to the extracellular matrix such as agrin, collagen (type XVIII) and perlecan and the third 
subgroup includes the secretory vesicle proteoglycan such as: serglycin (Sarrazin et al., 
2011). All HSPGs are recognised by a common structural feature which is the existence of 
heparan sulfate chain (HS) (Sarrazin et al., 2011); HSPGs molecules interact with different 
ligands to control and initiate many important cellular activities such as cell-ECM adhesion 
and invasion (Lim et al., 2015). ADAMs (a disintegrin and metalloproteinase) are a group 
of transmembrane proteins expressed on the cell surface and secreted to the 
microenvironment of the surrounding tissue (Edwards et al., 2008). ADAMs have a 
distinguishing structure feature, the existence of an integrin receptor-binding, a 
metalloprotease and a cytoplasmic domain (Seals and Courtneidge, 2003). It is reported 
that ADAMs are involved in many important cellular activates such as, controlling the 
fusion process of cell membranes (Primakoff and Myles 2007), secretion of cytokines, cell 
migration and invasion (Stamenkovic 2000).  
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1.8 Cell transendothelial migration (TEEM) (diapedesis)  
Transendothelial migration or diapedesis is the process where circulating cells migrate 
through the endothelial barrier in which cells leave the circulatory system towards 
surrounding tissue. Different leukocytes such as natural killer (NK), neutrophil, T-
lymphocytes and monocytes are induced to transmigrate out of the circulation by 
inflammatory reaction via the release of specific chemokines (Muller 2011). Leukocytes 
leave the circulation through two different mechanisms: paracellular transmigration in 
which emigrant cells find their way out by amoeboid movement between the borders of 
tightly connected endothelial cells and transcellular transmigration in which emigrant cells 
migrate through the endothelial cells themselves (Muller 2013). Transmigration is not a 
random process, it only occurs if there is an inflammatory response which is caused by the 
secretion of histamine and other mediators which induce the release of P-selectin from 
Weibel-Palade bodies in the endothelial cytoplasm and express it on the surface of the 
endothelial cells. This, in turn, induces the extracellular expression of E-selectin (McEver 
and Cummings, 1997). Selectins have an affinity to bind with members of the Lewis blood 
group family that are expressed on leukocytes (Munro et al., 1992) and on some cancer 
cells (Martin et al., 1995 and Jassam et al., 2015). Extravasation of leukocytes or 
circulating cancer cells starts with tethering and rolling, followed by formation of firm 
adhesion and transmigration (Muller 2011). It is an interactive process: migrating cells, 
express different types of cell-cell adhesion molecules which interact with adhesion 
molecules expressed on endothelial cells. Extravasation of leukocytes is strictly controlled 
by secreted cytokines. It is hypothesised that circulating cancer cells tend to mimic the 
physiology of leukocytes during extravasation (Strell and Entschladen, 2008) but the 
molecular machinery beneath the extravasation of cancer cell differs from the one in 
leukocytes (Miles et al., 2008). E-selectin is a key element in homing circulating cancer 
cells in various cancers where the cancer cells are attracted to endothelial cells that express 
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a high level of E-selectin (Burdick et al., 2006). In a study on colon cancer cells, CD44, 
which is a ligand of selectins, was found to be upregulated and involved in mediating the 
rolling of cancer cells (Hanley et al., 2006). In colon cancer cells, both E-selectin and its 
ligand (PSGL-1) are overexpressed in prostate cancer metastases which are involved in 
metastasis of prostate cancer to the bones (Dimitroff et al., 2005). Sialyl lewis x, another 
E-selectin ligand has also been reported to mediate metastasis in breast cancer (Julien et 
al., 2011).  
 
1.8.1 Paracellular and transcellular transendothelial migration   
Paracellular transendothelial migration refers to the migration of leukocytes or cancer cell 
between adjacent endothelial cells. Transmigrating cells transmigrate between the tight 
junctions and adhering junctions. This process requires communication between migrating 
and endothelial cells. Many adhesion molecules and signaling receptors are shown to be 
involved in leukocyte paracellular transmigration, for instance the involvement of VCAM-
1 (CD105) and ICAM-1 (CD54) signaling (Yonekawa and Harlan 2005), deletion of tight 
junction proteins such as VE-cadherin and activation of MLCK through increased cysolic 
free calcium which creates a tension in the endothelial cells (Muller 2013). It was also 
reported that the aggregation of ICAM-1 triggered the activation of RhoA which in turn 
stimulated PP1phosphorelation by signals generated by ICAM-1. All these events lead to 
the initiation of contraction against the cell-cell junctions in between endothelial cells 
(Yonekawa and Harlan 2005; Muller 2013). This contraction creates a space for 
leukocytes to cross the circulation. CD31 is also proposed to play an important role in 
leukocyte transmigration and blocking of CD31 has been shown to significantly reduce the 
transendothelial migration ability of NK cells and monocytes (Muller 1995) but not 
lymphocytes (Bird et al., 1993). Extravasation is an important step in cancer cell metastasis 
where circulating cancer cells leave the circulation at the site of metastasis. The molecular 
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bases underlining this process are still not fully understood, but it is suggested that some 
cancer cells may mimic leukocytes during transendothelial migration (Tremblay et al., 
2006). It was also reported that transmigration of cancer cells may cause irreversible 
damage to the intact barrier of endothelial cells due to the large size of the cancer cells 
compared to the size of leukocytes (Strell and Entschladen, 2008). Metastatic breast cancer 
cells are able to undergo paracellular transmigration which is accompanied by disruption of  
the endothelial barrier (De Bruyn and Cho, 1982).  
Transcellular transendothelial migration refers to transmigration of the migrating cell 
through the endothelial cells. This occurs less frequently than paracellular transmigration. 
It is proposed that leukocytes may use this route as well (Ley 2007 et al.; Petri and Bixel 
2006). ICAM-1 plays a key role in transendothelial migration by binding to the 
lymphocyte fusion-associated antigen-1 (LFA-1) expressed on the surface of leukocytes. 
This binding leads to relocation of ICAM-1 molecules which are more condensed at 
vesiculo-vacuolar organelles to establish the intracellular channels (Ley et al., 2007). It has 
been reported that leukocytes and cancer cells are both able to transmigrate through the 
endothelial cells (Khuon et al., 2010) as well as cross through the endothelial cells in 
transcellular migration without inducing endothelial cell death (Khuon et al., 2010). It is 
suggested that in transcellular migration both cancer cells and leukocytes use the same 
mechanism, which is dependent on endothelial cell cytoskeleton activity in response to 
adhesion of the migrating cell (Arvanitis et al., 2014).  
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1.9 Non-small cell lung cancer (NSCLC)  
Lung cancer represents the most common cause of cancer-related deaths (Jemal et al., 
2009). Histologically, lung cancer is classified into two major types: small cell lung cancer 
(SCLC) which represents 10% of lung cancer cases and Non-small cell lung cancer 
(NSCLCs) which is the most common type and represents 85% of lung cancer cases (Jemal 
et al., 2009). Approximately 70% of patients with NSCLC show multi-focal or metastatic 
tumours at the time of diagnosis (Molina et al., 2008). NSCLC is classified pathologically 
and genetically into distinctive three subtypes (Horn et al., 2012): adenocarcinoma, which 
originates from cells that line the peripheral tissue of the lung and secrete mucus. Most 
carcinoma cells appear with a glandular cell morphology with distinctive duct formation 
(Travis et al., 2004), this type of cancer represents about 40% of lung cancer cases and 
affects both smokers and non-smokers (Liu et al., 2010). The second subtype is squamous 
cell carcinoma, which develops from squamous epithelial cells of the lung. It is the most 
common type of NSCLC that affects smokers (Travis et al., 2004). The third subtype is the 
large-cell carcinoma which also arises from epithelial cells in the lung; cells appear with 
overabundant cytoplasm, large nuclei and prominent nucleoli (Travis et al., 2004). 
Roughly 9% of lung cancer cases are large-cell carcinoma. NSCLC is clinically sub-
grouped based on the development and spread of primary tumour (Tsim et al., 2010) to 
different stages. This classification is used to select the most appropriate treatment through 
providing essential information about tumour prognosis and patient response in clinical 
trials. The TNM staging system (T: tumour, N: lymph node and M: metastasis) was 
established by the international association for the study of lung cancer (IASLC) 
(Goldstraw et al., 2007 and AJCC).  
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This system depends on the morphological characteristics of the primary tumour (T), the 
involvement of lymph node (N) and the formation of metastatic secondary tumours (M) 
(Green et al., 2002; Sobin and Wittekind 2002). According to the most recent edition of the 
TNM system (7
th
 edition), integration of three descriptors T, N and M are utilised to 
generally describe the stage of the disease as in table 1 (Goldstraw and Crowley, 2006) and 
table 2 (Goldstraw et al., 2007 and Tsim et al., 2010). The management of NSCLC patients 
varies depending on the stage of the disease, tumour prognosis and patient age. Surgery has 
a key role in patients who are diagnosed with early-stage (I-II) and (IIIA) NSCLC 
particularly (T3N1) (Scott et al., 2007) and pulmonary lobectomy is recommended for the 
patients at stage I-II and T1N0 NSCLC with no lymph node involvement (Scott et al., 
2007). In some cases, radiotherapy is the most widely used choice in early-stage NSCLC 
(Rowell and Williams, 2001). Adjuvant chemotherapy was recently highlighted to increase 
the survival rate (5.4%) of early stage NSCLC particularly patients with stage II and IIIA 
disease. It has also been reported that adjuvant therapy is helpful to control the disease in 
patients with NSCLC at stage IB (Strauss et al., 2008). However, adjuvant therapy was 
seen to be correlated with poor prognosis in patients with NSCLC stage IA (Pignon et al., 
2008). Chemoradiotherapy is applied as the standard therapy for patients with locally 
advanced NSCLC, such as stages IIIA and IIIB. This regimen shows a high survival rate in 
patients with good physical fitness (Furuse et al., 1999). In patients at stage N2, surgery 
was seen to cause a high level of toxicity; in this approach, the European trial 
recommended three cycles of cisplatin-based chemotherapy followed by surgical resection 
or successive thoracic radiotherapy for the patients who were not fit enough for surgery 
(Furuse et al., 1999). Chemotherapy is the choice of treatment in metastatic NSCLC 
patients and has been reported to increase the survival rate to 9% at 12 months (Lilenbaum 
et al., 2005). A Cisplatin-based double regimen has also been correlated with one-year 
survival rates compared with regimens without platinum (which is usually used 
alternatively for patients who are sensitive to platinum) (Azzoli et al., 2009).  
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There is no unified standard regimen for patients with advanced NSCLC however, 
cisplatin/gemcitabine or cisplatin/pemetrexed regimens are recommended based on the 
histological characteristics of the tumour (Scagliotti et al., 2008). The regimen for patients 
with NSCLC brain metastases is chosen depending on the history of treatment that was 
previously used against primary lung tumour. Cisplatin is recommended for naïve patients 
(Kleisbauer et al., 1990) and Temozolomide (TMZ) is suggested to treat the recurrent 
NSCLC-brain metastases, with a 20% positive response (Giorgio et al., 2005). In addition, 
inhibition of the epidermal growth factor receptor (EGFR) was recently reported to elicit 
27% response rate (Shimato et al., 2006).  
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T Primary tumour 
T1  Tumour< 3 cm in diameter, surrounded by lung or visceral pleura, without invasion moreproximal 
than lobar bronchus. 
T1a Tumour < 2 cm in diameter. 
T1b  Tumour >2 cm but <3 cm in diameter. 
T2 Tumour >3 cm but <7 cm in diameter, or tumour with any of the following features: 
 Involvement of the main bronchus _2 cm distal to the carina. 
 Invasion of visceral pleura. 
 Associated atelectasis or obstructive pneumonitis that does not involve the entire lung. 
T2a  Tumour<5 cm in diameter. 
T2b  Tumour >5 cm but <7 cm in diameter. 
T3  Tumour >7 cm in diameter, or tumour with any of the following features: 
 Direct invasion of the chest wall, diaphragm, phrenic nerve. 
 Direct invasion of mediastinal pleura or parietal pericardium. 
 Associated atelectasis or obstructive pneumonitis of the entire lung. 
 Tumour within the main bronchus <2 cm to the carina, without involvement of the carina. 
 Satellite tumour nodules in the same lobe. 
T4   Tumour of any size that has any of the following features: 
 B Invasion of the mediastinum. 
 B Invasion the heart or great vessels. 
 B Invasion of the trachea, oesophagus or recurrent laryngeal nerve. 
 B Invasion of a vertebral body or carina. 
 B Separate tumour nodules in a different ipsilateral lobe. 
Regional lymph nodes (N) 
N0 No regional lymph node metastasis. 
N1 Involvement of ipsilateral hilar or peri-bronchial nodes. 
N2 Involvement of ipsilateral mediastinal or subcarinal nodes. 
N3 Involvement of contralateral mediastinal or hilar nodes or involvement of ipsilateral/contralateral 
scalene or supraclavicular nodes. 
Distant Metastasis (M)  
M0 No distant metastasis. 
M1 Distant metastasis present. 
M1a Separate tumour nodule(s) in a contralateral lobe or tumour with pleural nodules or malignant 
pleural/pericardial effusion. 
M1b Distant metastases. 
 
Table 1: The TNM staging system of NSCLC showing the bases of staging protocol of 
NSCLC by patients grouping the depending on the features of primary tumour (T), 
lymphnode involvement and formation of secondary tumours (M) (Goldstraw et al., 2007 
and Tsim et al., 2010). 
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Stage  cTNM Subset Five-year Survival 
0 Carcinoma in situ  
IA T1a/T1b, N0M0 50-80% 
IB T2aN0M0 47% 
IIA T1a/T1b, N1M0 
T2aN1M0 
T2bN0M0 
T2bN1M0 
36% 
IIB T2bN1M0 
T3N0M0 
26% 
IIIA T1/T2,N2M0 
T3,N1/N2,M0 
T4,N0/N1,M0 
19% 
IIIB T4N2M0 
Any T, N3, M0 
7% 
IV Any T, Any N, M1a/M1b  
 
Table 2: The clinical TNM subsets staging of NSCLC which goes in parallel with the 
subgrouping of cTNM subsets and the percentage of rate five-year survival (Goldstraw et 
al., 2007 and Tsim et al., 2010). 
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1.10 Brain metastasis   
Metastasis is the main cause of death among cancer patients and correlates with poor 
prognosis (Liotta et al., 1993 and Hunter et al., 2008). Brain metastasis accounts for 25% 
of all metastatic cancers and secondary brain tumours are diagnosed in 20-40% of cancer 
patients (Salhia et al., 2014). Around 40%-50% of brain secondary tumours originate from 
lung cancer, 15%-20% from breast cancer, 5%-10% from skin cancer and 4%-6% from 
gastrointestinal tract cancer (Barnholtz-Sloan et al., 2004). In general, 80% of brain 
metastases are localised in the cerebral hemispheres, 15% in the cerebellum and 5% in the 
brainstem.  It is suggested that the tissue volume of the brain or the amount of blood 
supplied to these parts may reflect these differences (Delattre et al., 1988).  Secondary 
brain tumours are also frequently seen to present at grey-white junctions (Chang et al., 
2007), where circulating cancer cells arrest or are trapped in small blood capillaries 
(Svokos et al., 2014). In patients with metastatic non-small-cell lung cancer (NSCLC), 
synchronous brain metastases are diagnosed in 35% and metachronous brain metastases in 
65% of cases (Burt et al., 1992). The survival rate varies among patients: 55% of NSCLC 
patients with brain metastasis survive for 1 year; 27% for 2 years; 18% for 3 years and 
13% for 5 years (Burt et al., 1992 and Ali et al., 2013). Circulating cancer cells enter the 
brain through haematogenous pathways via the blood brain barrier capillaries (Wilhelm et 
al., 2013). However, in mice malignant lymphoma cells have been seen to enter the brain 
through the choroid plexus and cranial nerve (Hochman et al., 2001) and recent reports are 
highlight the possibility of existence of lymphatic vessels network in mouse brain 
(Aspelund, et al., 2015).  
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Three pioneering theories were proposed to explain the mechanism of metastasis.  
(1) The “seed-and-soil” theory proposed by Stephen Paget (1889) hypothesised that, 
metastasis does not occur randomly, but rather cancer cells target specifically certain 
organs to initiate secondary tumours. This theory considers the cancer cell to be the “seed” 
and the site of secondary tumour to be the “soil”. It is based on studying 735 cases of 
advanced breast cancer (Stephen Paget, 1889 reviewed by Mendoza and Khanna, 2009); 
the “seed-and-soil” theory also explains the selectivity of initiating secondary tumours in 
specific organs but does not explain why not all cancer cells are able to form secondary 
tumours. In fact, less than 0.01% of circulating cancer cells are able to initiate new 
metastases (Chambers et al, 2002). In a quantitative study, one gram of rat mammary 
adenocarcinoma primary tumour may release approximately 4x10
6 
metastatic, circulating 
tumour cells (Butler and Gullino, 1975).  
 
(2) The “mechanical entrapment” theory proposed by James Ewing (1923) speculates that 
metastasis is purely a mechanical process and cancer cell dissemination depends on the 
circulation, it also explains why not all circulating cancer cells are able to initiate a new 
secondary tumour. However, it does not explain why cancer cells seed some organs rather 
than others.  
 
(3) The third theory proposed by Duda (2010) states that “the metastatic cancer cell 
“seeds” grow preferentially in secondary sites within a “permissive microenvironment”. 
He also reported that metastatic cancer cells could bring their own soil from primary site 
such as activated fibroblasts (Duda et al, 2010).  
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1.10.1 Diagnosis of brain metastases  
Three main types of examinations are applied to diagnose a brain tumour; they include a 
neurological examination, brain scan, biopsy and pathology examination. 
- A neurological examination: it includes a physical examination, medical history 
as well as, a group of different tests used to assess the function of the nervous 
system, sensory and motor responses particularly reflexes. In case of any 
abnormalities, the patient will be referred for further investigations such as brain 
scan (Nicholl and Appleton 2015). 
- A brain scan (neuroimaging): it refers to imaging internal structures of the brain.  
Brain scan is conducted by using highly specialised and computed devices. There 
are many types of scans are established since Hounsfield and Ambrose launched 
the axail tomography (CAT or CT scanning) technique in 1971. CT scan is still 
used for a quick and general scan to investigate the brain structure (Filler 2009). 
Diffuses optical imaging or tomography (DOI) or (DOD) is another brain scanning 
technique, that is employ the near infrared light in imaging and depends on the 
optical absorbance of haemoglobin based on various oxygenation level. Magnetic 
resonance imaging (MRI) also is used in brain scanning, it based on using radio 
waves and magnetic fields to generate two- or three-dimensional images. Some of 
brain scans employ a contrast agents or dyes, which are useful to differentiate the 
abnormal brain tissue, for example the gadolinium-based medium is the most 
common used in MRI brain scan (Mitsumori et al., 2014). 
- Biopsy and pathology examination: A biopsy is a surgical operation, which is 
conducted to obtain a tissue sample from the site of the tumour. In biopsy test, the 
tissue is usually fixed, stained and microscopically examined. The pathological 
analysis of the biopsy provides information on the type and the grade of the tumour 
(Filler 2009).  
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1.10.2 Treatment approaches of brain metastases    
 
The treatment options of brain metastasis are limited and tend to be local therapy (Berghoff 
AS and Preusser, 2015). Management of brain metastasis may include one or more of the 
following treatments:  
1.10.2.1 Surgery 
Once a metastatic brain tumour has been diagnosed, the patient may undergo surgery 
depending on the tumour size and location (Schuette 2004). In general, surgical removal of 
secondary brain tumour is used to manage an accessible, single or two, large, life 
threatening brain tumour; surgical resection aims to eliminate the neurological symptoms 
caused by the tumour. In addition, the candidate has at least six-month life expectancy and 
well enough to tolerate the surgery (Caffo et al., 2013). Surgery significantly reduces the 
neurological symptoms, renovates the flow of CSF, mitigates symptomatic intracranial 
hypertension and lessen peritumoral edema and steroid dependence. Furthermore, surgery 
offers is helpful in conforming the correct pathological diagnosis. However, surgical 
resection is a limited choice in the case of multiple brain metastases (Adenot et al., 2007).   
 
 
1.10.2.2 Radiotherapy 
Radiotherapy is the most commonly used treatment in brain metastasis and the whole brain 
radiation therapy (WBRT) is routinely used in treatment of patients with brain metastases, 
It aims to treat the diagnosed secondary brain tumours as well as to prevent the new ones 
(Berghoff AS and Preusser, 2015). Treatment with only WBRT is seen to increase survival 
rate up to six months (Caffo et al., 2013) although, 11% of the patients develop late brain 
toxicity following the WBRT. Recently, it was reported that 23% of patients with brain 
metastases at a risk to develop a radiation-refractory and post-radiation 
leukoencephalopathy, which are defined by gait disturbance, dementia, incontinence in 
addition to, attention and executive deficit (Spiceland et al., 2015). However, that does not 
reduce the importance of radiotherapy in fact; WBRT following a surgical resection is 
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considered as an effective treatment for a single accessible metastatic brain tumour for 
patients with controlled primary tumour and well condition (Gaspar et al., 2010). 
Moreover, WBRT is seen to control the presenting neurological symptoms in 70-90% of 
patients with multiple brain metastases without causing acute neurological symptoms side 
effects (Hoegler, 1997). Treatment with prophylactic cranial irradiation (PCI) reduces the 
incidence rate of developing brain metastasis in patients with small cell lung cancer 
(SCLC) from 18% to 8%; unfortunately, PCI deteriorates memory function in some 
patients (Sun et al., 2011). There are different WBRT protocols which are prescribed based 
on the patient general condition and the nature of the secondary tumour; a short radiation 
therapy courses with 20 Gy to 30 Gy total dose which is usually given in a 300 to 400 cGy 
fractionated dose (Hoegler, 1997).     
 
1.10.2.3 Radiosurgery  
It is a radiotherapy treatment technique, in which, a high dose of ionised radiation 
selectively applied on a targeted tissue (tumour). Stereotactic radiosurgery (SRS) is 
considered as a successful short-term treatment option. Unlike WBRT, the SRS targets a 
specific tissue area with less than 3.5 cm diameter, using a multiple cobalt-60 sources 
(gamma-knife) or a linear accelerator (Caffo et al., 2013). SRS is highly recommended 
choice for patients with inaccessible brain tumours or, for patients who unable to tolerate 
surgery or patients with resistant metastatic brain tumours. SRS showed a high control rate 
of local tumours, up to a 85% control rate at 12 months and a 65% control rate at 24 
months (Alexander et al., 1995). Cyberknife (CK) is a recent radiosurgery treatment 
technique, in which higher radiation doses applied directly to the tumour. Treatment with 
single-fractionated doses about 10-36 Gy showed a high control rate up to 95% in patients 
with metastatic brain tumours (Chang et al., 1998). Another study showed a symptomatic 
improvement occurred in 90% of patients with a 77.8% control rate following treatment 
with CK (Wang et al., 2009). 
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1.10.2.4 Chemotherapy 
Chemotherapy is known for its limited potency in treatment of cerebral metastasis due to 
the effect of blood brain barrier, drugs delivery is seen to be interrupted or turned over 
quickly in the brain or not distributed equally. Chemotherapy is often applied for patients 
with poor response to other treatments. However, in some cases systematic chemotherapy 
has shown a response rate of 50% in patients with cerebral metastasis from NSCLC and 
SCLC (Schuette 2004). Chemotherapy efficacy varies according to the sensitivity of 
secondary tumour cells to the drug of choice; brain metastases that originated from lung 
(NSCLC) and breast are tend to be less sensitive to chemotherapy (Caffo et al., 2013). A 
previous study reported that cisplatin and etoposide gave a significant objective response 
rate at 55% in breast to brain metastases (Boogerd et al., 1992). Topotecan is a new 
chemotherapy, it has the ability to cross the BBB and used to control primary and 
secondary brain tumours; it is a semi-synthetic camptothecin derivative. Topotecan inhibits 
topoisomerase I during S-phase of cell cycle causing cell proptosis (Ardizzoni et al., 1997). 
However, topotecan is effective in treatment of brain metastases originated from SCLC 
and less effective in metastases from other organs (Wong et al., 2004). Temozolomide 
(TMZ) is an alkylating agent with a small molecular weight, which enables it to cross the 
BBB (Lorusso et al., 2006). TMZ is associated with low incidence of side effects and it has 
been suggested that TMZ may decrease brain metastases (110). A recent study showed that 
afatinib can be used in treatment of brain metastatic NSCLC with EGFR mutations (LUX-
Lung 3) (Schuler et al., 2016). 
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1.10.2.5 Molecular Targeted Therapy  
Overexpression of many receptors and activity of some signalling pathways have been 
demonstrated, to be associated with brain metastasis such as, tyrosine kinase receptors, 
which trigger many oncogenic pathways. A specific blocking of these receptors and 
pathways could interrupt proliferation, invasion, and migration of cancer cell. These new 
target therapies inhibit the activation of oncogenic pathways through; ligand-receptor 
binding or by blocking downstream signal transduction in order to prevent the disease 
progression. In theory, the molecular targeted therapies are designed to be highly specific 
and safer with less systemic cytotoxic effect (Caffo et al., 2013). 
-  Trastuzumab is human monoclonal antibodies against extracellular domain of 
human epidermal growth factor receptor 2 (HER2), this receptor overexpression is 
noted to be correlated with formation of brain metesteses in breast cancer patients 
(Caffo et al., 2013). Recently, trastuzumab is used either alone or combined with 
chemotherapy in treatment regimen of breast cancer patients. A retrospective study 
showed that trastuzumab is significantly effective in HER2-positive breast cancer 
patients but not in HER2-negative patients (Caffo et al., 2013). 
 
- Lapatinib is another molecular targeted therapy; it is a small-molecule tyrosine 
kinase inhibitor that blocks the phosphorylation of both, epithelial growth factor 
receptor EGFR and HER2, as well as prevents the downstream-signalling proteins 
that trigger cell proliferation and migration (Schuler et al., 2016). Lapatinib has the 
ability to cross BBB (Caffo et al., 2013) and it is used when patients develop 
trastuzumab resistance (Caffo et al., 2013). Lapatinib is recently used to treat 
HER2-positive breast cancer patients with brain metastasis, at dosage of 750 mg 
twice daily after a cranial radiation (Caffo et al., 2013).   
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- Bevacizumab is a monoclonal antibody that designed to bind vascular endothelial 
growth factor receptor b (VEGF-b), in order to prevent formation of new blood 
vessels during angiogenesis process (Caffo et al., 2013). Bevacizumab is associated 
with a risk of developing an intracranial hemorrhage, as it has been reported in a 
phase II trial of  bevacizumab in which, the use of this treatment was excluded in 
NSCLC patents with brain metastasis (Caffo et al., 2013).        
 
- Multi-target Tyrosine Kinase Inhibitors are mainly target Mitogen-activated 
protein kinases (MAPK) pathway which is a key intracellular signal transduction 
pathway; it is involved in cell proliferation, differentiation, mitosis, gene 
expression and apoptosis (Zahuo et al., 215). Sorfenb or sunitinib are active 
inhibitors of multi-tyrosine kinase inhibitors, they inhibit cell proliferation via 
blocking the activity of intracellular kinases in Raf/MEK/ERK pathway (134); it is 
also reported that Sorfenb or sunitinib prevent angiogenesis by inhibiting VEGFR-
2, VEGFR-3, FLT, FMA, RET, c-KIT and PDGFR-b. A CNS hemorrhage was 
reported in metastatic renal cell carcinoma (RCC) patients who, were treated with 
Sorfenb or sunitinib (Zahuo et al., 215).  LGX818, dabrafenib and vemurafenib are 
potent inhibitors of mutated BRAFV600E but not BRAF-wild type cells, 
unfortunately these inhibitors are associated with a specific toxicities and drug 
resistance (Zahuo et al., 215).  
 
- Rapamycin and its analogs (mTOR inhibitor) are anti-tumour, lipophilic 
molecules, they can cross the BBB. mTOR inhibitors (at high concentration) reduce 
the invasion of metastatic breast cancer cells in vitro (Caffo et al., 2013). In vitro,  a 
high dose of mTOR inhibitors CCI-779 combined with MEK inhibitor (SL327) 
reduced perivascular invasion and angiogenesis (Zahuo et al., 215).  
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1.11 Metastasis mechanism and pathways   
Metastasis is a complex multi-step process; inducing the development of secondary 
tumours from a distant primary tumour (Stephen Paget, 1889 reviewed by Mendoza and 
Khanna, 2009). Metastasis is the main cause of death among cancer patients and correlates 
with poor prognosis and treatment outcomes (Liotta et al., 1993 and Hunter et al., 2008). 
The molecular mechanisms underlining metastasis are still ambiguous, although numerous 
studies have highlighted that the cancer cells disseminate through two modes: (a) the 
“serial model” (Liotta et al., 1993 and  Pavelic et al., 2011) in which, the metastatic cells 
arise from a primary tumour and metastasis is the terminal stage of tumuorigenesis; this 
model does not explain the genetic differences between primary tumour and the new 
secondary tumour (Schmidt-Kittler et al., 2003 and Gray 2003). (b) “Parallel” model, 
where the dissemination of cancer cells occurs in parallel with primary tumour progression 
This model may explain the early formation of secondary tumours but does not explain 
why metastasis occurs at an advanced stage of primary cancers.  
Once metastatic cancer cells successfully detach from the primary tumour, they may use 
one or more pathways to disseminate and reach the site of the secondary tumour. These 
pathways or routes can be summarised as: tissue spaces (Transcoelomic) which refers to 
the infiltration of metastatic cancer cells by invading the compact tissue which may also 
include the fibrous membrane of the periosteum as in bone metastases (Liu et al., 2015), 
pericardium as in cardiac metastases (Bussani et al., 2007), dura matter (Agarwal et al., 
2010), ligaments (Akhavan 2013), tendons (Jozsa and Renner 1991), derma (Sesterhenn et 
al., 2013) and viscera that surrounds the liver, kidneys and spleen (Drake 2015). Cancer 
cells potentially destroy these barriers via proteolytic enzymes (Morgan-Parks, 1995).   
An additional potential route for brain metastasis is via the cerebrospinal spaces by 
metastatic cancer cells through cerebrospinal fluid (CSF) by invading the leptomeninges 
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surrounding the brain, spinal cord and ependymal lining of the brain ventricles (Pilkington 
and Parker 2007).  
Epithelial cavities constitute another pathway of cancer cell dissemination which occurs by 
direct implantation or contact of cancer cells on the epithelial surface, this type is rarely 
seen in the digestive and respiratory system due to the heavy mucus secretions and 
bacterial normal flora (Morgan-Parkes 1995). Lymph vessels (lymphatic spread) another 
pathway of cancer cell dissemination. In this path cancer cells do not require any 
proteolysis activity to enter the lymphatic drainage, since lymphatics do not have a 
continuous basement membrane (Oliver and Harvey 2002). There is in depth knowledge 
that metastasis to the lymph nodes occurs before or in parallel with the diagnosis of 
malignant primary tumours. Therefore, it is considered as an important diagnostic indicator 
of metastasis in some types of cancer (Fidler 2003 and Shayan et al., 2006). Some cancer 
cells express specific receptor molecules such as CCR7 which increases the affinity 
towards lymphatic vessels as in breast cancer and melanoma (Wiley et al., 2001). From 
cancerous lymphatic nodes, cancer cells frequently invade the blood circulation, through 
the blood venules, lymphaticovenous anastomoses in the lymph node, neighbouring veins 
and lymphatic tributaries of veins (Morgan-Parkes 1995). A haematogenous route in which 
the spread of circulating cancer cells occur through blood circulation starts with 
angiogenesis where the primary tumours are in direct contact with the blood vessels due to 
the angiogenesis process. Circulating cancer cells are detected in blood samples in 50% of 
cancer patients at the time of primary tumour diagnosis (DeVita et al., 1975). Cancer cell 
transmigration does not occur via arteries, since the elastic fibrous area surrounding large 
blood vessels contain anti-proteolytic factors (Willis, 1973 and Morgan-Parkes, 1995). 
Venous invasion occurs in most cancer types. Cancer cells invade the small venules 
surrounding primary tumours either in single cell form (Hart 2009) or in clumps to form a 
tumour embolus, which subsequently arrests in the nearest venous (Hart 2009). The site of 
primary tumour also plays an important role in spread of cancer cells, for instance, cancer 
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emboli that are released in systemic veins are seen to arrest in the lungs (Heithaus et 
al.,2013), while those released in the portal venous system are generally  arrest in the liver 
(Morgan-Parkes 1995). Cancer emboli released in pulmonary veins tend to arrest in 
various sites in peripheral tissues such as the brain or even the bone (DAntonio et al., 
2014).  
 
1.11.1 Initial steps of metastasis    
Metastasis is a complex, multi-step process where a metastatic cancer cell has to undergo 
various steps of cancer cell-host interactions (Liotta et al., 1989). Interrupting any of these 
steps may prevent the formation of secondary tumours (Figure 8). Local invasion 
represents the first step to metastasis where malignant cells start invading the surrounding 
tissue aligned with the primary tumour. Cancer cells are able to digest the extracellular 
matrix and the basement membrane, the intestinal stroma and bone as invading cancer cells 
attach themselves to the basal membrane or extracellular matrix using tumour cell surface 
receptors (Morgan-Parks 1995). The locomotion of invading cancer cells may be 
influenced by self-derived motility factors (autocrine) as in human melanoma cells 
(Stetler-stevenson 1989 and Adada et al., 2015) or influenced by host-derived motility 
factors (paracrine) as in hepatocyte growth factor (HGF) which stimulates the migration of 
lung carcinoma, colon and melanoma cells to the liver (Ogasawara and  Suzuki  2004). The 
growth of the primary tumour induces formation of new host-blood capillaries into the 
tumour mass in a process called angiogenesis, which involves host endothelial cell 
migration, growth and differentiation and is a crucial process in the progression and growth 
of a local tumour in becoming a large and potentially malignant tumour (Folkman 1994). It 
is revealed that formation of new vessels is critical for a tumour to grow larger than 2 mm 
diameter and inhibition of angiogenesis reduces tumour growth (Muthukkaruppan et al., 
1983). Angiogenesis is induced by tumour and stromal cells via secretion of angiogenesis 
factors which are controlled by activators and inhibitors (Dameron et al., 1994). The 
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vascular endothelial growth factor (VEGF) family is considered to play a major role in 
angiogenesis in cancerous tissue (Folkman 1990) and a significant correlation is reported 
between cancer progression and upregulation of VEGF in many cancers such as lung 
(Decaussin et al., 1999), breast (Kurebayashi et al., 1999) and colorectal cancer (Andre 
2000). Some cancer cells are able to escape from the local tumour and enter into the 
circulation via invading the local blood or lymphatic vessels through a process called 
intravasation (Reymond et al., 2013), it was reported that the number of secondary tumours 
is correlated with the number of progressive circulating cancer cells (Liotta et al., 1991) 
and newly formed blood vessels during angiogenesis are potentially the favorite target for 
metastatic cells since the new vessels are imperfectly formed with many abnormalities 
(Netland and Zetter 1989). It was also shown that intravasation can occur either actively in 
which only viable cancer cells invade the circulation and there is considerable evidence, 
showing the involvement of cytoskeletal activation (Condeelis and Pollard 2006) integrin 
upregulation (Hood and Cheresh 2002) during intravasation; or may occur passively where 
cancer cells both dead and viable enter into the circulation. The passive intravasation has 
been reported to occur when parts of a tumour mass impacts upon a tenuous blood vessel 
and that may explain why only 1% of circulating cancer cells are viable cells  (Bockhorn et 
al., 2004) (Figure 8).  
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Figure 8: Initial steps of metastasis steps at the site of the primary 
cancer   
 
SAJ2015 
Figure 8: Schomatic showes metastasis steps at the site of primary tumour. (1) 
Local invasion starts at primary tumour site by degradation of basement 
membrane and ECM. (2) Uncontrolled proliferation of malignant cells takes 
place followed by angiogenesis. (3) Intravasation where some of cancer cells 
succeed to enter the circulation.       
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1.11.2 Metastasis steps within the circulation and at entry site of secondary tumour   
Millions of malignant cells are distributed from the site of the primary tumour, either in 
single cell form (Morgan-Parks 1994) or in clumps (Aceto et al., 2014). The blood 
represents a hostile environment for circulating tumour cells (CTCs) (Fidler 2003 and 
Mehlen and Puisieux 2006) and less than 0.01% of total CTCs form a secondary tumour 
(Fidler 2003 and Liotta 1989). In circulation, platelets and leukocytes play an important 
role in survival of CTCs, for instance cancer cells expresses VCAM-1 which binds to 
α4integrin on the surface of macrophages and this interaction protects the cancer cell 
against the effect of the pro-apoptotic cytokine TRAIL (Chen et al., 2011). Cancer cells 
stop traveling in the circulatory system after a while through a process called cancer cell 
arrest. Two major patterns of cancer cell arrest are described: passive CTC arrest, where 
the disseminated cancer cells arrest at the nearest capillary beds, which are a network of 
fine capillaries where the gaseous and nutrients exchange occurs. It is also characterised by 
slow rate of blood flow. These beds may represent an ideal adhesion site for the circulating 
cells in blood capillary of the primary tumour. This occurs mechanically and is caused by 
trapping individual cells or groups of clumping cancer cell in capillaries with small-
diameter as in metastasis from breast to lung and from colon to liver (Chambers et al., 
2002). It has however, also been reported that lung cancer cells may arrest in the large-
diameter vessels (Al-Mehdi et al., 2000). The other pattern is active arrest of cancer cells 
where CTCs actively adhere to the vascular endothelium, via specific cell-cell adhesion 
molecules such as the interaction of selectins with their ligands: Sialyl Le x and Sialyl Le a 
(Orr and Wang 2001), integrins (Felding-Habermann et al., 2001). Active cancer cell arrest 
is detected in many cancers and may explain the selectivity of cancer cell adhesion; for 
example CD62E, ICAM-1, VCAM-1, ALCAM, β4 integrin and VLA-4 which are shown 
to play a key role in the adhesion process of breast cancer cells to brain endothelium during 
metastasis from breast to brain (Soto et al., 2014). CD15 and CD62E are also localised at 
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the site of adhesion between brain endothelium and NSCLC cells during metastasis from 
lung to the brain (Jassam et al., 2015).  
Furthermore, arrest and adhesion of cancer cells are seen to be correlated with the presence 
of specific cytokines such as TNF-α, IL-1α and IL-β that induce the expression of E-
selectin, P-selectin, ICAM-1 and VCAM-1 at the surface of endothelial cells (Iwai et al., 
1993). Approximately, 90% of CTC arrest at capillaries or at the wall of a vessel (Morgan-
Parkes, 1995). It is reported that arrested CTCs start degradation and invasion of the 
lamina (basal membrane) of vessels after 8-24 hours of adhesion on the endothelial cells in 
a process called extravasation (Liotta, 1989); extravasation is controlled by the type of 
cancer cell and the host-inflammatory reactions such as secretion of TNF-α which is 
known to regulate adhesion of cancer cells (Bissell et al., 2005). A varying degree of 
ability of extravasation is seen in different cancer cells, for instance lung metastatic cancer 
cells are able to disrupt the integrity of endothelial barrier by expressing VEGF-A and 
Angpt14 factors which are known to affect the junction between endothelial cells during 
cancer cell endothelial transmigration (Weis et al., 2004 and Padua et al., 2008) and 
EREG, COX2, MMP1 and MMP2 which have been reported to mediate the extravasation 
of lung cancer cells (Gupta et al., 2007). It is proposed that direct contact of cancer cell-
platelets activates both NF-ҡB and TGFβ/Smad in cancer cells which triggers the 
epithelial-mesenchymal transition in lung cancer cells in vitro. Cancer cells may thus 
acquire a “invasive mesenchymal phenotype” in vivo. The absence of TGFβ1 also 
significantly reduced the extravasation of lung cancer cells (Labelle et al., 2011). In colon 
carcinoma metastasis, cancer cells express CCL2 (monocyte chemotactic protein 1) which 
directly affects CCR2 that is released by endothelial cells; both proteins are seen to be 
correlated with increased permeability of the endothelial cell barrier (Wolf et al., 2012) 
(Figure 9).    
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Figure 9: Metastasis steps at circulation and entry to the site of secondary 
tumour. (4) Survival and education of cancer cells in the circulation through 
interacting with leukocytes and platelets. (5) Tethering and rolling of cancer 
cells followed by adhesion on the endothelium of the capillary. (6) 
Extravasation, some cancer cells are able to leave the circulation by 
transendothelial migration. (7) Cell growth of metastatic cancer cells at the 
site of secondary tumour.       
Figure 9: Metastasis steps during the circulation and at site of entry of 
secondary tumours   
SAJ2015 
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1.11.3 Seeding of cancer cells into the brain  
Little is known regarding the mechanisms underlining the entry of cancer cells into the 
brain during the early stage of metastasis to the brain. Recent studies have, however, 
highlighted the role of endothelial cells. It was shown that activated brain microvascular 
endothelial cells expressing CD62E plays an important role in extravasation as they 
mediate cell-cell adhesion between cancer-endothelial cells (Brodt et al., 1997 and Jassam 
et al., 2015). Vascular adhesion molecules such as ALCAM, ICAM-1, VLA-4, VCAM-
1and β4 integrin, have been shown to play an important role in mediating cancer cell 
extravasation, via initiation of adhesion of breast cancer cells to brain endothelium (Soto et 
al., 2014). Although most of the cells of the brain develop from common neuroepithelial 
cells of the embryonic nervous system, the brain still has a distinctive cellular asymmetry 
(Gotz and Huttner, 2005). According to the differences in morphology and functional 
characteristics, brain cells are categorised into two major types: Neurons: characterised 
large cell body, prominent transmitting axon and processes dendrites (Ferris, 2012); there 
are at least 100 types of neurons (Kandel et al., 2012) and  glial cells which can be 
classified into: microglia which constitute some of the phagocytes of the brain (Banati, 
2003) and macroglia which include: astrocytes, oligodendrocytes and ependymal cells 
(Noble et al., 1990). Glial cells function as supportive cells. The brain cells receive solutes 
and oxygen through a unique circulation system incorporating the neuro-vascular unit 
which constitutes the blood brain barrier (Abbott et al., 2002). 
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1.12 Structure and function of the blood brain barrier (BBB) 
The blood brain barrier (BBB) represents the first line of defence in the central nervous 
system (CNS) and any disorder which leads to disruption of the BBB can cause many CNS 
dysfunctions (Wilhelm et al., 2013). The BBB helps regulate the homeostasis of the CNS 
as it controls the entry of solutes and cells between the circulatory system and neuronal 
tissue (Lee et al., 2006). It is composed of the neurovascular unit (Abbot et al, 2012), 
which consists of three fundamental elements: endothelial cells, pericytes, and astrocytes 
(Figure 10). The transportation process across the BBB is strictly controlled by several 
barriers including the interendothelial tight junctions (TJs) between endothelial cells. TJs 
are composed of four transmembrane proteins (claudins, occludin, tricellulin/marvelD2 
and marvelD3) which regulate the entry of water soluble molecules (Willelm et al., 2011). 
In addition, transcellular barrier, another defence line, is characterised by a low level of 
transcytosis and endocytosis within cerebral endothelial cells which inhibits the transport 
of substances via the cytoplasm. The enzymatic barrier consists of a complex group of 
enzymes such as, alkaline phosphatase, gamma-glutamyl transpeptidase, 
acetylcholinesterase, monoamine oxidases and other metabolizing enzymes which are able 
to catalysis variety of drugs and chemicals. Efflux transporters are also considered as a 
defence line, expressed by cerebral endothelial cells and include: ABC-B1,-C1,-C4,-C5 
and G2 and regulate the gaseous exchange, transport of nutrients and elimination of 
metabolites. The transport of amino acids and polar molecules such as glucose, are 
regulated actively by solute carrier proteins (SLC transporter family) (Wilhelm et al., 
2011).  
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Figure 10: The structure of neurovascular unit  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Schematic of the cellular structure of the BBB and cells 
involved in its function and integrity. Endothelial cells are in contact with 
pericytes on the basal lamina and the end-foot of astrocytes to form the 
morphological basis of the BBB, interneurons, microglia and 
perivascular macrophages are also seen to be distributed around the 
neurovascular unit. 
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The BBB has a unique cellular structure, starting with highly specialised cerebral 
endothelial cells (CECs) that line the lumen of BBB vessels. Unlike other non-cerebral 
endothelial cells, CECs have a high number of mitochondria (Oldendorf 1977), a reduced 
number of caveolae (Nag 2003), low level of pinocytosis (Nag 2003) and are tightly 
connected by the tight junctions (TJs), which are localized at the apical side of the BBB 
capillaries (Brightman and Reese 1969). In terms of BBB permeability, CECs are 
considered the most important cell type, as they form a continuous sheet lining the inner 
surface of BBB capillaries. The permeability of the brain endothelial monolayer can be 
measured by the value of transendothelial electric resistance (TEER). CECs also possess 
endothelial-like characteristics similar to the other non-CNS endothelial cells; such as 
expressing factor VIII (anti-hemophilic factor AHF), von Willebrand factor, high activity 
of alkaline phosphatase, high activity of γ-glutamyl transpeptidase and uptake of 
lipoproteins (Wilhelm et al., 2013). The second cell type of the BBB is the pericyte which 
is contractile cell related to smooth muscle. The role of pericytes in the formation and 
function of BBB is still not fully explored; however these cells are located at the basement 
membrane of BBB capillaries in close contact with the endothelium. Gap junctions 
between both cell types have been reported (Cuevas et al., 1984) and in BBB the ratio 
between pericytes to endothelial is about 1/3-5 (Pardridge 1999). It is reported that the 
absence of pericytes leads to endothelial hyperplasia, increased permeability of the BBB 
and abnormalities in vasculogenesis (Hellstrom et al., 2001 and Armulik et al., 2010). The 
interaction between pericytes and endothelial cells is reported to play an important role in 
regulating the BBB during embryogenesis (Daneman et al.,2010). Astrocytes also play an 
important role in the stability of BBB (Abbott et al., 2006 and Krizbai et al., 2012). In 
coronal brain sections in the rat, the end-feet of astrocytes are seen to fold around the BBB 
capillaries and cover both endothelial and pericyte cells (Kacem et al.,1998) as well as 
being in contact with nerve cells and with basal membrane (Cohen et al.,1998; Paspalas 
and Papadopoulos, 1996). High levels of the P-Kir 4.1 K
+
 channel glycoprotein (P-gp), 
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glucose transporter 1, aquaporin-4 and connexin-43 are detected on the adhesion site of 
astrocytic end-feet and endothelial cells. It was shown that the outer side of cerebral 
endothelial cells are folded within the basement membrane which is composed mainly of 
proteins such as collagen type IV, fibronectin, tenascin, proteoglycans and laminin (Nag, 
2003). Basal membrane symbolizes anchor on which endothelial cells adhere via the 
interaction between endothelial integrins and the proteins of the basement membrane 
(Hynes, 1992). These interactions regulate many signaling events and expression of tight 
junction proteins described below (Tilling et al., 2002 and Savettieri et al., 2000). It is also 
reported that the basal membrane plays a vital role in regulating adhesion and migration of 
endothelial cells as well as in arresting and colonization of metastatic cancer cells during 
metastasis to the brain (Carbonell et al., 2009). The ECM proteins and receptors are 
expressed at the neurovascular unit play a pivotal role in regulating the growth and motility 
of the BBB cells as well as, they are involved in connecting the cellular and matrix 
compartments of the BBB (Baeten and Akassoglou 2011). ECM proteins and receptors are 
secreted by the component cells of the BBB, for instance, endothelial cells excrete 
fibronectin (Webersinke et al., 1992), collagen (Kose et al., 2007), laminin, laminin α4, 
laminin α5 (Tilling et al., 2002), agrin (Stone and Nikolics 1995), nidogen-1 (Stratman et 
al., 2009) and SPARC (Vincent et al., 2008). Endothelial cells also secrete the matrix 
receptors, dystroglycan (Engelhardt and Sorokin 2009) and integrins α1β1, α4β1, α5β1, 
α6β1, α6β4, αvβ1, αvβ3 (Paulus et al., 1993, Wang and Milner 2006, Milner and Campbell 
2002, Tagaya et al., 2001). Additionally, ECM and matrix receptors are secreted by 
pericytes; fibronectin (Webersinke et al., 1992), glycosaminglycans, collagen, laminin 
(Allt and Lawrenson 2001), nidogen (Brachvogel et al., 2007) and perlecan (Stratman et 
al., 2009). Pericytes have been shown to express matrix receptors such α4β1 and α4β2 
integrins (Grazioli et al., 2006 and Balabanov et al., 1996). Astrocytic cells are shown to 
generate collagen (Kose et al., 2007), fibronectin (Webersinke  et al., 1992), laminin 
(Tilling et al., 2002), agrin (Grimpe et al., 1999), SPARC (Vincent et al., 2008) and 
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nidogen-1 (Wolburg et al., 2009) as well as matrix receptors such as, dystroglycan 
(Engelhardt and Sorokin 2009) and integrins (Paulus et al., 1993).  
Finally, microglia cells are reported to generate ECM and matrix receptors such as SPARC 
(Vincent et al., 1992), αvβ3, αvβ5, αvβ8, αmβ2, αLβ2 and αXβ2 (Zhu et al., 2009 and 
Milner et al., 2009). The BBB also has a unique junctional complex that is localised in the 
cerebral interendothelial space at the neurovascular unit, which is composed mainly of 
adherent junctions (AJs) (Schulze and Firth, 1993), tight junctions (TJs) (Kniesel and 
Woblburg, 2000) and gap junctions (Tao-Cheng et al., 1987). TJs and AJs are both 
involved in regulating the permeability of the endothelial layer while, gap junctions are 
thought to play a role in intracellular communication (Bazzoni and Dejana, 2004). AJs 
facilitate the cell-cell adhesion of endothelial cells in the endothelial monolayer and 
inhibition of AJs leads to polarisation of endothelial cells (Bazzoni and Dejana, 2004). AJs 
are composed of cadherin which initiates cell-cell adhesion as it binds with other cadherin 
molecules on the adjacent endothelium; the intracellular part of cadherin binds to 
plakoglobin and β-catenin which is connected to the actin cytoskeleton of the endothelium 
(Wataba-Uchida et al., 1998). Disrupting the AJs increase the permeability of the BBB 
(Abbruscato and Davis 1999).  
TJs are localised at the apical region of the endothelial barrier tissue. They play a key role 
in tightly binding the endothelial cell to facilitate a “zipper” like structure which isolates 
the apical region from the basolateral region of the endothelium. TJs consist of the 
following protiens: junctional adhesion molecule (JAM-1) which is a 40 kDa IgG and has a 
single membrane-span chain and a large extracellular domain. Its main function is to 
mediate the initial cell-cell adhesion via homophilic interactions. JAM-2 and JAM-3 
related proteins are localised on the surface of epithelial cells but their role in the BBB is 
still not fully understood (Bauer et al., 2004). Occludin is a 60-65 kDa protein which has 4 
transmembrane domains characterised with carboxyl and amino terminal ends and 
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extracellular loops (Furuse et al., 1993). Occludin is seen to be overexpressed and 
continuously distributed on the marginal edges of cerebral endothelial cells (Lippold et al., 
2000) whereas a faint and discontinuous expression is detected in non-cerebral 
endothelium. It is revealed that overexpression of occludin is correlated with high electric 
resistance in endothelial tissues (Hirase et al., 1997). Claudins are a group of 20-24 kDa 
proteins which have similar structure to occludin without the homologous sequence 
(Furuse et al., 1998). At least 24 claudins are known in mammals, all of them sharing a 
similar predicted folding (Heiskala et al., 2001). The Claudin extracellular loop may 
initiate a homophilic or heterophilic interaction with different molecules. It is shown that 
claudins form the primary scaffold of TJs and occludin facilitates the additional seal of the 
TJs. Claudin-1,-3 and -5 are characteristic of the cerebral endothelium (Witt et al., 2003). 
TJs also contain membrane-associated guanylate kinase proteins (MAGUK) and three 
other proteins (ZO-1, ZO-2 and ZO-3). These proteins are recognised by a Src-homolog-3 
domain, multiple postsynaptic density-95 binding domains and are shown to be associated 
with the structure of tight junctions such as ZO-1 (220 kDa) which is localised at the site of 
TJs (Stevenson et al., 1986).     
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Hypothesis  
1- CD62E plays an important role in cancer cell adhesion during metastasis from lung to  
brain. 
2- The interaction between CD15/CD15s and CD62E may play important role in adhesion 
and trans-endothelial migration of lung cancer cells (Figure 11 A). 
3- Interrupting the interaction between CD15/CD15s and CD62E may play an important 
role in adhesion and trans-endothelial migration of lung cancer cells through brain vascular 
endothelium (Figure 11 A, B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
Figure 11: Metastasis from lung to brain  
 
SAJ2015 
Figure 11: Schematic representation of the metastatic cascade/progression 
of lung cancer cells metastasising to the brain. The diagram above shows 
key steps of metastasis process, focusing particularly on the role of 
CD15/CD15s and CD62E interaction in adhesion (A) and transendothelial 
migration (B) of circulating lung cancer cells.    
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Aims 
1- To characterise the extracellular expression of CD15, CD15s and CD62E both 
qualitatively and quantitatively in human non-neoplastic adult astrocytes (SC-
1800), human brain microvascular endothelial cells (hCMEC/D3), human primary 
lung cancer cells (COR-L105 and A549), human GBM cells (UP-007 and SNB-
19), human  metastatic lung to lymph node (NCI-H1299) cells and metastatic 
biopsy-derived lung cancer cells to the brain (SEBTA-001 and SEBTA-005), tissue 
sections of normal brain and lung to brain secondary tumours.  
2- To evaluate the effect of TNF-α on expression of CD62E in brain endothelial cells.  
3- To investigate the effect of mAb-blocking of CD15/CD15s on adhesion of primary 
and metastatic lung cancer cells to brain endothelial cells. 
4-  To determine the effect(s) of mAb-blocking of CD15/CD15s on ability lng cancer 
cells to cross an endothelial monolayer (transendothelial migration). 
5- To examine the effect(s) of knockdown and overexpression levels of FUT4 and 
FUT7 on the expression levels of CD15 and CD15s downstream.  
6- To study the effect of knockdown and overexpression of CD15/FUT4 or 
CD15s/FUT7 on the adhesion ability of cancer cells on brain endothelia monolayer 
ability of cancer cells through brain endothelium monolayer. 
7- To study the effect of knockdown and overexpression of CD15/FUT4 or 
CD15s/FUT7 on the transendothelial migration potential of cancer cells via the 
brain endothelium. 
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Objectives  
The aims will be conducted via: 
1- Immunocytochemistry (ICC), flow cytometry (FC), Western blotting (WB) and 
immunohistochemistry (IHC) (in human fixed tissue sections). These techniques 
will be used to localise and characterise the expression of CD15, CD15s and 
CD62E in the cell lines below:  
 SC-1800 (adult astrocytes non-neoplastic) 
 hCMEC/D3 (brain microvascular endothelial cells) 
 COR-L105 and A549 (Primary non-small cell lung cancer, NSCLC) 
 SEBTA-001 and SEBTA-005 (metastatic NSCLC obtained from brain) 
 NCI-H1299 (metastatic NSCLC obtained from lymph node) 
 UP-007 and SNB-19 (GBM) 
 
2- Immunocytochemistry (ICC), flow cytometry (FC) and Western blot (WB) will be 
conducted to investigate the expression of CD62E on activated brain endothelial 
cells at different concentrations of TNF-α. In parallel, cells will be stimulated with 
TNF-β as well to assess specificity of CD62E/ TNF-α. 
 
3- A fluorometric qualitative and a quantitative cell-cell adhesion assay will be 
employed to examine the role of CD15 and CD15s on adhesion ability of NSCLC 
cells. This will be conducted under both static and shear stress conditions using 
Cellix microfluidics and live cell imaging with and without immunoblocking via 
anti-CD15 and anti-CD15s monoclonal antibodies. 
4- The role of CD15 and CD15s in cancer cell transendothelial migration potential 
with and without immunoblocking via anti-CD15 and anti-CD15s monoclonal 
antibodies will be assessed via:  
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 EVOM™ (Voltohmmeter)   
 ECIS™ (Electric Cell-Substrate Impedance Sensing) 
 Cellzscope® (Automated transendothelial resistance monitoring system). 
 
5- The effect of genetically manipulating FUT4 and FUT7 on the expression of CD15 
and CD15s respectively, will be assessed by, ICC, FC analysis and WB.   
 
6- The effect of knockdown and overexpression of FUT4/CD15 and FUT7/CD15s on 
the adhesion of cancer cells will be determined by cell-cell adhesion assay. 
 
7- The effect of knockdown and overexpression of FUT4/CD15 and FUT7/CD15s on 
the transendothelial migration ability of cancer cells via an endothelial monolayer 
will be assessed by EVOM™, ECIS™ and Cellzscope®. 
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CHAPTER TWO   
MATERIALS AND METHODS  
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2.1 Cell culture and cell lines 
All cell culture work was carried out aseptically in a sterile laminar flow cabinet 
(NUAIRE™ Biological safety cabinet-class II). All plasticware and glassware used for 
tissue culture were sterilised by autoclaving (121
o
C under 1.1 Bar G for 20 mins). All cell 
lines used within the scope of this project were of human origin. Cell lines were cultured in 
each of their appropriate media supplemented with different concentrations of heat-
inactivated human serum (Sigma, UK) as described in Table 1. Cells were passaged into 
new T25 or T75 cell culture flasks (Greiner Bio One, UK) every 3-5 days by washing with 
Hank’s balanced salt solution (HBSS) (Invitrogen, UK) followed by harvesting using 
TrypLE™ (Invitrogen, UK). All cell cultures were maintained in a humidified incubator 
(NUAIRE DH AUTOFLOW CO2 Air-Jacketed) supplemented with 5% CO2 and 95% air 
at 37
o
C.       
 
2.1.2 Establishment of Primary cultures  
Human tumour biopsies were obtained from excised gliomas or from brain metastatic 
tumours of patients from King`s College Hospital (London, UK), with Ethics permission 
11/SC/0048. Biopsies were placed in sterile Petri dishes, washed with HBSS then dissected 
into homogenised small explant suspensions which were then transferred into DMEM+1% 
Penicillin/Streptomycin supplemented with 20% fetal calf serum (FCS) then gradually 
changes to medium supplemented with human serum in T12.5 tissue culture flasks and left 
to adhere for a week in a humidified incubator at 37
o
C and 5% CO2 (Table 3).  
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Cell line ID Histological grading and 
characteristics 
Donor`s 
gender 
Media + serum 
supplementation used 
SC-1800 Astrocytes (non-neoplastic) 
ScienceCell™ Research 
Laboratories, UK 
Male ABM+ AGM-2+ 3% HS  
hCMEC/D3 Immortalized cerebral 
microvascular endothelial 
cells (SV 40 transfected) 
Donated by 
Professor Pierre O. 
Couraud (Institute of 
Cochin, Paris, France) 
Male EBM+ EGM-2+ 2% HS 
COR-L105 Established cell line; Lung 
adenocarcinoma 
Sigma, UK 
Male DMEM+10% HS 
A549 Established cell line;  lung 
adenocarcinoma 
Sigma, UK 
Male DMEM+10% HS 
SEBTA-001 Low passage; metastatic 
lung carcinoma to the brain 
In-house,  biopsy-derived 
Male DMEM+10% HS 
SEBTA-005 Low passage; metastatic 
lung carcinoma to the brain 
In-house,  biopsy-derived 
Female DMEM+10% HS 
NCI-H1299 Established cell line; 
metastatic lung carcinoma 
to cervical lymph nodes 
Sigma, UK 
Male DMEM+10% HS 
UP-007 Low passage; 
heterogeneous Grade IV 
GBM 
In-house,  biopsy-derived 
Male DMEM+10% HS 
SNB-19 Established cell line, Grade 
IV GBM 
DSMZ, Germany 
Male DMEM+10% HS 
 
 
 
      
 
 
 
 
 
Table 3: Primary cell cultures and cell lines used which show the histological 
grading and characteristics of cells used in the scope of this thesis, donor’s 
gender and age. ‘UP’ stands for University of Portsmouth and ‘SEBTA’ for 
South of England Brain Tumour Alliance. These cultures were established ‘in-
house’ from biopsies received from surgical resections. Growth medium and 
serum concentration used to maintain cell cultures throughout the project are also 
mentioned.  
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2.1.3 Cryopreservation of the cell lines  
Recovery
TM
 cell culture freezing medium (Invitrogen, UK) was used which was supplied 
complete with a dehydrating agent; dimethlysulfoxide (DMSO), which reduces the water 
content of the cells thus reducing ice crystal formation and therefore preventing damage to 
cell membranes. Briefly, cells were harvested as previously described, centrifuged and re-
suspended in 1mL of cell culture freezing medium before transferring to cryotubes 
(Greiner, Bio-One, Germany).  The cryotubes were placed in a freezing container which 
containing isopropanol to allow cells to be cooled at a rate of 1
o
C/minute and kept at -80 
o
C freezer overnight. The cryotubes were immersed in liquid nitrogen at -196 
o
C and stored 
for an indefinite period of time. 
 
2.1.4 Resurrection of cells from liquid nitrogen stores 
Cells were removed from the liquid nitrogen tank, thawed in a water bath at 37
o
C.  The 
contents were transferred drop-wise to T25 flasks with 6mL of fresh pre-warmed medium 
(Table 3). Media was changed after incubating overnight to remove the cryopreserving 
chemical: dimethlysulfoxide (DMSO). Flasks were then returned to the incubator and 
maintained as previously described. 
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2.1.5 Cell counting  
Two types of automated cell counter ViCell
XR
 Cell Viability Analyzer (Beckman Coulter, 
UK) and Countess II FL
®
 (Invitrogen, UK) were used to determine cell viability using the 
trypan blue exclusion assay (Strober, 2001). Trypan blue is taken up passively by dead 
cells while live cells with intact cell membrane exclude the dye. To perform a cell count, 
harvested cells were re-suspended in 1mL of growth media from which 10 µL of cell 
suspension removed and mixed with 10µL of trypan blue solution stain (Invitrogen, UK). 
10µL of this cocktail was then mounted on Countess II FL
®
 slides (Invitrogen, UK) and 
slotted in the machine for the cell count to be carried out. To calculate the required volume 
of cell suspension that contained the required cell count, the following equation was used 
(Maherally, 2008): 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(1000) X (number of cells required) 
                                                                  = Required volume (µL) of cell suspension  
Total number of viable cells counted  
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2.1.6 Growth curves and cell population doubling time 
Most of the rapidly dividing cells grow in a sigmoid growth curve form (s-shape) starting 
with the lag phase then log or exponential phase and the saturation phase (plateau). To 
create a growth curve, cells were harvested and subcultured in T25 flasks at different 
seeding densities starting with: 1x10
3
, 1x10
4
 and 1x10
5
 cells in triplicate. Cells were 
incubated for 24 hours then counted.  Sampling and counting were repeated every 24 hour 
until a plateau was reached. Cell densities were plotted against time and population 
doubling time calculated as in Figure 12. Doubling time was calculated according the 
following equation: doubling time (DT) =T ln2/ ln (Xe/Xb)  
T: incubation time, Xb: cell number at the beginning of incubation time, Xe: cell number 
at the end of incubation time, (Growth curves of the studied cells: appendix 2).    
 
 
Figure 12: Growth curve for cell culture  
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time 
Figure 12: A sigmoid growth curve shows the growth phases of a 
cell culture which is comprised of lag phase while cells are 
adapting to the new environment and adhering followed by 
exponential phase which is a period of rapid growth and  
stationary phase where cells growth rate stabilises.       
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2.1.7 Cell population doubling time (PDT) 
It is important to determine the population doubling time of the cell lines before starting 
the experiments as it helps to estimate the initial seeding density. To determine the 
population doubling time for each cell line, increase in viable cell number was recorded 
and plotted against time on a semi-log scale.  
 
2.2 Mycoplasma test  
All cell lines were tested every two weeks using MycoAlert™ Mycoplasma detection Kit 
(Lonza, UK). This test is based on a biochemical reaction to detect active mycoplasmal 
enzymes in cell culture supernatant. In principle, MycoAlert™ (Lonza, UK) substrate is 
catalyzed by viable mycoplasma enzymes in which ADP converted to ATP; and in turn 
luciferase enzyme in MycoAlert™ reagent (Lonza, UK) reacted with ATP is to produce a 
light signal (chemiluminescence). Briefly, cell culture medium supernatant was collected 
and centrifuged at 1000rpm for 5 minutes then; 25µL of the supernatant was mixed with 
25µL of MycoAlert™ reagent in a solid white, F-bottom, 96-well plate. Plates were 
incubated at room temperature for 5 minutes then, reading-A was taken using a 
POLARstar microplate reader (BMG, UK); then 25µL of MycoAlert™ Substrate was 
added, followed by incubation for 10 minutes at room temperature and reading-B was 
taken; results were analysed by dividing reading-B value on reading-A and samples with a 
ratio lower than one considered mycoplasma free, while results higher than one referred to 
a contamination with mycoplasma. 
 
 
 
85 
 
2.3 Flow cytometry (FC) 
Flow cytometry was conducted by harvesting cells with gentle scraping, collected in 1mL 
of complete medium and centrifuged at 1000 rpm for 5 minutes using a 5415R microfuge 
(C&M Scientific Ltd, UK). Samples were re-suspended in 1mL of phosphate buffered 
saline (PBS) (Sigma Aldrich, UK) and split into five eppendorf tubes as follows: one 
negative control (cells resuspended in PBS only), one isotype control to ensure primary 
antibodies specificity and efficiency and three positive samples (Table 4). Samples were 
incubated with 100µl of specific primary antibody for 30 minutes at 4
o
C. This step was 
omitted for the negative control.  Samples were centrifuged, supernatant discarded and 
pellet suspended in 1mL of PBS+2% Bovine serum albumin (BSA) (Sigma Aldrich, UK), 
followed by incubation with 200µL of secondary antibodies at a dilution of 1:100 for 30 
minutes at 4
o
C (Table 6). Samples were washed twice before pellets were suspended with 
500 µL of PBS then transferred to FACS tubes (BD Biosciences, UK).  5µL of Propidium 
Iodide (PI) (Sigma Aldrich, UK) was added to all the samples to stain the nuclei of dead 
cells thus excluding them from the gated cell count. Each sample was tested in triplicate 
(negative control + isotype control + 3 positives) in at least three independent experiments. 
Samples were analysed using a dual-laser FACS Calibur (BD Biosciences, UK) designed 
for multicolour analysis, equipped with a 488 nm Argon gas laser and a 635 nm red diode 
laser. Acquisition and analysis were conducted via Pro software.   
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2.3.1 Statistical analyses of flow cytometry results  
Results were statistically analysed using one-way ANOVA followed by Tukey`s multiple 
comparison post-test with a probability of less than 0.01 was regarded as a significant 
using Graph Pad Prism 3.02 software. N=3.             
 
 
 
 
 
Primary 
antibodies 
Dilution Company Secondary 
antibodies 
Dilution Company 
CD15 1:10 Sigma, UK Goat anti-mouse 
Alexa Fluor 488 
IgM 
1:100 Invitrogen,
UK 
CD15s 1:10 Millipore, 
UK 
Goat anti-mouse 
Alexa Fluor 488 
IgM 
1:100  
Invitrogen,
UK 
CD62E 1:10 Sigma, UK Goat anti-mouse 
Alexa Fluor 488 IgG 
1:100 Invitrogen,
UK 
IgM isotype 
control 
1:10 Invitrogen,
UK 
Goat anti-mouse 
Alexa Fluor 488 
IgM 
1:100 Invitrogen,
UK 
IgG isotype 
control 
1:10 Invitrogen, 
UK 
Goat anti-mouse 
Alexa Fluor 488 IgG 
1:100 Invitrogen,
UK 
Table 4: Primary and Secondary Antibodies used for Flow cytometry (FC). The table 
shows the primary, secondary and isotype control antibodies with their corresponding 
species and dilutions which were used for flow cytometry. 
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2.4 Immunocytochemistry (ICC)  
Cells were harvested from 80% confluent tissue culture flasks and seeded onto 8 mm 
sterile coverslips (UKEG, UK) at 1x10
4
/well and incubated overnight at 5% CO2 and 
humidified atmosphere at 37
o
C and allowed to reach 70-80% confluency. Cells were fixed 
with 4% paraformaldehyde (PFA), pH 7.4  (Sigma Aldrich, UK) for 3 minutes followed by 
three washes with PBS then blocking with 10% normal serum (species dependent on 
secondary antibody used) (Sigma Aldrich, UK) followed by incubation with primary 
antibody for one hour and secondary antibody for 30 minutes at room temperature. Nuclei 
were counterstained with 1µg/mL Hoechst Blue solution (HB) (Sigma Aldrich, UK) for 30 
seconds. Coverslips were mounted on slides using Vectashield® (Vector Laboratories, 
UK). Washes with PBS (5 minutes x 3) were carried out prior and post every incubation 
step. Where Multi-labelling was needed, antibodies were cocktailed (raised in different 
species host) for both antibody incubation time.  No primary antibody was added to 
negative control or isotype control. An isotype control was used to ensure primary 
antibodies specificity and binding efficiency (Table 5).    
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Prima
ry 
antibo
dies 
Dilution Company Secondary 
antibodies 
Dilution Company Blocking 
buffer 
CD15 1:100 Sigma, UK Goat anti-
mouse Alexa 
Fluor 488 
IgM 
1:500 Invitrogen,
UK 
10% goat 
serum 
CD15s 1:50 Millipore, 
UK 
Goat anti-
mouse Alexa 
Fluor 488 
IgM 
1:500 Invitrogen,
UK 
10% goat 
serum 
CD62E 1:500 Sigma, UK Goat anti-
mouse Alexa 
Fluor 488 
IgG 
1:500 Invitrogen,
UK 
10% goat 
serum 
IgM 
isotype 
control 
1:100 Invitrogen,
UK 
Goat anti-
mouse Alexa 
Fluor 488 
IgM 
1:500 Invitrogen,
UK 
10% goat 
serum 
IgG 
isotype 
control 
1:100 Invitrogen, 
UK 
Goat anti-
mouse Alexa 
Fluor 488 
IgG 
1:500 Invitrogen,
UK 
10% goat 
serum 
Table 5: Primary and secondary antibodies used with their corresponding blocking buffers 
for ICC. The table shows the primary, secondary and isotype control antibodies with their 
respective dilution and blocking buffers. 
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2.5 Immunoblotting                                                       
A semi-quantitative analysis was demonstrated to measure the level of expression of target 
antigen in cell lysate. 
 
2.5.1 Preparing cell membrane lysate  
Cell cultures were grown to reach 80-90% confluency. To lyse, growth medium was 
removed and cells were washed three times with 5mL ice-cold phosphate buffer saline 
(PBS) (Sigma Aldrich, UK), the subcellular protein fractionation kit was used (Thermo-
scientific, UK) following manufacturer`s instructions and cellular compartments were 
sequentially extracted using variant lysis buffers from the kit. First, cells were incubated in 
cytoplasmic extraction buffer (CEB) for 10 minutes at 4 
o
C then a cell pellet was collected 
in cold eppendorf tubes and centrifuged at 2893 rpm for 5 minutes at 4 
o
C using 5418R 
centrifuge (Eppendorf, UK); the supernatant was removed (cytoplasmic extract) and cell 
membrane extraction buffer (MEB) was added to the remaining pellet followed by 
incubation for 15 minutes at 4
o
C with frequent vortex on the highest speed then, 
centrifuged at 7085 rpm for 5 minutes at 4
o
C, the supernatant (membrane extract) was 
collected and stored at -20
 o
C.  
     
2.5.2 Bicinchoninic Acid Protein Assay (BCA)   
The BCA assay was used to quantify the amount of total protein in the concentration range 
0.2-1.0 mg. This assay relies on the formation of Cu
2+
-protein complex at alkaline 
conditions and reduction of Cu
2+ 
to Cu
1+ 
which coordinates the amount of protein in the 
solution with formation of purple-blue colour complex. Colour density indicated the 
reduction of Cu2
+
 (Smith et al., 1987). Different concentrations of BSA (0-2000 µg/mL) 
were prepared from BSA stock solution 2 g/mL (Sigma Aldrich, UK) and used as 
standards. BCA working solution stock was prepared by mixing 50 parts of reagent A 
(bicinchoninic acid, sodium tartrate, sodium carbonate, sodium bicarbonate in 0.1 N 
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NaOH, pH=11.25) (Sigma, UK)  with 1 part of reagent B (4% w/v CuSO45H2O) (Sigma, 
UK). BCA working solution was added to BSA-standards and samples at ratio 20:1 
respectively, in 96-Well Plate (Thermo Scientific, UK). Plates were then incubated for 30 
minutes at room temperature before absorbance was measured by POLARstar microplate 
reader (BMG, UK) at a wavelength between 540-590 nm. A standard curve was plotted 
and its equation was used to calculate the total amount of protein in unknown samples.       
 
2.5.3 Western blotting (WB)  
WB was performed using cell membrane extracts which were isolated using the cell 
fractionation kit and the total amount of protein was quantified by BCA assay (2.7.2). Cell 
lysates were separated through gel electrophoresis using a 10% acrylamide SDS-PAGE gel 
cassette (8cmx10cmx5mm) (Thermo Scientific, UK) at room temperature for 90 minutes at 
100 volt/ 400 Watt then samples were transferred (wet transfer) to a polyvinylidene 
fluoride (PVDF) (Bio-Rad, UK) membrane for 90 minutes followed by blocking with 5% 
skimmed powdered milk (Marvel, UK) or 5% BSA (Sigma Aldrich, UK)  in Tris buffered 
saline (TBS) (150 mM NaCl, 10mM Tris, pH 7.4 with 0.05% Tween 20) (Sigma, UK) for 
an hour at room temperature. Primary antibody incubation was carried out overnight at 4
o
C 
as shown in table 6, followed by applying the secondary antibody horseradish peroxidase-
conjugates. Extensive washing of the membranes was carried out in TBST (Thermo 
Scientific, UK) after incubation and immunocomplexes were revealed using an enhanced 
chemiluminescence reagent (Millipore, USA). Blots were visualised using a GBOX Chemi 
XT16 system (Syngene, UK).  
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Primary 
antibodies 
Dilution Company Secondary 
antibodies 
Dilution Company Blocking 
buffer 
CD15 1:500 Sigma, 
UK 
Goat anti-
mouse 
(HRP) 
1:500 Invitrogen, 
UK 
5% 
skimmed 
powdered  
milk  
CD15s 1:50 Millipore, 
UK 
Goat anti-
mouse 
(HRP) 
1:500 Invitrogen, 
UK 
5% BSA 
CD62E 1:500 Sigma, 
UK 
Goat anti-
mouse 
(HRP) 
1:500 Invitrogen, 
UK 
5% 
skimmed  
powdered 
milk 
ABCE1 1:500 Novus,  
UK 
Goat anti-
mouse 
(HRP) 
1:500 Invitrogen, 
UK 
5% 
skimmed  
powdered 
milk 
Table 6: Primary and secondary antibodies used with their corresponding blocking buffers 
and respective dilutions and blocking buffers used for Western blotting. 
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2.6 Immunohistochemistry (IHC)  
IHC was performed on human tissue sections kindly provided by Dr Federico Roncaroli, 
Institute of Brain Behaviour and Mental Health, The University of Manchester. IHC was 
conducted on paraffin embedded, formalin fixed tissue sections (FFPE) of human lung to 
brain metastatic cancer biopsies using antibodies to CD15, CD15s and CD62E (Table 7). 
Briefly, 4μm thick FFPE sections were dewaxed in Xylene then, rehydrated with 100%, 
95%, 70% Ethanol and deionized water respectively, followed by 40 minutes of heat-
induced epitope retrieval with citrate buffer (6.0 pH) at 95
o
C then incubated for 30 minutes 
with 3% hydrogen peroxide in methanol to block endogenous peroxidase and biotin 
activity. Tissues were blocked for 30 minutes with 3% horse serum and probed with 
primary antibodies as shown in table 5 for one hour at room temperature. The Elite Vector 
Stain ABC system (Vector Labs, UK) was employed as a detection system and DAB stain 
(Vector Labs, UK) was used as a chromogen.  Meyer`s haematoxylin (Sigma Aldrich, UK) 
was used as a counterstain.  Mouse IgM isotype was used instead of primary antibodies in 
negative controls. Tissue sections were examined using a bright field automated 
microscope Ariol (Leica, Germany) for qualitative image analysis. 
 
 
 
 
 
 
 
 
 
 
 
Primary antibodies Dilution Company Blocking buffer 
CD15 1:150 Dako, USA 3% horse serum  
CD15s 1:100 Millipore, USA 3% horse serum  
CD62E 1:200 Sigma, UK 3% horse serum  
Table 7: Primary, secondary antibodies and blocking buffers used for 
IHC. The table shows the primary antibodies and their respective 
dilutions and buffers used for IHC. 
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2.7 Confocal Microscopy 
Confocal images were obtained using the X40 and X100 (oil immersion) objectives of a 
Zeiss LSM 510 Meta Axioskop2 confocal microscope using four lasers with excitation 
wave lengths of 405nm (blue), 488nm (green), 568nm (red) and 674 (purple), with diode, 
argon and HeNe1 lasers respectively. Microscopic images were obtained using optimized 
setting of pinhole diameter, offset acquisition and signal gain to lower the background 
noise. Two-dimensional (X-Y) and 3-dimansional (X,Y and Z-stack) Multi track images 
were captured with four separate channels with different colors, to avoid possible 
overlapping in excitation spectra. Samples stained with isotype control antibodies were 
used to set up the optimal setting.       
2.8 Live cell imaging (Real-time Kinetic Microscopy) 
A live cell imaging microscope consisting of an inverted Zeiss Axiovert 200M live cell 
(time-lapse) microscope with a modified stage, which is temperature controlled by an 
external heating sensing system and CO2-controlled, operated by a CO2 concentration 
sensing unit connected to a regular cylinder of pure CO2 gas was used to study the cellular 
behaviour of cancer cell-hCMEC/D3 co-culture in real time. hCMEC/D3 (7.5x10
4
/well) 
were plated in 24-well plates (Corning, UK) and incubated overnight to form a monolayer. 
Cancer cells (1.0x10
4
/well) were tagged with green fluorescent live cell tracker (Abcam, 
UK) and seeded on top of the hCMEC/D3 monolayer. The Zeiss Axiovert 200M live cell 
(time-lapse) microscope was then set up to image three different points in each well, once 
every 30 minutes over 48 hours. Two types of filters were used to capture the images: 
DAPI filter for the brightfield and FITC filter set for green-tagged cells or GFP transfected 
cells.  Images were collated and a movie sequence generated using Volocity 6 software.   
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2.9 Genetic modification of FUT4 and FUT7 (stable transfection)  
CD15/CD15s are trisaccharide epitopes formed by fucosylation of the polylactosamine 
chain via α1,3-fucosyltransferase (α1,3-FUT4) enzyme (Lowe et al., 1991). It was revealed 
that a high level of CD15 was correlated with the overexpression of FUT4 enzyme due to 
transfection with FUT4 gene (Clarke 1996, Kudo et al., 1998, Kaneko et al., 1999 
Nakayama et al., 2001). It has been previously reported that upregulation of FUT7 gene 
led to overexpression of CD15s (Sasaki et al., 1994, Natsuka et al., 1994, Marer et al., 
1997, Kimura et al., 1997 and Nakayama et al., 2001) and FUT4 knockdown has been 
shown to decrease the expression of CD15 (Lowe and Marth, 2003 and Allahverdian et al., 
2010, Weston et al., 1999 and Allahverdian et al., 2010). Thus, FUT4 and FUT7 gene were 
chosen to regulate the extracellular expression of CD15 and CD15s respectively. Four 
different human cell lines were transfected: lung-brain metastatic cancer (SEBTA-001), 
lung-lymph node metastatic cancer (NCI-H1299), primary lung cancer (COR-L105) and 
GBM (UP-007). Transfection was carried out by liptofection using TurboFection 8.0 
(Origene, USA) and DNA retroviral GFP vectors (Origene, USA).    
 
2.9.1 Up-regulation (overexpression) of FUT4/CD15 and FUT7/CD15s  
To enhance the extracellular expression of CD15 and CD15s, target cells were transfected 
with cDNA of the FUT4 gene and the FUT7 gene respectively by introducing a full length 
cDNA of FUT4 (GeneBank accession number: M58596) and FUT7 (GeneBank accession 
number: U11281) (Origene, UK). cDNA constructs were cloned into a retroviral GFP 
vector: pCMV6-AC-GFP by the manufacturer and were ready for immediate use 
(commercially available from; Origene, USA) (Appendix 3). 
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2.9.1.1 Transfection with cDNA of FUT4 and FUT7   
 Prior to transfection, within 24 hours 1x10
5
 of target cells (SEBTA-001, NCI-H1299, 
COR-L105 and UP-007) were seeded onto sterile 12-well tissue culture plate in full growth 
medium, to obtain 50 to 70% confluency. On the day of transfection, cDNA complex was 
prepared by adding 100µL of Opti-MEMI
®
 serum free medium (Gibco, UK) into sterile 
plastic micro-tubes then 4 µL of TurboFection 8.0 (Origen, USA) followed by gentle 
mixing by re-pipetting, the mixture was incubated for 5 minutes, then 3 µg/well of dd H2O 
diluted plasmids were added to the complex followed by 30 minutes incubation. 
Meanwhile, the old medium was removed from plated cells and replaced by 2 mL of fresh 
Opti-MEMI
®
 serum free medium. cDNA complex was added in a drop wise manner. The 
plate was rocked gently to distribute the complex evenly. Transfected cells were incubated 
for 48 hours then cells were passaged at a dilution of 1:10 into 24-well plates in full growth 
medium (DMEM+10% FCS) containing 1000µg/mL of neomycin (G 418) as a selective 
medium. A mock transfection well (vehicle) was applied using non-coding pCMV6-AC-
GFP tagged plasmid (PS 1000010) (Origen, USA), for each cell line in parallel with the 
positive transfection and wild type control well.   
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2.9.1.2 cDNA vectors and constructs  
 
 FUT4- human cDNA ORF clone: pCMV6-AC-GFP retroviral GFP vector ready-
cloned, contained a unique construct of alpha (1, 3) fucosyltransferase, a myeloid-
specific protein (FUT4), a CMV promoter, a T7 promoter, a G418 resistance gene 
and a C-terminal TurboGFP tag (Appendix 3) (Origene, USA). 
 FUT7- human cDNA ORF clone: pCMV6-AC-GFP retroviral GFP vector ready-
cloned: which included a unique construct of alpha (1, 3) fucosyltransferase (FUT7) 
protein, a CMV promoter, a T7 promoter, a G418 resistance gene and a C-terminal 
TurboGFP tag (Appendix 3) (OriGene, USA). 
 
2.9.2  Knockdown of FUT4 and FUT7  
 
FUT4 and FUT7 genes were knockdown in the following cell lines: UP-007, SEBTA-001, 
NCI-H1299 and COR-L105 by transfecting cells with four different human-FUT4 and 
FUT7 unique 29mer shRNA constructs in pGF-V-RS GFP vectors, all interfering plasmids 
were designed according to the sequence of the human FUT4 gene (GeneBank accession 
number: M35531) and FUT7 gene (GeneBank accession number: U11281), designed using 
the siRNA-designing program (Ambion Inc). All constructs were cloned into the vectors 
and ready for immediate use (OriGene, USA). Target cells were seeded in 12-well plates in 
serum supplemented growth medium (DMEM+10% FCS) (Gibco, UK) for 24 hours to 
reach 50-70% confluency. Cells were washed twice followed by addition of 2 mL of serum 
free medium Opti-MEMI
®
 serum free medium (Gibco, UK). To prepare the shRNA 
complex, 50mL of sterile ddH2O was added to dilute the shRNA then mixed by gentle 
vortexing. 3µg of shRNA was added to 250 µL of Opti-MEM
®
 serum free medium (Gibco, 
UK) in sterile plastic micro-tubes and mixed with 3µL of TurboFection 8.0 (OriGene, 
UK). The complex was mixed by pipetting. Tubes were then incubated for 30 minutes at 
37
o
C. The developed transfection complex was added to target cells, in a drop wise manner 
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and rocking for an even distribution. The transfected cells were incubated for 48 hours 
followed by harvesting and seeding at 1:10 dilution in DMEM+10%FCS+ 1000 µg/mL 
G418 as a selection medium.    
 
 
2.9.2.1 shRNA vectors and constructs  
   
 FUT4- human, 4 unique 29mer shRNA constructs in lentiviral GFP vector 
ready-cloned (TG312897).  This kit was comprised of one set of four unique 
constructs of shRNA ready-cloned under U6 promoter for mammalian cells, a T7 
promoter, a G418 resistance gene and a C-terminal TurboGFP tag (Origene, USA). 
 
 
FUT4 shRNA constructs  
 
1- AGGAGGTGGATCTGCGCGTGTTGGACTAC(GI351581)(Origene, USA)  
2- TGCGAAGCCTGGCAAGTAACCTCTTCAAC (GI351582)(Origene, USA)  
3-TTCGAGAACTCGCAGCACCTGGATTATAT (GI351583)(Origene, USA)  
4- AGCTACGCTGTCCACATCACCTCCTTCTG (GI351584)(Origen, USA) 
 
 FUT7- human, 4 unique 29mer shRNA constructs in retroviral GFP vector 
ready-cloned (TG312894).  This kit was comprised of one set of four unique 
constructs of shRNA ready-cloned under a U6 promoter for mammalian cells, a T7 
promoter, a G418 resistance gene and a C-terminal TurboGFP tag (Origene, USA). 
 
 
             FUT7 shRNA constructs  
 
1- TCAGCCACCTCCGAGGCATCTTCAACTGG  (TG312897A)(Origene,USA) 
2- TGAATGAGCCGATACCAACGCTTCTT(TG312897B) (Origene,USA) 
3- TCTACCTGTCCTTTGAGAACTCTCAGCAC (TG312897C)(Origene,USA) 
4- CCACGATCACCATCCATCCTTGTCTCTGGCATGG(TG312897D)    
(Origene,USA) 
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2.9.3 Determining the optimal concentration of selection marker (G418)    
Optimisation is a critical step in stable transfection. The transfected cells were positively 
selected using G418 as a selection marker. The optimal concentration of G418 was 
determined for each cell line by generating a kill curve which is a dose-response 
experiment. 1x10
3
 cells were seeded on sterile 96-well plates and cells were subjected to 
increasing doses of G418 (0μg/mL-1300μg/mL). The viability of cells was tested using an 
MTS assay described in 2.12 every 24 hours over one week. The optimal concentration 
was the lowest G418 concentration at which all cells were non-viable after one week of 
incubation in selecting medium.    
 
2.9.4 Selection of stable transfected cells   
It was necessary to establish a stable transfected cell line to assess the transfection 
efficiency and to ensure the reliability of the functional studies. Stable transfected cells of 
FUT4 and FUT7 (overexpressing and knockdown) were established and used within the 
scope of this project. After 48 hours post-transfection, cells were passaged into 1:10 and 
transfection medium was replaced with growth medium with the optimal concentration of 
selection marker G418 (Geneticin) (1100 µg/mL). The optimal concentration was 
determined according to the cell line kill curve as in (2.11.3). One week after, the cells 
were transferred in 48-well plates, grown in growth medium to expand the number of 
transfected cells followed by assessment of expression when cells were preserved in liquid 
nitrogen for further investigation.  
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Forma
2.10 Cell viability assay (MTS)   
The colourimetric CellTiter 96® Aqueous one solution cell proliferation assay (MTS) 
(Promega, UK) was used to assess the viability of cells under study. The CellTiter 96® 
Aqueous one solution Reagent works by reducing the tetrazolium compound (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulf0phenyl)-2H-tetrazolium) in 
viable cells to formazan products as shown in Figure 13. Briefly, cells were seeded at 1 x 
10
4
 in 96-well plates and incubated at 37
o
C and 5% CO2 for 24 hours. 0.33mg/mL of 
CellTiter 96® Aqueous one solution cell proliferation reagent (MTS) was added to wells 
and incubated for 3 hours. Absorbance was measured at 490 nm using a POLARstar™ 
OPTIMA microplate reader (BMG, UK).  
 
2.10.1 Statistical analyses for viability  
All experiments were performed 3 times in triplicate unless stated otherwise. Data is 
expressed as +/- SE. Statistical analyses were performed using One-way ANOVA followed 
by Tukey’s multiple comparison post-hoc tests. Graph Pad Prism 6 software was used for 
analysis. Results were considered significant when *p<0.05, **p<0.01 and ***p<0.001. 
N=3 
Figure 13: Mechanism of action of MTS 
   
 
 
 
 
 
 
 
Viable cell  
   NAD+  
   NADH  
 Dehydrogenase  
 H  
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Figure 13: Mechanism of action of MTS. It shows the electron transition 
(reduction) in the MTS solution to Formazan achieved by an intermediate 
electron acceptor from NADH in viable cells  
 
100 
 
2.11.1 Quantitative adhesion assay (under static conditions)  
The CytoSelect™ Tumour-Endothelium Adhesion Assay Kit (Cell Biolabs, UK) was used 
to evaluate the adhesion potential of tumour cells on the brain endothelial cell monolayer, 
following an amended version of the manufacturer’s protocol (Jassam et al, 2015) (Figure 
14). 1x10
6
 cells/well of hCMEC/D3 were seeded onto a 96-well plate pre-coated with 
fibronectin (10µg/mL) and grown to reach 80-90% confluency. The endothelial cell 
monolayer was first treated with 25pg/mL of TNF-α overnight to activate the extracellular 
expression of CD62E. Primary and secondary lung cancer cell lines were then tagged with 
a green fluorescent dye (Cyto Tracker™) (Cell Biolabs, UK). 1x105 cancer cells were then 
seeded on top of the activated hCMEC/D3 monolayer for 90 minutes. Non-adherent cells 
were washed off with pre-warmed PBS, the whole co-culture was lysed using 2x lysing 
buffer (Cell Biolabs, UK) and the relative number of  adherent cancer cells was quantified 
by reading the plates on fluorescence plate reader at 485nm/538nm filter set and 530 cut-
off using a POLARstar™ OPTIMA microplate reader (BMG, UK). The experiment was 
repeated at least three times in triplicate.  
 
2.11.2 Qualitative adhesion assays  
To qualitatively evaluate adhesion, ICC and confocal image analysis was used. 1x10
6
 
cells/well of hCMEC/D3 were seeded on top of 8mm sterile glass coverslip pre-coated 
with fibronectin (10µg/mL). Cells were incubated in complete growth medium 
supplemented with 25pg/mL of TNF-α to reach confluency. 1x105 of green fluorescently- 
tagged cancer cells were added on an hCMEC/D3 monolayer and incubated for 90 
minutes. Non-adherent cancer cells were washed away with pre-warm HBSS. Cells were 
fixed with 4% PFA and counterstained with HB. Coverslips were mounted on slides and 
examined using a Zeiss confocal microscope. Semi-quantification of adhesion was 
assessed using confocal images and Zeiss ZEN software (Figure 14).  
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Figure 14: Cancer cell-brain endothelium adhesion assay. Schematic shows 
the protocol of cancer cell-brain endothelium assay, 96-well plates were pre-
coated with fibronectin (10µg/mL) and hCMEC/D3 cells at 1x10
6
 
cells/well were seeded and grown to confluency, endothelial cells were 
activated with 25pg/mL of TNF-α overnight. NSCLC cell were tagged with 
a green fluorescent dye (Cyto Tracker™) cancer cells and then 1x105 cells 
were applied on top of the hCMEC/D3 monolayer and the co-culture was 
incubated for 90 minutes. Non-adherent cells were washed off using pre-
warmed PBS, the co-culture was lysed using 2x lysing buffer and the 
relative number of  adherent cancer cells was quantified by reading the 
plates on fluorescence plate reader at 485nm/538nm filter set and 530 cut-
off using a POLARstar™ OPTIMA microplate reader, results were 
valedated with qualitative adhesion assay by using the confocal microscope 
(Jassam et al., 2016). The experiment was repeated at least three times in 
triplicate.  
 
 
Figure 14: Cancer cell-brain endothelium adhesion assay 
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2.11.3 Cancer cell adhesion (under shear stress)  
A microfluidic assay was carried out by seeding endothelial cells in Vena8 Endothelial™ 
biochips (channel volume: 2.69µL) (CellixLtd, UK). The biochips were pre-coated with 
0.5mm of 10µg/mL fibronectin solution (Sigma, UK) and incubated for one hour. 1.5x10
6 
of hCMEC/D3 cells were seeded in each channel and incubated for 2 hours. The biochips 
were then connected to a Microfluidic pump (CellixLtd, UK) and the whole unit was kept 
overnight in an incubator at 37
o 
C, 5% CO2 under shear stress [flow on perfusion mode 
with a 15mL/hr volumetric flow rate (2.5 dyn/cm
2
)]. The biochip was connected to a Zeiss 
Axiovert 200M inverted live cell (time lapse) (as detailed in 2.10) microscope and cancer 
cells (green fluorescently-tagged) at 1x10
6 
cells/mL were then pumped onto the 
hCMEC/D3 monolayer at 2.5 dyn/cm
2
 controlled by a Mirus Evo nanopump (CellixLtd, 
UK) and analyzed via Vena Flux Assay software. Live cell images were taken once every 
10 minutes over 72 hours to monitor cancer cell adhesion on the hCMEC/D3 monolayer. 
The images were collated and movie sequences generated using Volocity software V5.4. 
The experiment was repeated three independent times in triplicate.  
 
2.11.4 Statistical analyses for adhesion assays  
All experiments were performed 3 times in triplicate unless stated otherwise. Data is 
expressed as +/- SE. Statistical analyses were performed using One-way ANOVA followed 
by Tukey’s multiple comparison post-hoc tests, Graph Pad Prism 6 software was used for 
analysis. Results were considered significant when *p<0.05, **p<0.01 and ***p<0.001. 
N=3 
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2.12 Transendothelial migration assays  
Endothelial cells are characterised by a unique feature which is the formation of a 
monolayer that are tightly connected with specific regions called tight junctions (Abbott et 
al., 2006) to form an intact barrier consistency of a continuous membrane of endothelial 
cells. One of the suggested and generally used methods was measuring the resistance of the 
barrier according to Ohm`s law. This method is based on the qualitative measurement of 
electric resistance of the barrier which reflects the cellular barrier integrity (Benson et al., 
2013). In this method, the resistance of the monolayer is measured by applying direct 
alternating current (AC) (I) square wave with a frequency of 12.5 Hz with defined voltage 
(U). The resistance of the barrier can be calculated according to Ohm`s law: Resistance (R) 
= Voltage (U) / Current (I) (Benson et al., 2013). In this project, three methods were used 
to study the changes in the resistance of brain endothelial cells monolayer (hCMEC/D3) 
and used as a suggestive indicator on the ability of cancer cells to undergo transendothelial 
migration across the monolayer of brain endothelial cells.   
 
 
2.12.1 Endothelial Voltohmmeter (EVOM)    
EVOM was used to measure the resistance of the barrier formed by a continuous 
monolayer of endothelium cells grown on a porous membrane. EVOM (World Precision 
Instruments, USA) is a battery-operated device equipped with a set of STX2 two chopstick 
electrodes. One is silver/silver-chloride pellet to measure the voltage and the other is silver 
electrode for passing current. Before measurement, the EVOM was set on a resistance 
range of 2000 ohm and alternating current input. 24 well plate, polycarbonate membrane, 
8.0μm pore size Transwell® inserts (Corning, UK) were pre-coated with 10μg/mL 
fibronectin (Sigma Aldrich, UK). Fresh medium [EBM+ EGM-2+ 2% HS + TNF-α 
(25pg/mL)] (Lonza, UK) was added in the insert and the 24-well plate then, 1x10
5 
of
  
hCMEC/D3 cells were seeded onto the luminal (upper) part of the insert. Two hours post-
seeding, EVOM electrodes were placed into the transwell chambers (Figure 14).  
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Five readings per transwell were taken three times a day for 7-9 days. Results were 
averaged and resistance values plotted against time. At the end of the experiment, cells in 
the transwell inserts were fixed using the fixing solution from the Diff quick staining kit 
(Thermo Scientific, UK). A cotton bud was used to remove cells from the luminal side of 
polycarbonate membrane of the insert and the basolateral side of the insert stained. To 
count transmigrated cells, inserts were examined using a bright field microscope. All 
experiments were done in triplicate and repeated at least three times (N=3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Measurement of resistance of hCMEC/D3 monolayer using 
Endothelial Voltohmmeter (EVOM). It illustrates the measurement of the 
resistance of hCMEC/D3 monolayer using EVOM and the compartments of 
transwell-insert unit. 
 
Figure 15: Measurement of resistance of hCMEC/D3 monolayer using 
Endothelial Voltohmmeter (EVOM) 
EVOM 
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2.12.2 Electric cell-substrate impedance sensing system (ECIS
®
)  
ECIS was used to assess the effect of cancer cells on the integrity and resistance of brain 
endothelial monolayers at a two dimensional level. The ECIS
® 
model 1600R, relay bank, 
lock-in amplifier and the software all were purchased from applied Biophysics, USA. ECIS 
is an automated real-time, label-free and impedance-based instrument for monitoring and 
recording different cellular activities of the barrier using non-invasive alternating current 
(AC) signals (Giaever and Keese, 1991). The measurement system consisted of 8-well cell 
culture dish array (8W10E+PC) (Ibidi, UK), equipped with a gold large counter and 40 
small sensing electrodes per well with a diameter of 250µm (Figure 16). To set up the 
experiment, tissue culture dish arrays (8W10E+, PC) (0.9 cm
2
 in basal area and 0.7 mL 
total volume) were washed with HBSS and activated with 10mM L-cysteine for 10 
minutes at 37
o
C in an humidified incubator. Wells were washed with HBSS then coated 
with 10mg/mL Fibronectin for 2 hours followed by seeding of 75,000 hCMEC/D3 per well 
in 400µL of EBM+ EGM-2 +2% +TNF-α (25pg/mL). The arrays were then connected to 
the instrument, the electrodes (large and small) were connected by relay bank to a phase-
sensitive lock-in amplifier then AC current was applied through a 1-MΩ resistor to 
monitor the formation of an intact endothelial cell monolayer. Once the resistance 
plateaued/reached the peak resistance, 20,000 of cancer cells were added on top of the 
endothelial cell monolayer. The confluency of the endothelial cell monolayer was 
evaluated by light microscopy imaging. The electrical resistance of each well was 
measured every 2.5 minutes. 16 wells were tested at the same time; time series data were 
collected and analysed using ECIS core software.   
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Figure 16: Measurement of resistance of adherent cells by ECIS.  
 
 
 
 
 
 
 
 
 
 
 
2.12.3 Impedance spectroscopy (CellZscope
®
) 
The impedance spectroscopy technique was used to measure the transendothelial electric 
resistance (TEER) of monolayers of cells grown on porous membranes in standard tissue 
culture inserts (Figure 17). CellZscope
®
 is an automated computer controlled system which 
is based on applying a non-invasive AC voltage and measuring the resistance of the 
monolayer barrier. In this project, all the system compartments including the cellZscope
®
, 
the external controller and the software were obtained from (nanoAnalytics, Germany). 
CellZscope
® 
was mainly used to measure the resistance of brain endothelial cell                   
(hCMEC/D3) monolayer barriers, formed by growing cells on 8µm pore size permeable 
membranes in transwells. The electric resistance of the cell monolayer barrier was 
measured by an electric equivalent circuit and data analysed as a TEER value via a 
corresponding mathematical model. To start the experiment, 24-well type cell module 
wells were cleaned with 70% ethanol (Sigma Aldrich, UK) then washed with HBSS and 
800 µL of  EBM+ EGM-2 +2% +TNF-α (25pg/mL) was added to the sample wells.  
Figure 16: Measurement of resistance of adherent cells by ECIS. The 
schematic illustration, shows the measurement of resistance of hCMEC/D3 
monolayer. Cells were directly adhering on a non-porous electrode with the 
current passing directly through the cell the monolayer, particularly through 
cells the membrane. 
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Pre-coated (fibronectin: 10µg/mL) transwell-inserts with a polycarbonate translucent 
membrane, 8µm pore size (Corning, UK) were placed in the sample well of the cellZscope 
module, then 1x10
5
 hCMEC/D3 cells were seeded onto the inserts. The cellZscope module 
was placed in a sterile, humidified, 37
o
C and 5% CO2 mini GalaxyE incubator (C and M 
Scientific) and connected to the cellZscope external controller, which in turn was 
connected to the cellZscope 1.5.0 software throughout a USB port. Once TEER values 
plateaued/reached a peak, 20,000 cancer cells were added on top of the brain endothelial 
cell monolayer. Readings of monolayer resistance and cell impedance were automatically 
monitored every 30 minutes. TEER values and histograms were collated and analysed 
using the same operating software.     
 
        Figure 17: Measurement of transendothelial resistance by CellZscope
®
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Measurement of transendothelial resistance by CellZscope
®
. A 
schematic illustration shows equivalent circuit diagram of a the measurement 
of resistance of hCMEC/D3 monolayer. Cells were grown on a porous 8µm 
translucent membrane. Non-invasive AC current passes through the 
monolayer of cells. Any disruption that occurs to the barrier is shown as a 
decrease in resistance value. 
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2.13 Synchronization of cell cultures  
Expression of CD15 and CD15s were characterised in non-synchronised cell cultures in 
primary and secondary brain tumour cells as per the flow chart below (Figure 1). Cell 
cultures were synchronised at G1 phase by serum starvation, at S phase via Hydroxyurea 
(1mM) and at G2/M phase via Nocodazole (Timson 1975).  
G1 phase: cells were arrested at G1 phase by serum deprivation. 1x10
6
 cells were seeded 
in T25 tissue culture flasks containing serum supplemented growth medium until 50% 
confluency was reached. Cells were then washed with pre-warmed sterile Hank`s buffered 
salt solution (Fisher, UK) followed by addition of growth medium supplemented with 1% 
human serum followed by overnight incubation. Cells were then grown in serum-free 
medium for 48-72 hours then replaced every 12 hours to avoid cell cytotoxicity due to the 
pH change. 
S phase: cells were arrested at S phase by first arresting cells at G1 phase then replacing 
the medium with growth medium supplemented with serum and Hydroxyurea (Sigma, UK) 
at a final concentration of 1mM and incubated overnight. 
G2/M phase: cells were grown in serum-free medium for 24 hours followed by 
replacement with fresh growth medium supplemented with 2μg/mL Nocodazole (Sigma, 
UK). Growth factors in the medium induce cells to progress to G2/M phase while 
Nocodazole causes cell arrest at G2/M phase since Nocodazole depolarizes the tubulin in 
microtubules.  
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2.14 Detection of cell cycle stage 
To determine the distribution of cell cycle stages, non-synchronized and synchronized cell 
cultures were harvested by gentle scraping. Cellular pellets were washed with PBS and 
fixed with ice-cold 70% Ethanol for 48 hours at 4
o
C. Fixed cells were washed with 
PBS+2% goat serum, resuspended in 250μL of Propidium iodide/RNase solution 
(FxCycle™) (Life technology, UK) and incubated for an hour at room temperature. Cells 
were then washed with PBS+2% goat serum and cell cycle analysis was conducted using a 
BD FACS Calibur (BD Biosciences, UK). 
 
2.15 Immunocytochemistry using Premo™ (FUCCI) Cell cycle Sensor (BacMam 2.0) 
A fluorescence ubiquitination cell cycle indicator (FUCCI) was used according to the 
manufacturer`s instructions (Life Technology, UK) to assess cell cycle progression. Cell 
cultures were transfected with the BacMam 2.0 gene delivery system which combines two 
main cell cycle regulators: Cdt1-tagged with red fluorescent protein (RFP) and geminin-
tagged with green fluorescent protein (GFP). Cells in G0/G1 phase expressed Cdt1-tagged 
with RFP were visualised as cells with red nuclei in G0/G1 phase. Cells in S phase co-
expressed Cdt1-RFP and geminin-GFP and were visualised with yellow nuclei. Geminin-
GFP is predominately expressed in cells during G2/M phase allowing cells with green 
nuclei to be observed. Briefly, 1x10
3
 BacMam2.0™ particles were diluted in 200μL serum 
free Opti-MEM™ (Gibco, UK) followed by addition of 1x103 cells and incubated for 10 
minutes. Treated cells were seeded on 10mm sterile coverslips in 48-well plates followed 
by 48-hour incubation. Cells were fixed with 4% paraformaldehyde (Sigma, UK) and non-
specific antigens were blocked with 10% goat serum (Sigma, UK). CD15 and CD15s 
primary antibodies were applied for one hour followed by incubation in secondary 
conjugates for 30 minutes. Cells were counterstained with 10mM Hoechst blue. 
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CHAPTER THREE 
The role of both CD15 and CD15s in adhesion of NSCLC cells 
to brain endothelium 
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Cellular morphology of cell cultures  
Phase contrast microscopy revealed morphological differences of cell lines according to 
culture and passage number. The monitoring of cell morphology and confluency also 
ensured that bacterial or fungal contamination in cell cultures would be detected. SC-1800 
a human non-neoplastic astrocyte is an adherent cell culture, at passage 5 displayed slender 
cells with elongated processes, and a low number of dividing cells as seen in Figure 18A. 
hCMEC/D3 a human cerebral microvascular endothelial cell line, at passage 28 showed a 
homogenous spindle shape body and continuous monolayer without overlapping or random 
aggregation, as in Figure 18B. COR-L105, passage 25 is a human primary non-small cell 
lung cancer (NSCLC) cell line. It is an adherent culture with rapidly dividing cells, 
growing in a monolayer. Most cells appear to display nuclear atypia (Figure 18C). A549, 
passage 50 is a primary NSCLC cell line. A549 cells are round, adherent and rapidly 
dividing cells, growing in a continuous monolayer with a ‘honey-comb’ cell organisation 
(Figure 18D). UP-007 (passage 23) is a human high-grade glioblastoma multiforme cell 
line (GBM) cell line, derived from biopsy material cultured in-house. UP-007 culture 
shows high cell heterogeneity and this can be noted in mixed cell populations with some 
elongated cells with many processes at the end, some short more rounded cells and some 
big flat cells (Figure 18E). SNB-19 (passage 30) is a human established, homogenous 
high-grade glioblastoma multiforme cell line (GBM). Cells are short, small and lack the 
ability to form long processes (Figure 18F). SEBTA-001 (passage 4) is a human metastatic 
NSCLC established in-house from biopsy-derived materials from a patient with brain 
secondary tumour. SEBTA-001 showed a high level of morphological heterogeneity. Cells 
appear round with a tendency to grow in clusters or papillary structure (Figure 18G). 
SEBTA-005 (passage 3) is a human biopsy-derived metastatic NSCLC, established in-
house from secondary tumour in the brain. Cells appeared large and homogenous 
monolayer. Cells tend to form multiple-processes. Cell-cell contact is rarely seen (Figure 
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18 H). NCI-H1299 (passage 31) is an established cell line derived from a human metastatic 
lung carcinoma to cervical lymph node. Cells appeared to be rapidly dividing, round in 
shape and grow in a monolayer (Figure 18 I) 
 
 
 
 
 
 
 
                
 
 
 
 
 
 
 
 
 
 
SC-1800 
A 
hCMEC/D
3 
B 
UP-007 
E 
SNB-19 
F 
COR-L105 
C 
A549 
D 
SEBTA-001 
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Figure 18. Cellular morphology of (A) SC-1800 a human non-neoplastic astrocyte 
cell line (passage 5), cells appear to be spindle shaped and stellate in culture (B) 
hCMEC/D3 a human brain microvascular endothelial cell line (passage 28), 
reveals homogenous monolayer cell culture, spindle and polygonal cells with long 
and fine foot processes. (C) COR-L105  human primary lung NSCLC cells, 
passage 25 cells are large, round and multinuclear cells are occasionally seen. (D) 
A549 a human primary lung NSCLC cell line (passage 50), small, round cells with 
short, fine processes, mono-nuclear cells. (E) UP-007 a human grade IV GBM, 
passage 23, large cells with spindle or cylindrical shape. Cells have prominent 
nucleus. Multinuclear cells were occasionally seen. (F) SNB-19 a human grade IV 
GBM cell line (passage 30), small sized cells. (G and H) SEBTA-001(passage 4) 
and SEBTA-005 (passage3) respectively both are human metastatic NSCLC 
obtained from the brain passage. SEBTA-001 cells appear round and poorly 
differentiated while; SEBTA-005 cells are heterogeneous in nature (I) NCI-H1299 
a human metastatic lung NSCLC to cervical lymph node passage 31 cells appeared 
poorly differentiated. The images were obtained using a X10 objective via a phase 
contrast microscope. Scale bar= 20 μm.   
Figure 18: Cellular morphology of studied cells. 
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Cell population-doubling time (PDT) 
The population doubling time could then be defined from the exponential part of the 
growth by calculating the time taken for the cell to double (Table 8).    
 
Cell line Population doubling 
time (PDT) (hours)  
Seeding density 
(cells/mL) 
SC-1800 71 1 x 10
6
 
hCMEC/D3 24 1 x 10
6
 
COR-L105 21 1 x 10
5
 
A549 19 1 x 10
5
 
UP-007 23 1 x 10
5
 
SNB-19 20 1 x 10
5
 
SEBTA-001 28 1 x 10
5
 
SEBTA-005 31 1 x 10
5
 
NCI-H1299 18 1 x 10
5
 
 
 
 
 
 
 
 
  
 
 
Table 8: Population doubling times and seeding densities of 
cells used throughout the project. Results are representative 
of three independent experiments carried out in triplicate. 
114 
 
3.1 Role of CD15 in adhesion of non-small cell lung cancer cells to brain endothelium  
CD15 has been reported as a cell-cell adhesion molecule, it plays a key role in non-CNS 
metastasis and is overexpressed on various cancers. However, the role of CD15 in brain 
metastasis is largely unexplored.  Intravasation and extravasation through the BBB are key 
steps for brain metastasis to occur; evidence points to the important role of endothelial 
cells in both lymphocyte trafficking and non-central nervous system (CNS) cancer cell 
metastasis (Strell S, Entschladen 2008). Although cancer cell extravasation has been 
intensively studied, the molecular mechanisms underlying metastasis to the brain are not 
fully understood. In particular, it is associated with human polymorphonuclear 
granulocytes and lung
 
(Kadota et al., 1999), breast (Elola et al., 2007), prostate and kidney 
cancer cells
17
. CD15 is crucial in the cell-cell recognition process (Streit and Stern 1995) 
and it was suggested that its absence from human glioma cells might explain why brain 
tumors rarely metastasize extraneurally. Recently CD15 has been identified as a potential 
cancer ‘stem-like’ cell marker in human and murine glioma spheroids (Mao et al., 1995 
and Jelen et al., 2013). Significantly, it is a marker for metastatic lung adenocarcinoma  
(Kadota et al., 1999 and Nolte et al., 2013) being correlated with metastasis to non-CNS 
sites. However, the functional role of CD15 in metastasis from lung to brain remains 
obscure. CD62E is a cell-surface glycoprotein and CD15 ligand whose expression is 
induced by TNF-α, IL-1β and lipopolysaccharide (LPS) (Kaszubska et al., 1993).  
Currently, no definitive model of the metastatic process of cancer entry to the brain exists; 
previous studies in other tissues indicate that circulating cancer cell extravasation occurs in 
a similar manner to that of leukocytes with sequential steps of tethering, rolling, adhesion 
and transmigration studies on metastasis into colon and liver suggested interactions 
between selectins and their ligands regulate cancer cell adhesion (Brodt et al., 1997 and 
Tremblay et al., 2006) 
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.In vivo study showed that, CD15 accumulates on the invasive edges of breast carcinoma 
boli, suggesting its potential role in metastasis (Brooks SA, Leathem 1995). Few studies 
have focused on the role of CD15 in metastasis to the brain. CD15 is rarely expressed on 
primary brain tumor cells; this observation providing a plausible explanation as to why 
glioma rarely metastasize extraneurally (Martin et al., 1995 and Pilkington et al., 1997) 
 
CD15 and E-selectin (CD62E) expression was demonstrated in both human primary and 
metastatic NSCLC cells using flow cytometry, immunofluorescence and Western blotting. 
The role of CD15 was investigated using an adhesion assay under static and physiological 
flow live-cell conditions. Human tissue sections were examined using. This study enhances 
understanding of cancer cell-brain endothelial adhesion and confirms that CD15 plays a 
crucial role in adhesion in concert with TNF-α activation of its binding partner CD62E.  
This part of the project aims to provide a better understanding of CD15/CD62E interaction, 
enhanced by tumor necrosis factor-α (TNF-α), and its correlation with brain metastasis in 
non-small cell lung cancer (NSCLC).  
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3.1 CD15 expression in brain endothelial and NSCLC cell lines 
CD15 cell surface expression and localization were characterized on brain endothelial 
cells, primary and metastatic NSCLC cells using ICC, Flow cytometry and WB analysis. 
Semi-quantitation of confocal images (Figure 19) demonstrated that when compared to 
isotype controls, CD15 immunoreactivity was highest on metastatic lung cancer cells NCI-
H1299 (p<0.0001) followed by SEBTA-001 and SEBTA-005, A549, COR-L1299 and 
hCMEC/D3 respectively (Figure 19 A-B). There was no significant difference between 
CD15 expression in hCMEC/D3 compared to isotype control and to A549. There was a 
significant increase in CD15 expression compared to isotype control with positivity levels 
of NCI-H1299: 79%, SEBTA-001: 54%, SEBTA-005: 39%, COR-L105: 31%, A549: 23% 
and hCMEC/D3: 19.69% (Figure 19 C-D). There were no noted differences in CD15 
expression in hCMEC/D3 compared with A549 and COR-L105. Western Blot results were 
consistent with these analyses (Figure 19 E).  
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Figure 19. Extracellular expression of CD15 in brain endothelial and lung cancer cell 
lines. A: Representative immunocytochemical images showing extracellular 
expression of CD15 in human brain endothelial cells (hCMEC/D3), human NSCLC 
metastatic cells obtained from cervical lymph node (NCI-H1290), brain (SEBTA-001 
and SEBTA-005) and in non-metastatic NSCLC cells (A549 and COR-L105). B: 
Semi-quantitation analysis of CD15 cells from confocal images (A) using Zeiss’s ZEN 
image software. C: Representative flow cytometric histogram. D: Flow cytometric 
analysis of CD15 expression on hCMEC/D3, NCI-H1299, SEBTA-001, SEBTA-005, 
A549 and COR-L105. CD15 was highly expressed on NCI-H1299 and SEBTA-001 
with less expression on COR-L105 and SEBTA-005 which expressed relatively the 
same amount. N=3, ***p<0.0001, **p<0.001 and *p<0.01. There was also less CD15 
expression on A549 and hCMEC/D3 cells. E: Western blot of proteins from the cell 
lines showed highest CD15 expression in NCI-H1299, followed by SEBTA-001, 
SEBTA-005, COR-L105, A549 and hCMEC/D3. ABCE1 was used as a protein 
loading control. 
 
Figure 19. Extracellular expression of CD15 in brain endothelial and NSCLC 
cells 
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3.2 TNF-α increases CD62E expression in human brain endothelial cells and NSCLC 
cell lines 
MTS assay was used to determine the effect of TNF-α and TNF-β on the viability of 
hCMEC/D3 cells. Cells were incubated at different concentrations of TNF-α or TNF-β (0, 
5, 10 and 25 pg/mL) and then cells viability was tested every 24 hours for 4 days. Results 
showed that TNF-α had no effect on hCMEC/D3 viability (Figure 20). However, TNF-β 
significantly reduced the cells viability (p<0.05) (Figure 20B), therefore TNF-α was 
selected for activating hCMEC/D3. TNF-α treatment of brain derived endothelial cells 
(hCMEC/D3), resulted in an increase in CD62E protein expression in a concentration 
dependent manner compared with non-stimulated cells (Figure 21A-C, E). To ensure this 
was a specific effect of TNF-α, CD62E expression was further examined in hCMEC/D3 
cells treated with TNF-β (Figure 21A-B, D-E). ICC, flow cytometry and Western blotting 
were used to evaluate CD62E expression in brain endothelial cells cultured for 18 hours at 
three different concentrations of TNF-α and TNFβ: 5pg/mL, 10pg/mL and 25pg/mL. While 
CD62E expression was significantly higher in TNF-α treated hCMEC/D3 cells compared 
to the lung cancer cell lines (p<0.0001), there were also significant differences in CD62E 
expression within the group of lung cancer cell lines that were also treated for 18 hours 
with 25pg/ml of TNF-α (Figure 21 A-D). Semi-quantitation of confocal images (Figure 
22A-B) demonstrated highest CD62E expression associated with hCMEC/D3 cells (Figure 
22B). CD62E expression in hCMEC/D3 cells was significantly higher than CD62E 
expression in all the lung cancer cell lines tested (p<0.0001). CD62E expression in 
SEBTA-001cells was significantly higher than NCI-H1299 (p<0.01), SEBTA-005 
(p<0.001) and A549 (p<0.0001). 73.88% of brain endothelial cells (hCMEC/D3) expressed 
CD62E and was significantly higher than isotype controls and the NSCLC cells (p<0.001). 
Flow cytometric analysis of lung cancer cells revealed CD62 positive cells in SEBTA-001 
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(34.17%), in SEBTA-005 (27.6%), in NCI-H1299 (20.6%), in COR-L105 (32.7%), and in 
A549 (17.53%) (Figure 21 C-D).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
A 
Figure 20 : TNF-α and TNF-β effect on hCMEC/D3 viability 
Figure 20: TNF-α (A) and TNF-β (B) effect on human brain endothelium 
viability. Representative analysis of hCMEC/D3 cell viability following 
treatment with TNF-α and TNF-β, using MTS assay to assess cells 
viability. Results were obtained by  N=3, *p< 0.05. 
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Figure 21. CD62E expression in TNF-α and TNF-β treated 
endothelial cells. 
Figure 21. CD62E expression in TNF-α treated endothelial cells. A: 
hCMEC/D3 cells were positively stained for CD62E extracellular expression 
at different TNF-α and TNF-β concentrations (green). B: Western blotting of 
hCMEC/D3 cultured in increasing concentrations of TNF-α and TNF-β. C, D: 
Overlay histogram of flow cytometric analysis of CD62E expression in 
hCMEC/D3 cells cultured with different concentration of TNF-α and TNF-β. 
E: Flow cytometric analysis of CD62E expression in hCMEC/D3.  N=3, 
***p<0.0001, **p<0.001, *p<0.01. 
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Figure 22. CD62E expression in TNF-α treated NSCLC cell lines. 
Figure 22. CD62E expression in TNF-α treated lung cancer cell lines. A: 
Representative immunocytochemical images showing expression of CD62E in 
cancer cell lines following treatment with TNFα (25pg/ml). CD62E was highly 
expressed and well-distributed across cell membrane of hCMEC/D3 cells, at 
lower levels on NSCLC metastatic cells (NCI-H1299 SEBTA-001 and SEBTA-
005) and primary NSCLC cells (A549 and COR-L105). B: Semi-quantitation 
analysis of CD62E cells from confocal images (A) using Zeiss’s ZEN image 
software. C: Overlay histogram of flow cytometric analysis of CD62E 
expression in cells treated with TNFα (25pg/ml). D: Flow cytometric analysis of 
CD62E expression in NCI-H1299, SEBTA-001, SEBTA-005, A549 and COR-
L105. N=3, ***p<0.0001, **p<0.001, *p<0.01. 
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3.3 CD15 and CD62E mediate adhesion of NSCLC to hCMEC/D3 monolayer under 
static conditions 
We first wanted to determine if the TNF-α increased CD62E in endothelial cells led to an 
increase in tumor cell adhesion. hCMEC/D3 cells were plated and treated with TNF-α or 
TNF-β for 18 hours, followed by several washes and addition of serum free media 
containing lung cancer cells pre-labeled with a green fluorescent dye (Cyto Tracker™).  
Following 90 minute incubation, co-cultures were washed and cells were lysed and 
evaluated for levels of fluorescence. hCMEC/D3 cells incubated with TNF-α resulted in a 
significant increase in NSCLC adhesion with the highest relative fluorescent units 
associated with the NCI-H1299 cells followed by the lung cancer cells (Figure 23A, 
p<0.001). There was no effect on adhesion when hCMEC/D3 cells were treated with TNF-
β (Figure 23A). To rule out that a change in viability via TNF-α may have contributed to 
this increase in adhesion, viability assays were conducted. There was no change in 
hCMEC/D3 cell viability following TNF-α treatment (Figure 24). However, hCMEC/D3 
cells treated with TNF-β demonstrated significantly less viability when measured over four 
days (Figure 24). The time course for the adhesion assay described above consisted of an 
18 hr incubation with TNF-α or TNF-β and then the cancer cell lines were added and 
allowed to adhere for 90 minutes. Therefore the change in cell viability seen with TNF-β at 
later time points would not have accounted for the lack of adhesion (Figure 23A).  In a 
separate method to evaluate adhesion, we used confocal image analysis. The same 
conditions used in the assay above were repeated except on coverslips and prepared for 
ICC. Semi-quantification of confocal images using Zeiss Zen software revealed that the 
metastatic cell lines NCI-H1299 cells were the most adherent, followed by metastatic cells 
(SEBTA-001 and SEBTA-005) and primary NSCLC cells (COR-L105 and A549) (Figure 
23B). These results suggest a strong correlation between CD15 expression and NSCLC 
cell adhesion. To determine whether CD15 plays a key role in NSCLC cell adhesion to 
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brain endothelial, an adhesion assay was conducted in the presence of CD15 antibodies or 
isotype (IgM) controls (Figure 23C). CD15 mAb-blocking significantly decreased 
metastatic (NCI-H1299, SEBTA-001 and SEBTA-005) and primary NSCLC (COR-L105 
and A549) adhesion compared to non-treated cells and cancer cells adhere on hCMEC/D3 
endothelial culture while, after CD15 blocking cells sit on the surface but are not attached. 
Furthermore, there was no significant change in adhesion of cancer cells due to blocking 
with non-specific Isotype (IgM) (p<0.0001) (Figure 23 C). In addition, there were no 
observed toxic effects of antibody incubation with the various cancer cell lines or the 
endothelial cell line (Figure 24).  
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Figure 23.  NSCLC adhesion to TNF-α treated brain endothelial cells and the effect CD15 
immunoblocking. A: Qualitative adhesion of NSCLC cells on human brain endothelial cell 
monolayer. Primary and metastatic NSCLC cancer cells were incubated for 90 minutes on 
a monolayer of activated hCMEC/D3 cells. Non-adherent cancer cells were washed away 
and adherent cells were lysed and quantified via a microplate reader at 480-520nm. N=3, 
P<0.0001=***. The results showed the strong effect of CD62E, once stimulated by TNF-α 
on lung tumour cells (red bars). Absence of TNF-α showed a significant decrease in cancer 
cells adhesion (white bars) (P<0.001=***). B: Confocal Images (Top panel) showing 
adhesion of green fluorescently labelled NSCLC cells on brain endothelial cell 
monolayer(blue) and semi-quantitation analysis of confocal images (lower panel) using 
Zeiss’s ZEN image showing a significant increase in NCI-H1299, SEBTA-001, and 
SEBTA-005 adhesion to TNF-α treated hCMEC/D3 cells. N=3, ***p<0.0001, **p<0.001, 
*p<0.01. 
Figure 23.  NSCLC adhesion to TNF-α treated brain endothelial cells 
and the effect CD15 immunoblocking 
125 
 
 
 
 
 
 
 
 
 
Figure 23C: Quantitative adhesion of human primary and metastatic NSCLC cells blocked 
with CD15 mAb (red bar) and with non-specific Isotype IgM (white bar) to assess CD15 
mAb-blocking efficiency and specificity. Adhesion of NSCLC cells on a monolayer of 
hCMEC/D3 (grey bar) act as a negative control. N=3, P<0.0001=***. 
 
 
 
 
 
 
Figure 24. CD15 mAb blocking effect on cell viability. Effect of CD15 mAb-blocking on 
hCMEC/D3 and NSCLC cell viability. There were no significant difference in cell viability 
in cells treated with CD15 mAb-blocking compared to non-treated cells. (N=3), 
p>0.05=ns. 
 
 
Figure 24: CD15 mAb blocking effect on cell viability 
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3.4 CD15 mAb-blocking decreases adhesion of NSCLC cells under shear stress 
To determine if the adhesion results obtained from static experiments would hold when 
experimental conditions were conducted under sheer stress, we used the Vena 8 
Endothelial+™ biochip and micro-pump (Cellix-Ireland) and conducted live cell 
microscopy to determine the effect of CD15 immunoblocking on dynamic adhesion of 
metastatic lung to brain cancer cells (SEBTA-001) over a 40 minute time range with a 
perfusion rate at 2.5 dyn/cm
2
 of fresh medium (Figure. 25A).  CD15 mAb-blocking was 
shown to decrease the number of adherent cancer cells on the brain endothelial cell 
monolayer lining the Vena 8 biochip channel compared to non-blocked cells (Figure. 25A, 
lower panel and side graph). The aggregation of the SEBTA-001 cells seen in Figure 25A 
(arrows) without immunoblocking suggests homophilic binding of CD15 on cancer cells as 
well as heterophilic binding between CD15 and CD62E. This is supported by confocal 
images of ICC performed on co-cultures of green fluorescently tagged metastatic cancer 
cells (SEBTA-001) adhering on a monolayer of activated brain endothelial cells (Figure. 
25B-C). Results showed prominent and condensed expression of CD15 on adherent cancer 
cell surface and cell processes (Figure. 25C arrows). Both CD15 and CD62E were also 
localized at the site of cancer cell-brain endothelial cell adhesion and CD62E was seen 
distributed on the activated endothelial cells and co-localised with CD15 supporting 
heterophilic adhesion sites between cancer cells and brain endothelial cells (Figure. 5C 
arrows). To confirm CD15 and CD62E localisation at the site of adhesion, three-
dimensional confocal images created from z-stacks (Figure. 5D) was analysed in culturing 
SEBTA-001 on a monolayer of endothelial cells.  
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Figure 25. CD15 mAb-blocking reduces adhesion of NSCLC cells under dynamic 
conditions. A: A dynamic cell adhesion assay was carried out on highly brain metastatic 
cells (SEBTA-001) using an AxioVert 200M microscope (C.Zeiss, UK) within an 
environmentally-controlled incubator. SEBTA-001 cells were incubated with isotype 
control (IgM) or CD15 mAb followed by perfusion of 1x10
6
 cells over a monolayer of 
hCMEC/D3 cells at 2.5 dyn/cm
2
 for 40 minutes. Phase contrast and fluorescent images 
were acquired at real-time every 10mins with a X5 objective using Volocity software. 
Scale bar=20μm. Right panel: Representation of (left panel) in relative fluorescent units 
of SEBTA-001 cell adhesion with and without CD15 mAb for 10, 20, 30 and 40 minute 
time points. 
 
 
Figure 25. CD15 mAb-blocking reduces adhesion of NSCLC cells under 
dynamic conditions. 
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Figure 25. B-D: Confocal images of green-fluorescently labelled adherent brain to lung 
metastatic cancer (SEBT-001) cells cultured on a monolayer of hCMEC/D3 cells (blue). B: 
CD15 expression (red) on the edges of SEBT-001 (green). ICC images showed expression 
of CD15 (red) on the adherent cancer cells (green) on a monolayer of human brain 
endothelial cells stained with Hoechst blue C: The merged image showed expression of 
CD15 (red) on adherent tumour cells (SEBTA-001) (green) on an activated monolayer of 
human brain endothelial cells (blue) expressing CD62E (purple) D: Optical sections of 
three-dimensional confocal image created from z-stack. The top and lower view represents 
one image/different angles through the z-stack showing an adherent SEBTA-001 
expressing CD15 (purple) on an activated monolayer of brain endothelial cells expressing 
CD62E (red). Right side view represents an optical section through the depicted z-stack 
shows the precise interaction between CD15 and CD62E during NSCLC-brain 
endothelium cell adhesion. 
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3.5 CD15 and CD62E expression in human biopsy of lung to brain metastasis  
Immunohistochemistry on paraffin embedded formalin fixed tissue sections of human lung 
metastasis to brain biopsies using antibodies to both CD15 and CD62E was conducted 
(Supplemental figure 3). Both CD15 and CD62E positive cells could be seen throughout 
the tumor core whereas in adult normal brain cortex neither was detected. In patient 1 there 
was an area of host tumor interface where CD15 positive cells were detected within 
vessels, and in the same patient CD62E was associated with endothelial cells lining the 
vessels.  
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Figure 26. CD15 and CD62E immunohistochemistry in human derived biopsy tissue. 
Representative images from 3 patient derived lung to brain metastasis, 1 control human 
brain and 1 human Hodgkin lymphoma (Reed-Sternberg cells) as a positive control for 
CD15 staining. Both CD15 and CD62E expression was detected in tumor core in all 
metastatic cases examined (n=5). In one case (patient 1) an area of host tumor interface 
was examined as seen in the top panel. CD15 positive cells were detected in host brain 
tissue and associated with blood vessels and CD62E staining associated with the lining of 
capillaries. Biopsies from metastatic brain lesions were obtained from frontal lobe (patient 
1-2) and parietal lobe (patient 3). Images were obtained using an Ariol microscope (Leica, 
Germany) at x40 magnification 
Figure 26: CD15 and CD62E immunohistochemistry in human derived 
biopsy tissue 
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3.6 CD15s-CD62E interaction mediates the adhesion of non-small cell lung cancer 
cells on brain endothelial cells during metastasis to the brain.  
 
CD15s (SLe
x
) is a tetra-polysaccharide cell-cell adhesion molecule, it acts as a ligand for 
E-selectin and P-selectin (Polley et al., 1991) and involved in adhesion of cancer cells to 
endothelial cells (Vestweber and Blanks 1998, Giavazzi et al., 1993, Kitayama et al., 2000
 
; Burdick et al., 2003). It mediates the initial steps of tethering and rolling of white blood 
cells during WBC homing process. The circulating cells head to the site of injury by initial 
binding between CD15s and E-selectin (Munro 1993; Aruffo and Glycosci 1994). Burdick 
et al.,(2003) highlighted that metastatic colon adenocarcinoma cells adhere to human 
umbilical vein endothelial cells (HUVECs), through CD15s-glycolipids and CD15s-
glycoproteins which bind to E-selectin. Wang et al., (2003) reported that CD15s 
expression is associated with malignancy of human non-small pulmonary cancer (NSCPC) 
and human primary liver cancer (PLC) tissue while they are not expressed in the adjacent 
non-malignant tissue. Moreover, Ikeda et al.,(1996) showed that CD15s is expressed in 
60% of patients with primary lesions of gastric cancer and in 51% of patients with 
advanced primary gastric tumour and metastatic lymph nodes. It is further reported that 
expression of CD15s may be used as a marker for the early diagnosis of cervical cancer 
(Nakagoe et al., 2002). Very little is however, known about CD15s in the CNS but we 
have  recently reported that overexpression of CD15s is seen to be correlated with cell 
arrest in G1 phase of cell cycle in glioblastoma cells (GBM) and metastatic lung to brain 
cancer cells (Jassam et al., 2015b). This part of the project indicates the important role of 
CD15s/E-selectin heterophilic interaction, in cancer cell adhesion. Also, the study reveals 
that CD15s may play a crucial role in homing process of NSCLC cells during brain 
metastasis. 
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3.7 Characterisation of CD15s in brain endothelium and NSCLC cultured cells 
Localisation and extracellular expression of CD15s were characterised in human brain 
endothelial cells as well as primary and metastatic NSCLC cells via ICC, WB and flow 
cytometry analysis. CD15s was localised and prominently expressed on the surface of 
brain metastatic lung cancer cells (SEBTA-001 and NCI-H1299). Lower levels of 
expression were seen on the surface of brain endothelial cells and on primary lung cancer 
cells (COR-L105 and A549) compared with the isotype control (Figure 27A). Semi-
qualitative Western blotting analysis showed intense immunopositive bands in the 
metastatic cells while less intensity was observed in primary cancer cells and endothelial 
cell membrane extracts (Figure 27B). Qualitative analysis of flow cytometry showed 
highest levels of CD15s positivity were observed in metastatic lung cancer cells: NCI-
H1299 (39% positive) and SEBTA-001 (35% positive). Lower level was seen in brain 
endothelial cells (25% positive) followed by the primary lung cancer cells: COR-L105 
(21% positive) and A549 (18% positive), (Figure 27C and D).       
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Figure 27. Expression of CD15s in brain endothelial and lung cancer cell lines. A 
:Representative ICC images showing CD15s in hCMEC/D3, NCI-H1299, SEBTA-001, 
A549 and COR-L105 B: Western blot analysis of CD15s of proteins from the cell lines 
showed highest CD15s expression in NCI-H1299 and SEBTA-001 followed by 
hCMEC/D3, COR-L105 and A549. ABCE1 was used as a protein loading control.C: 
Representative flow cytometric histogram and D: Quantitative flow cytometric analysis of 
CD15s expression on hCMEC/D3, NCI-H1299, SEBTA-001, COR-L105 and A549. 
CD15s was overexpressed in NCI-H1299 and SEBTA-001 with less expression in 
hCMEC/D3, COR-L105 and A549. N=3, ***P<0.001, **P<0.01 and *P<0.05.  
 
 
 
 
Figure 27: Expression of CD15s in brain endothelial and NSCLC cells 
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3.8 Interrupting CD15s-CD62E interaction reduces the adhesion of cancer cell-brain 
endothelium   
To explore the role of CD62E in adhesion of NSCLC cell-brain endothelium we conducted 
a qualitative and quantitative adhesion assays under static conditions using a confocal 
microscopy and microplate reader to assess the relative number of adherent NSCLC cells. 
CD62E expression was activated by TNF-α (25pg/mL) and then green fluorescently tagged 
NSCLC were applied onto activated and non-activated brain endothelia cells. Findings 
showed that absence of CD62E (non-activated cells) significantly reduced the adhesion of 
all cancer cells (P<0.001), (Figure 28A and B) compared with the high numbers of 
adherent cells on the activated brain endothelial cells that expressing CD62E. These results 
suggested that CD62E and TNF-α have a key role in adhesion of NSCLC during seeding 
into the brain. 
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Figure 28. Role of CD62E in adhesion of NSCLC cells-brain endothelium. A:Qualitative 
adhesion of NSCLC cells onto brain endothelium monolayer were grown on glass 
coverslips, green fluorescent NSCLC cells were applied onto a monolayer of hCMEC/D3 
cells and incubated for 90 minutes with and without activation via TNF-α, non-adherent 
cells were washed out and co-cultures were fixed and examined by confocal microscope. 
B: A Quantitative adhesion of NSCLC cells were conducted to verify the quantitative 
results, hCMEC/D3 cells were seeded into 96-well plate, then green fluorescent tagged 
NSCLC cells were applied on the hCMEC/D3 monolayer, after 90 minutes incubation the 
non-adherent cells were washed out and adherent cells were lysed followed by 
quantification via microplate reader at 480-520nm. Results showed a strong reduction 
caused by absence of TNF-α (White bar) compared to TNF- α stimuli. N=3, ***P<0.001, 
**P<0.01 and *P<0.05. Scale bar=20µm 
 
 
 
Figure 28: Role of CD62E in adhesion of NSCLC cells-brain 
endothelium  
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3.9 Immunoblocking of CD15s reduced the adhesion of cancer cell-brain endothelium 
under static conditions    
A qualitative adhesion assay under static conditions was performed using a confocal 
microscopy and a quantitative assay via a plate reader to assess the role of CD15s in 
adhesion. Results showed that metastatic cancer cells (NCI-H1299 and SEBTA-001) were 
more adherent than the primary lung cancer cells (COR-L105 and A549) (Figure 29 A and 
B) and immunoblocking of CD15s was significantly (P<0.001) reduced the relative 
number of adherent cancer cells onto an activated brain endothelial cell monolayer. These 
results suggested a correlation between the expression of CD15s and adhesion of lung 
cancer cells (Figure 29 A). In addition, mAb-immunoblocking against CD15s reduced the 
adhesion ability of cancer cells compared to the adhesion ability of cancer cells without 
mAb-CD15s immunoblocking. However, no reduction in adhesion was detected during 
blocking with non-specific isotype (IgM) monoclonal antibodies; these results assessed the 
specificity of mAb-CD15s blocking and validated the correlation of CD15s and adhesion 
ability of cancer cells under static conditions (Figure 29B).       
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Figure 29 A: CD15s immunoblocking reduced the adhesion of lung cancer cells under 
static conditions.  Confocal images (top panel) showing adhesion of green fluorescently 
labelled NSCLCs on a brain endothelial cell monolayer (blue) and Semi-quantitative 
analysis of confocal images (lower panel) show a significant decrease in adhesion ability 
of NSCLC cells to adhere to hCMEC/D3 cells. N = 3, ***P<0.001, **P<0.01, *P<0.05. 
Scale bar=20µm. In a previous study the optimal concentration of TNF-α was optimised 
(Jassam et al., 2015)
 5
 the same concentration of TNF-α was used to activate the expression 
of CD62E on brain endothelial cells. Brain endothelial cells (hCMEC/D3) were exposed to 
25 pg/mL of TNF-α for 18 hours and levels of CD62E were detected using flow cytometry 
(Data not shown). 
 
 
 
 
 
 
 
 
Figure 29 A: CD15s immunoblocking reduced the adhesion of 
lung cancer cells under static conditions. 
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Figure 29. B: Blocking with CD15s mAb significantly reduced the adhesion of NSCLC to 
brain endothelium. Quantitative adhesion assay of human primary and metastatic lung 
cancer (NSCLC) cells blocked with CD15s mAb (blue bar), non-specific isotype IgM 
(white bar) to assess the efficiency and specificity of CD15s mAb-blocking efficiency and 
NSCLC cells on a monolayer of hCMEC/D3 (grey bar) as a negative control. N= 3, 
***P<0.001.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29 B: Blocking with CD15s mAb significantly reduced 
the adhesion of NSCLC to brain endothelium 
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3.10 CD15s mAb blocking decreases adhesion of NSCLC cells under shear stress 
condition  
 
To examine whether CD15s plays a role in adhesion of cancer cells under physiological 
shear stress (blood flow) as well as its role under static conditions, an activated endothelial 
monolayer was allowed to grow on a Vena8 endothelial+ biochip and green fluorescent 
tagged NSCLC cells were perfused onto the endothelial monolayer via a micropump 
(Cellix). Live cell microscopy was then conducted to monitor the effect of CD15s 
immunoblocking on the adhesion cancer cells. Highly metastatic lung to brain cancer cell 
line (SEBTA-001) was perfused at a rate of 2.5 dyn/cm
2 
with warmed fresh EBM+EGM2 
medium supplemented with 2% of human serum and 25pg/mL TNF-α.  
Cells adhesion was then studied over a 40-minute time range. Results showed that SEBTA-
001 cells started to adhere onto activated endothelial monolayer where no CD15s 
immunoblocking and the number of adherent cells was increased in a time dependent 
manner (Figure 30). In parallel, same number of SEBTA-001 cells (previously incubated 
with mAb-CD15s for 10 minutes) were perfused and this time with mAb-CD15s the cancer 
cells were seen to stay in a suspension rather than adhering on the endothelial cells as 
observed in the non-blocked well (Figure 30). These findings confirmed the key role of 
CD15s in adhesion of lung cancer cells on the brain endothelial cells under physiological 
shear stress conditions.            
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Figure 30.  Immunoblocking with CD15s mAb significantly decreased the adhesion ability 
of NSCLC under dynamic conditions (2.5 dyn/cm
2
). A dynamic cell adhesion assay was 
carried out on highly metastatic brain cells (SEBTA-001) using an AxioVert 200 M 
microscope (C. Zeiss). Top panel: cancer cells were incubated with isotype control (IgM) 
or CD15 mAb, followed by perfusion of 1×10
6
 cancer cells over a monolayer of 
hCMEC/D3 cells at 2.5 dyn/cm2 for 40 minutes. Phase contrast and fluorescent images 
were acquired at real time every 10 minutes with an X5 objective using Volocity software. 
Scale bar= 20 µm. Lower panel: results in relative fluorescent units of adherent cancer 
cells with and without CD15 mAb for 10, 20, 30, and 40 minute time points are given in 
the lower graph.  
 
 
 
 
Figure 30.  Immunoblocking with CD15s mAb significantly decreased 
the adhesion ability of NSCLC under dynamic conditions (2.5 dyn/cm
2
). 
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3.11 CD15s expression was localised at the adhesion sites of cancer cell-brain 
endothelium  
Finally, we conducted a microscopic study on a co-culture of adherent cancer cell 
(SEBTA-001) onto a monolayer of brain endothelial cells. The cancer cells were left to 
adhere and the co-culture was fixed before immunocytochemistry was performed against 
CD15s and CD62E. Results showed a prominent expression of CD15s was seen on the 
surface of green fluorescently tagged cancer cells (red) with accumulation on the 
surrounding outer edges and processes of the adherent cancer cells (Figure 31 A), Also, 
CD15s and CD62E were both co-localised at the site of NSCLC cell adhesion where 
CD15s (red) was seen to be expressed on green-tagged cancer cells and CD62E (purple) 
was observed on the surface of the activated brain endothelial cells at the site of the 
adhesion (Figure 31 B). These images assessed the involvement of CD15s-CD62E 
interaction in adhesion process of NSCLC cells onto brain endothelium.   
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Figure 31. Localisation of CD15s on the surface of adherent SEBTA-001 cells at the site of 
adhesion. Confocal image of green fluorescently-labelled adherent brain to lung metastatic 
cancer cells (SEBTA-001) on a monolayer of activated hCMEC/D3 cells (blue). A: 
Expression of CD15s (red) (white arrows) was seen on the edges of adherent cells SEBT-
001(green) at the site of adhesion on brain endothelial cells. B: Expression of CD15s (red) 
(white arrows) was observed on surface of adherent cancer cells SEBT-001(green) and 
CD62E (purple) (white arrows) was seen on the monolayer of activated brain endothelial 
cells (hCMEC/D3) at adhesion site of cancer cell-brain endothelium. Scale bar=20µm.  
 
 
 
Figure 31. Localisation of CD15s on the surface of adherent 
SEBTA-001 cells at the site of adhesion. 
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3.12 CD15s expression in human biopsy of lung to brain metastasis  
We showed that in vitro that CD15s and CD62E are expressed on the NSCLC and brain 
endothelium respectively. In addition, we showed their functional role in adhesion of 
NSCLC cell-brain endothelium in vitro. Then we wanted to explore if it is the same case in 
vivo; thus, paraffin embedded of formalin fixed tissue sections of human lung to brain 
metastatic tumour biopsy and healthy brain tissue section were immune-stained against 
CD15s and CD62E. Immunohistochemistry results showed that CD15s was expressed in 
brain metastatic tumour section, CD15s positive cells were seen throughout the tumour 
core and in the distant local lesions also, there was an area of host tumour interface where 
CD15s positive cells were detected within vessels. Whereas, no CD15s expression was 
noted in the non-malignant adjacent host brain tissue, as well as, CD15s was not seen in 
human healthy normal brain tissue section. In the same biopsy CD62E was observed to be 
expressed on the inner lining endothelial cells of the brain microvessels, however no 
expression were detected in the healthy normal brain section. Again, these in vivo results 
pointed to the importance of CD15s and CD62E in brain metastasis (Figure 32).  
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Figure 32. CD15s and CD62E immunohistochemistry in human derived biopsy tissue. 
Representative Immunohistochemistry images from one patient with lung-brain metastasis. 
CD15s was detected in tumour core and infiltrated into non-neoplastic host brain tissue. 
Images were obtained using an Ariol microscope (Leica) at x20 and x40 magnification. 
Scale bar=20µm. 
 
 
 
 
 
 
Figure 32 : CD15s and CD62E immunohistochemistry in human derived 
biopsy tissue 
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3.13 Discussion 
3.13.1 Role of CD15-CD62E interaction in adhesion of NSCLC-brain endothelium  
Three quarters of brain tumors are metastatic cancers originating from primaries in distant 
organs; the brain is known to be key target of secondary NSCLC, 20-40% of lung cancer 
patients develop oligo- or multiple- brain metastasis during their illness (Ali et al., 2013).
 
 
Metastasis to the brain is a complicated multi-step process requiring interaction between 
metastatic cancer cells and target environment. However, these interactions are not yet 
fully understood, particularly the adhesion of cancer cell on brain endothelium in early 
stages of entry into the brain. CD15 is cell adhesion fucosylated carbohydrate, expressed 
on leucocytes
 
and various types of non-CNS cancer cells (Gout et al., 2006) but rarely 
expressed in human brain (Pilkington et al., 1998). Moreover, CD15 overexpression has 
been correlated with a progression to metastatic stage. Indeed, significant correlation exists 
between CD15 overexpression and colorectal cancer metastasis, through prominent CD15 
expression on the invading edges of cancer lesions (Gout et al., 2006). CD15 is involved in 
the extravasation process through its interaction with selectins particularly E-selectin 
(CD62E), a glycosylated transmembrane and cellular adhesion molecule crucial for 
homing of circulating cells through its expression on endothelial cells (Gout et al., 2006) 
CD62E facilitates cancer cell adhesion to endothelial cells in various cancers such as, 
colon (Gout et al., 2006), breast (Lafrenie et al., 1994) and lung (Martin-Satue et al., 1998) 
Here we hypothesized that CD15 and CD62E interaction is involved in cancer cell 
adhesion during metastasis to the brain. Previous studies have shown that human bone 
marrow microvascular endothelial cells play an important role in metastasis to the brain via 
interaction between CD62E on endothelial cells and its ligands on metastatic neoplasms 
(Fazakas et al., 2011). However, most studies have used non-specialized experimental 
conditions such as human cells cultured in fetal calf serum, using non-specific medium and 
using non-brain derived endothelium. In our study, we used 2% human serum and medium 
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supplemented with specific growth factors for each cell line to maintain cell differentiation 
and characteristics.
43  
We used human brain endothelial cells (hCMEC/D3) established 
from temporal lobe microvessels from an  epileptic patient then immortalised by 
introducing human telomerase or SV40 T antigen employing lentiviral vectors (Kiem et 
al., 2009). Previously, HUVECs have been used to study metastasis to the brain (Martin-
Satue et al., 1998) however; functional differences were demonstrated between leukocyte 
adhesion on HUVECs and on brain derived endothelium (Rizzo et al., 2014 and Man et al., 
2008). In the present study, CD15 was overexpressed on metastatic NSCLC cell 
membranes (NCI-H1299, SEBTA-001 and SEBTA-005); while there was a lower 
expression on primary NSCLC cells (COR-L105 and A549). Moreover, CD15 was 
characterised on SEBTA-001 and SEBTA-005 (established in house metastatic NSCLC 
cell lines obtained from brain). CD62E, the natural ligand for CD15 was upregulated on 
brain endothelial cells (hCMEC/D3) and cancer cells in response to a TNF-α inflammatory 
stimulus, Also CD62E was expressed on the lung cancer cells, which is expected as they 
are carcinoma cells (epithelial origin); and that may suggest CD62E as a possible 
therapeutic target. Both mAb-blocking of CD15 and absence of CD62E/TNF-α correlated 
with significantly decreased adhesion of cancer cells on brain endothelium. Confocal 
microscopy revealed the expression of CD15 around adherent cancer cells and to localize 
CD15/CD62E interaction at adhesion sites of cancer cells/brain endothelial cells; these 
findings suggests that CD15 and CD62E play important roles in adhesion of NSCLC cells 
to brain endothelium in static conditions. We then explored the possible effects of vascular 
blood flow by combining live cell imaging and shear stress fluidics twinned with CD15 
mAb-blocking under TNF-α immune stimulus using in vitro model developed from human 
cell cultures maintained in a specialized environment to mimic in vivo environment inside 
blood brain microvessels. For this a microfluidic chip (Vena8-Cellix) was used with low 
shear stress 2.5 dyn/cm
2 
and volumetric Flow Rates 10mL/hr mimicking the low flow in 
brain microvessels (Mintun et al., 2001). Under these conditions, adhesion of cancer cells 
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was significantly decreased by absence of CD15 or CD62E/TNF-α, suggesting the critical 
role of CD15 and CD62E/ TNF-α in cancer cell adhesion during early stages of cancer cell 
extravasation. While in vivo data are lacking for NSCLC, a recent study reinforced the 
importance of CD62E in breast to brain metastasis in mice, by showing that the adhesion 
of breast cancer cells to brain endothelial cells was enhanced by the presence of VCAM-
1/VLA-4, ALCAM-1and (Soto et al., 2014). Our in vitro study has also shed light on the 
functional characterization and localization of CD15 and CD62E on the site of NSCLC 
seeding to the brain. CD15 expression levels correlated with the adhesion of cancer cells to 
stimulated brain microvascular endothelial cells. NSCLC metastatic cells obtained from 
brain lesions (SEBTA-001 and SEBTA-005) were more adhesive than the primary NSCLC 
cells (COR-L105 and A549). These results are consistent with previous studies that 
referred to the correlation between elevated level of CD15 and metastasis in different types 
of non-CNS cancer (Nolte et al., 2013 and Fazakas et al., 2011). CD15 mAb-blocking 
resulted in a decrease in the number of adherent cells on stimulated brain microvascular 
endothelium (hCMEC/D3) under both static and dynamic conditions. Thus, this study 
indicates CD15 as a possible target for prevention of brain metastasis in NSCLC patients. 
While this in vitro experimental model adds to our knowledge of metastatic cell adherence 
to brain endothelium, there are limitations in that it does not include other cell types that 
are known to be present. For example, the influence of circulating neutrophils in brain 
metastases and their role in this process is not known and is currently under investigation. 
Although little is known concerning the histopathology of CD15 expression in CNS 
tumours (Reifenberger et al., 1992) and human lung cancer to brain metastasis, there have 
been reports of CD15 expression in NSCLC and more recently associations with lung 
cancer stem-like cells. A more rigorous characterization of CD15 in human lung cancer to 
brain derived biopsy is now in progress. 
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3.13.2 Role of CD15s-CD62E interaction in adhesion of NSCLC-brain endothelium  
Brain metastasis is a complicated, multi-step process, despite its great clinical importance, 
the underlining molecular mechanisms are still not fully understood. Heretofore, the 
highest rate of brain metastases are originated from lung primaries and 20-40% of non-
small cell lung cancer (NSCLC) patients develop a brain metastasis at or within a short 
period of primary tumour diagnosis (Ali et al., 2013). Metastasis to the brain requires a 
well communication between the metastatic cells and its microenvironment, circulating 
cancer cells have to go through tethering, rolling, adhesion and transmigration during 
seeding into the brain. Although, not much known about the molecular bases of these 
interactions particularly, the adhesion process of cancer cell-brain endothelium. CD15s is a 
tetrasaccharide cell-cell adhesion and cell recognition molecule (Haselhorst et al., 2001), it 
is involved in adhesion of lymphocyte during homing process (Turunen et al., 1994). 
CD15s overexpression was reported to be correlated with distance metastasis in lung 
patients (Fukuoka et al., 1998). As well as in colorectal metastatic cancer (Nakamori et al., 
1997) and liver metastasis where, CD15s inaction with selectins mediate adhesion of 
cancer cells onto liver endothelium (Izumi et al., 1995). In addition, elevated levels of 
CD15s were revealed to be associated with metastasis in head and neck cancer (Renkonen 
et al., 1999). Our study showed that CD15s was expressed on cell surface of brain 
endothelial cells (hCMEC/D3), primary NSCLC cells (A549 and COR-L105) and the 
highest levels of expression was observed on the metastatic NSCLC obtained from cervical 
lymphnode (NCI-H1299) and metastatic NSCLC obtained from the brain (SEBTA-001) 
(Figure 1), these results agreed with Fukuoka et al., 1998  findings who, revealed that 
CD15s high expression was correlated with the metastasis of lung carcinoma. Same 
findings were shown by Kadota et al., 1999 suggesting CD15s correlation with distant 
metastatic lesions in lung carcinoma. Recently, elevated level of CD15s was revealed to be 
used as an independent marker to predict NSCLC patients at the metastasis stage (Komatsu 
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et al., 2013). Although, not much known about CD15s expression in CNS malignancies. 
However, we have shown in a previous study that CD15s overexpression was cell cycle 
dependent in high grade glioblastoma cells as well as in metastatic brain tumour cells 
originated from lung (Jassam et al., 2015b). It has been shown that brain endothelial cells 
play a key role in metastasis to the brain (Soto et al., 2014). In our study, we have used an 
adult human brain microvascular endothelial cell line (hCMEC/D3) established from 
microvessels of temporal lobe obtained from epileptic patient, these cells were successfully 
immortalised by transfection with lentiviral vector with human telomerase (SV40T 
antigen)(Hatherell et al., 2010), hCMEC/D3 was used as a BBB in vitro model; in previous 
study we have optimised the extracellular expression of CD26E which was enhanced by 
25pg/mL of TNF-α (Jassam et al., 2015b). hCMEC/D3 cells were grown and maintained in 
highly specialised medium supplemented with all essential factors and cytokines to 
maintain hCMEC/D3 original cellular characteristics in addition to, all the studied cells 
were maintained in medium supplemented with human serum to avoid any possible 
functional changes enhanced by bovine serum (Murray 2010). However, non-CNS 
endothelial cells such as HUVECs were used to study metastasis to the brain (Martin-Satue 
et al., 1998), Also, a functional differences were noted in adhesion of leukocytes on brain 
endothelial cells and adhesion on umbilical vein endothelial cells (Man et al., 2008). The 
importance of CD15s in cell-cell adhesion is due to its ability to interact with endothelial 
adhesion molecule as E-selectin (CD62E), as in lymphocytes homing process (Munro et 
al., 1992). Interestingly, our findings showed a correlation between expression of CD15s 
and adhesion ability, less adherent cells were noted in primary lung cancer cells (COR-
L105 and A549) compared to a high number in metastatic cells (NCI-H1299, SEBTA-01 
and SEBTA-005). A significant reduction in NSCLC adherent cells was caused by the 
absence of CD62E where, adhesion assay was conducted without TNF-α stimuli; Earlier 
study has shown the involvement of CD15s-CD62E interaction in metastasis in different 
non-CNS and revealed that entrapping the interaction between CD15s and CD62E largely 
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reduced the adhesion of lung carcinoma, colon and macrophages (Zeisig et al., 2004). We 
found a significant reduction (p<0.01) in adhesion of lung cancer cells was caused by 
blocking with monoclonal antibodies against CD15s. These results suggest that both 
CD15s and CD62E play an important role in adhesion of cancer cell onto brain 
endothelium under static conditions. We then moved to study whether blocking of CD15s 
reduces the adhesion of cancer cells under flow. Thus, we conducted live cell imaging of 
cell-cell adhesion under shear stress at perfusion rate 2.5 dyn/cm
2 
and volumetric flow rate 
10mL/hr resembling the blood flow in human brain microvascular system (Mintun et al., 
2001). Using highly metastatic NSCLC cells obtained from brain (SEBTA-001), results 
showed that blocking with antibodies against CD15s (reduced cells adhesion compared 
with non-blocked cells. Microscopic study showed a localisation of CD15s surrounding the 
adherent cells and co-localisation of CD15s/CD62E was seen at the site of adhesion of 
metastatic lung cancer cells (SEBTA-001) onto brain endothelial cells, these findings 
suggesting CD15s and CD62E play a key role in lung cancer cell adhesion. In addition, 
CD15s were seen to be expressed in human tissue section of metastatic lung to brain 
tumour. While, no CD15s was detected in the healthy brain tissue section. Although, not 
much known about in vivo and in vitro characterisation of CD15s expression in human 
CNS however, a single study revealed that CD15s was not expressed in any type of normal 
brain cells apart from microglia (Satoh and Kim,1994). The recent study showed a highly 
specialised in vitro experimental model to study cell-cell adhesion of cancer cells during 
lung-brain metastasis and added new findings regarding CD15s expression in human brain.     
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CHAPTER FOUR  
The role of CD15 and CD15s on transendothelial migration of 
NSCLC cells 
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4.1 The role of CD15 and CD15s on transendothelial migration of NSCLC cancer 
cells. 
 
The highest incidence of brain metastasis is seen in lung cancer patients (40-50%) 
followed by breast (20-30%) and melanoma (5-10%) (Wen and Loeffler, 2000). Metastasis 
to the brain is considered to be the cause of 95% of cancer related deaths (Denkins 2004  
and Sloan 2009). The BBB is a selective defensive barrier which maintains a highly 
specific environment within the CNS by inhibiting both fluctuations of plasma components 
as well as providing entry of substances that may potentially cause brain toxicity (Abbott et 
al., 2006  and Hatherell et al., 2011). The BBB is composed of endothelial cells, a 
basement membrane, pericytes and endfeet of astrocytes which form the neurovascular unit 
(Abbott et al., 2006). Endothelial cells of the BBB are specific to the BBB and on low 
pinocytosis and no fenestrations (Kis et al., 2006). It has been reported that endothelial 
cells have a crucial role in the homing process of brain metastasis from breast cancer (Soto 
et al., 2014) and melanoma (Fazakas et al., 2011). The cancer cell adhesion and 
transmigration processes are achieved through the interaction of metastatic cancer cells and 
the luminal surface of brain endothelial cells (Fazakas et al., 2011; Soto et al., 2014 and 
Jassam et al., 2015).   CD15 and CD15s (sialyl CD15) are cell adhesion molecules, which 
have been shown to play a role in non-CNS cancer metastasis. CD15 is correlated with 
adhesion in lung cancer, by homophilic binding with CD15, which is expressed on 
endothelial cells and heterophilicly with other cell adhesion molecules such as the selectins 
(Martin et al., 1995, Brooks and Leathem, 1995, Jassam et al., 2015). CD15s is also a 
ligand for E-selectin and P-selectin (Polley et al., 1991) and is involved in adhesion 
process between cancer and endothelial cells (Giavazzi et al., 1993, Paschos et al., 2010). 
CD15s also mediates the initial tethering and rolling of white blood cells (WBCs) during 
homing process (Mondal et al., 2015). Despite the clinical importance of metastasis from 
lung to the brain, little is known concerning the interaction of NSCLC cell with brain 
endothelial cells. Although non-leukocyte-like mechanisms have been suggested in the 
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extravasation process of some cancer cells (Miles et al., 2008 and Martinez et al., 2013), 
the transmigration of cancer cells particularly to the brain has not been thoroughly 
investigated. It has been reported that melanoma cells are able to cross the endothelial cell 
monolayer as determined by measuring the transendothelial electric resistance (TEER) 
values which is an indicator of BBB functioning (Fazakas et al., 2011). Indeed long term 
co-culture of melanoma and brain endothelial cells shows a significant increase in 
permeability of the endothelial monolayer, as indicated by a discontinuous staining of both 
tight junction protein (ZO-1) as well as claudin and in the formation of ruptures in the 
endothelial monolayer (reviewed by Wilhelm et al., 2013).    
This part of the project sheds light on the role of CD15 and CD15s in adhesion and 
transendothelial migration ability of NSCLC. Our findings suggest that overexpression of 
CD15 and CD15s increase the adhesion and transmigration of NSCLC cells during 
metastasis into the brain.    
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4.2 A strong correlation between genetic manipulation of FUT4 regulation and CD15 
expression  
Four different cell lines: SEBTA-001, NCI-H1299, COR-L105 and UP-007 were 
transfected with either a full-length FUT4-GFP for CD15-overexpression or four FUT4 
unique 29 mer shRNA constructs for CD15-knowckdown. CD15 expression in transfected 
cells with FUT4 cDNA was increased while, no CD15 expression was noticed on cells that 
treated with FUT4-shRNA. This was measured using immunocytochemistry, Western 
blotting and flow cytometry analysis (Figure 32 A, B and C). Results showed prominent 
bands between 110-95 kDa suggesting that overexpression of CD15 following transfection 
with FUT4 cDNA in SEBTA-001, NCI-H1299, COR-L105 and UP-007 cells, nearly the 
same amount of CD15 expression was seen in the wild type and cells that transfected with 
the vehicle control. Faint and weak bands were noted post transfection with shDNA of 
FUT4, which revealed that FUT4-knockdown decreased the expression of CD15 
downstream (Figure 32B). Flow cytometry results were consistent and showed similar 
trends in overexpression and knockdown, transfection of the FUT4 resulted in a significant 
increase (p<0.001) in CD15 expression in all cell lines (SEBTA-001, NCI-H1299, COR-
L105 and UP-007) (Figure 32C). In SEBTA-001 CD15 increased from 54.7% to 92%, in 
NCI-H1299 increased from 76% to 90%, in COR-L105 increased from 23% to 89% and in 
UP-007 the increase was from 13.4% to 84% (Figure 32C, blue versus green). shRNA 
knockdown of FUT4 resulted in a significant decrease (p<0.001) in CD15 expression  
where SEBTA-001 showed only 9% positivity, in NCI-H1299 decreased to 8%, in COR-
L105 decreased to 14% and to 6% in UP-007 cells (Figure 32C), (blue versus red). The 
findings revealed that genetic manipulation of FUT4 directly affected the expression of 
CD15 downstream. However, western blot results were not matching the flow cytometry 
results, and that may be caused by the protein precipitation in western blotting, which 
normally has no effect in flow cytometry analysis particularly, in cell membrane analysis.  
.   
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A 
Figure 32A: Localization of CD15 expression in FUT4-(cDNA and shRNA) transfected 
cells. Target cells (SEBTA-001, NCI-H1299, COR-L105 and UP-007) were transfected 
either with plasmids containing FUT4-cDNA to induce CD15 overexpression or four 
FUT4-shRNA constructs targeting FUT4 to inhibit the expression of CD15 downstream. 
Cells were grown on coverslips, fixed and extracellular immunostaining was performed to 
detect CD15 expression (red). All vectors were GFP. Scale bar=20μm. 
 
Figure 32A: Localization of CD15 expression in FUT4-(cDNA and shRNA) 
transfected cells 
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Figure 32B: Representative Western blots show the levels of CD15 expression on cell 
membrane lysates. Transfected cells were lysed and cell membrane was extracted then 
Western blot was performed. No treatment was applied to wild type controls and vehicle 
controls were transfected with non-coding plasmids. All vectors were tagged with GFP 
gene. 
 
 
 
 
 
 
SEBTA-001 NCI-H1299 
COR-L105 UP-007 
B 
Figure 32B: Representative Western blots show the levels of CD15 expression on 
cell membrane lysates 
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C 
Figure 32C: Representative flow cytometric analysis of CD15 expression in FUT4-
(cDNA and shRNA) transfected cells. The histograms show percentages of CD15 
positive cells in : wild type controls (blue) where no treatment applied, vehicle 
controls were transfected with non-coding plasmid (black), cells transfected with 
shRNA for FUT4 (red) and in cells transfection with cDNA for FUT4 (green). Data 
presented are mean±SE. Statistical significance is assessed by one-way ANOVA and 
Tukey’s post-hoc test, *(P<0.05), ** (P<0.01) difference compared to the wild type. 
Results are representative of three independent experiments carried out in triplicate. 
(N=3).  
 
 
Figure 32C: Representative flow cytometric analysis of CD15 
expression in FUT4-(cDNA and shRNA) transfected cells 
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4.3 A strong correlation between genetic manipulation of FUT7 regulation and CD15s 
expression  
CD15s expression was over expressed and knocked down by genetically manipulating the 
FUT7 in the following cell lines: SEBTA-001, NCI-H1299, COR-L105 and UP-007. ICC, 
Western blot and flow cytometry analysis were used to assess the expression of CD15s 
downstream. A prominent immunostaining of CD15s on the surface of the transfected cells 
with FUT7-cDNA. CD15s was evenly distributed across the cell body with intense staining 
on the edges of the cells, particularly at cell-cell junctions and adhesion sites. The absence 
of CD15s was noted in cells which were treated with FUT7-shRNA. All the transfected 
cells expressed GFP which confirmed the efficacy of transfection (Figure 33A). Western 
blotting results showed that bands between 180-100 kDa were identified suggesting that 
CD15s was highly expressed in cells which were transfected with FUT7-cDNA. Faint 
bands were noticed post-transfection with FUT7-shRNA indicating that knockdown had 
significantly decreased CD15s expression (Figure 33B). Results of flow cytometry analysis 
were consistent with ICC and WB results. CD15s expression was increased from 51% to 
88% in SEBTA-001, from 47% to 78% in NCI-H1299, from 26% to 53.8% in COR-L105 
and from 16.4% to 45% in UP-007 (Figure 33C) (blue line versus green line). Expression 
of CD15s was significantly decreased post-transfection with FUT4-shRNA in all the cell 
lines: in SEBTA-001 decreased to 12%, in NCI-H1299 decreased to 10%, COR-L105 
show 13.5% positive and UP-007 were 9.3%. The data show that genetic manipulation of 
FUT7 affects the expression of CD15s in the treated cell lines (Figure 33C). There is a 
slight difference between western blot results and flow cytometry, which may be related to 
the effect of cellular precipitated proteins in western blotting, which has no effect in flow 
cytometry analysis.    
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Figure 33A: Localization of CD15s expression in FUT7-(cDNA and shRNA) 
transfected cells. Target cells (SEBTA-001, NCI-H1299, COR-L105 and UP-007) 
were transfected either with plasmids containing FUT7-cDNA to induce CD15s 
overexpression or four FUT7-shRNA constructs targeting FUT7 to inhibit the 
expression of CD15s downstream. Cells were grown on coverslips, fixed and 
extracellular immunostaining was performed to detect CD15s expression (red). 
All vectors were GFP-tagged. Scale bar=20μm. 
 
Figure 33A: Localization of CD15s expression in FUT7-(cDNA and 
shRNA) transfected cells. 
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Figure 33B: Representative Western blots show expression of CD15s post-
transfection with (cDNA and shRNA)-FUT7. CD15s levels were confirmed using 
Western blotting and showed the effect of genetic manipulation of FUT7 on the 
expression of CD15s. ABCE1 protein was used as a loading control. No treatment 
was applied to wild type controls. Vehicle controls were transfected with non-coding 
plasmids.  
 
Figure 33B: Representative Western blots show expression of CD15s post-
transfection with (cDNA and shRNA)-FUT7. 
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Figure 33C: Representative flow cytometric analysis of CD15s expression in 
FUT7-(cDNA and shRNA) transfected cells. The histograms show percentages 
of CD15s positive cells in: wild type controls (blue) where no treatment 
applied, vehicle controls were transfected with non-coding plasmid (black), 
cells transfected with shRNA for FUT7 (red) and in cells transfection with 
cDNA for FUT7 (green). Data presented are mean±SE. Statistical significance 
assessed by one-way ANOVA and Tukey’s post-hoc test, *(P<0.05),** (P<0.01) 
difference compared to the wild type. Results are representative of three 
independent experiments carried out in triplicate. (N=3).  
 
Figure 33C: Representative flow cytometric analysis of CD15s expression in 
FUT7-(cDNA and shRNA) transfected cells. 
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4.4 CD15 expression correlates with cancer cell adhesion  
Following genetic manipulation of FUT4/CD15, cancer cell adhesion to a monolayer of 
human brain endothelial cells (hCMEC/D3) was investigated. In general, metastatic lung to 
brain cancer cells (SEBTA-001) and metastatic lung to lymph node cells (NCI-H1299) 
showed the highest number of adherent cells whereas lower adhesion was seen in primary 
lung cancer cells (COR-L105) and  GBM cells (UP-007) (Figure 34A). There was no 
statistical difference in adhesion potential which was observed in cells transfected with 
vehicle control in all cell lines. Following the overexpression of FUT4/CD15 in all the cell 
lines (SEBTA-001, NCI-H1299, COR-L105 and UP-007), a significant increase in 
adhesion (2 fold) was seen compared to the adhesion of wild type controls of the same cell 
line. Adhesion of cancer cells was significantly reduced following the knockdown of 
FUT7/CD15 and the number of adherent cells were less compared to the wild type 
(P<0.001) in all cell lines studied (SEBTA-001, NCI-H1299, COR-L105 and UP-007) 
(Figure 34 A) (blue versus green) . 
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Figure 34A: Quantitative adhesion of cancer cells following the genetic 
manipulation of FUT4/CD15. 
Figure 34 A. Quantitative adhesion of cancer cells following the genetic 
manipulation of FUT4/CD15. Adhesion of Primary (COR-L105), metastatic 
NSCLCs (SEBTA-001 and NCI-H1299) and GBM (UP-007) cells were assessed. 
Cancer cells were incubated for 90 minutes on a monolayer of activated brain 
endothelial cells (hCMEC/D3). Non-adherent cancer cells were washed off then 
cells were lysed and quantified via a microplate reader at 480–520 nm. Graphs 
show that cancer cell adhesion was significantly decreased following 
FUT4/CD15 knockdown (red bars). Overexpression of FUT4/CD15 increased 
adhesion of cancer cells (green bars) compared with wild type control, 
(**P<0.001). N= 3. 
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4.5 CD15s expression correlates with cancer cell adhesion  
 
After genetic manipulation of FUT7/CD15s, adhesion of cancer cells to brain endothelial 
cells (hCMEC/D3) was assessed. Metastatic lung to brain cancer cells (SEBTA-001) and 
metastatic lung to lymph node cells (NCI-H1299) showed the highest number of adherent 
cells whereas lower adhesion was seen in primary lung cancer cells (COR-L105) and  
GBM cells (UP-007) (Figure 34 B). There was no statistical difference in adhesion 
potential which was observed in cells transfected with vehicle control in all cell lines. 
Following the overexpression of FUT7/CD15s in all the cell lines (SEBTA-001, NCI-
H1299, COR-L105 and UP-007), a significant increase in adhesion (2 fold) was seen 
compared to the adhesion of wild type controls of the same cell line. A significant 
reduction was observed in the number of adherent cancer cells following the knockdown of 
FUT7/CD15s in SEBTA-001 by almost 2.5 fold decrease in adhesion ability followed by a 
2.7 fold decrease in NCI-H1299, a 2.8 fold decrease in COR-L105 and a 2.8 fold decrease 
in UP-007 cells compared to the wild type (P<0.001) (Figure 34 B) (blue versus green) . 
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Figure 34 B. Quantitative adhesion of cancer cells following the genetic 
manipulation of FUT7/CD15s. Adhesion of Primary (COR-L105), metastatic 
NSCLCs (SEBTA-001 and NCI-H1299) and GBM (UP-007) cells were 
assessed. Cancer cells were incubated for 90 minutes on a monolayer of 
activated brain endothelial cells (hCMEC/D3). Non-adherent cancer cells were 
washed off then cells were lysed and quantified via a microplate reader at 480–
520 nm. Graphs show that cancer cell adhesion was significantly decreased 
following FUT7/CD15s knockdown (red bars). Overexpression of FUT7/CD15s 
increased adhesion of cancer cells (green bars) compared with wild type control, 
(**P<0.001). N= 3. 
 
Figure 34 B: Quantitative adhesion of cancer cells following the genetic 
manipulation of FUT7/CD15s. 
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4.6 Different transendothelial migration ability among different cancer cells   
To investigate the transendothelial migration ability of target cells (SEBTA-001, NCI-
H1299, COR-L105 and UP-007), two assays were used: EVOM and ECIS. In both assays 
human brain endothelial cells (hCMEC/D3 were grown on a fibronectin (10μg/mL) coated 
surface. Cancer cells were added on top of the monolayer after the TEER value readings 
plateaued. The integrity of endothelial membrane was then monitored. EVOM results 
showed a significant (p<0.01) and accelerated decrease in TEER value from 28.9 to 15.1 
Ω.cm2 within 24 hours following SEBTA-001 cells addition. This indicates that cancer 
cells disrupted the endothelial membrane in attempt to cross the brain endothelial 
monolayer. A decrease in TEER value was also seen after NCI-H1299 cells were added 
from 28.9 to 20.0 Ω.cm2 however, NCI-H1299 took longer to decrease the resistance of the 
endothelial barrier compared to SEBTA-001 cells. No significant reduction in the 
transendothelial electrical resistance of brain endothelial monolayer was observed after 
addition of primary lung cancer cells (COR-L105) with resistance (TEER) change from 
28.9 Ω.cm2 to 26.9 Ω.cm2. Similarly, no decrease in TEER (28.9 Ω.cm2) induced by 
addition of GBM cells (UP-007) on the endothelial monolayer. (Figure 35 A and B). 
Readings were compared to the control well (no cancer cells added/ only monolayer of 
brain endothelial cells). The histograms generated by ECIS showed the resistance of the 
endothelial monolayer per time point. Results showed a decrease in TEER value (51%) 
post addition of SEBTA-001 cells compared to the control. Post addition of NCI-H1299 
cells caused a 42% decrease in TEER compared to control. These findings indicated that 
the endothelial barrier was disrupted by the secondary (metastatic) lung cancer cells. 
While, addition of primary lung cancer cells (COR-L105) did not cause a decrease in the 
resistance of the hCMEC/D3 barrier (only 4% decrease compared to the control). These 
results suggest that no disruption was induced by COR-L105 cells. Interestingly, an 
increase in resistance was observed following the addition of UP-007 cells suggesting that 
GBM cells were not able to cross the brain endothelial monolayer (Figure 35C). 
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Figure 35 (A-B): Changes in transendothelial electrical resistance (TEER) in the 
presence of cancer cells measured by EVOM. (hCMEC/D3) brain endothelial 
cells were grown on semipermeable filters (8 μm pore size). TEER values were 
pre and post-addition of cancer cells using EVOM. A: Graph showed a decreased 
TEER induced by SEBTA-001 and NCI-H1299 cells, only a small decrease in 
resistance was seen after addition of primary lung cancer cells (COR-L105). 
Addition of UP-007 however, increased the resistance of hCMEC/D3 (EC). B: 
Quantification of TEER at 24 hours post-addition of cancer cells. N=3.  
 
Figure 35 (A-B): Changes in transendothelial electrical resistance (TEER) 
in the presence of cancer cells measured by EVOM. 
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Figure 35C: Representative ECIS graphs showing changes in TEER following addition 
of cancer cells. Endothelial cells were seeded on gold electrode and TEER values were 
recorded in a real time manner using electric cell-substrate impedance sensing (ECIS). 
Results showed an increase in TEER before addition of cancer cells followed by a 
significant and accelerated decrease in TEER after addition of SEBTA-001 and NCI-
H1299 cells. These findings confirmed potential disruption in endothelial monolayer 
caused by the added cancer cells. No significant difference was observed after addition 
of primary lung cancer cell (COR-L105) and GBM (UP-007) cells. N=3.   
EC alone  
EC+SEBTA-001 
Blank (no cells)  
EC alone  
EC+NCI-H1299 
Blank (no cells)  
EC alone  
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Figure 35 C: Changes in transendothelial electrical resistance (TEER) in 
the presence of cancer cells measured by ECIS. 
169 
 
4.7 Cancer cell transendothelial migration was increased by overexpression of 
FUT4/CD15 and inhibited by FUT4/CD15 knockdown  
To investigate whether overexpression or knockdown of FUT4/CD15 may play a role in 
transendothelial migration of cancer cells during the early stages of brain metastasis, the 
changes in transendothelial electric resistance (TEER) of the brain endothelial monolayer 
was followed using three approaches: EVOM, ECIS™ and CellZscope®. The findings of 
EVOM showed a remarkable decrease in TEER value within few hours following the 
addition of wild type SEBTA-001 (18.0 Ω.cm2 compared to control 24.8 Ω.cm2) and NCI-
H1299 (19.2 Ω.cm2) compared to control where no cancer cells were added (24.8 Ω.cm2). 
A higher and more accelerated decrease in TEER was seen following addition of cancer 
cells overexpressing FUT4/CD15 from 24.0 Ω.cm2 to 15.6 Ω.cm2 in SEBTA-001 and 24.0 
Ω.cm2 to 16.1 Ω.cm2 in NCI-H1299 compared to control. No significant changes were 
noted in presence of  FUT4/CD15 knocked-down cells: SEBTA-001 (24.8 Ω.cm2) and 
NCI-H1299 (24.4 Ω.cm2). These findings indicated that knockdowned cells were not been 
able to disrupt the brain endothelial monolayer (Figure 4A). No changes were observed 
after addition of COR-L105 TEER: (23.0 Ω.cm2) and UP-007 (22.9 Ω.cm2) in wild type 
and FUT4/CD15 knockdown clones. A decline in TEER value was caused by 
overexpression of FUT4/CD15, where COR-L105 overexpressing CD15 decreased the 
resistance from 23.0 Ω.cm2 to 18.0 Ω.cm2 and UP-007 to from 23.0 Ω.cm2 to 18.4 Ω.cm2 
after 24 hours (Figure 36 A).  
ECIS results were consistent with EVOM findings. A strong correlation was noted 
between the expression of FUT4/CD15 and the decrease in resistance (TEER) of brain 
endothelial monolayer. Overexpression of FUT4/CD15 was seen to be correlated with 
decrease in resistance (TEER) in all cell lines compared to the wild type controls and 
existence of overexpressing cells decreased TEER: SEBTA-001 (63%), NCI-H1299 
(61%), COR-L105 (60.8%) and UP-007 (58%) and knockdown of FUT4/CD15 showed 
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only a slight decrease in TEER values: SEBTA-001 (3%), NCI-H1299 (1.5%), COR-L105 
(0.5%) and UP-007 (6%) (Figure 36 B).  
CellZScope
® 
studies showed that overexpression of FUT4/CD15 was correlated with a 
decrease in TEER value after 3 to 5 hours post-addition of cancer cells: SEBTA-001 
induced a 65 % decrease, NCI-H1299 68% decrease, COR-L105 60 % decrease and UP-
007 66% decrease compared to the control were no cancer cells were added. Knockdown 
of FUT4/CD15 only showed a slight decrease in resistance value: SEBTA-001 (2%) NCI-
H1299 (2.8%), COR-L105 (1.6%) and UP-007 (0.5%) compared to control (Figure 36 C).     
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Figure 36 A page 1. Effect of overexpression and knockdown of FUT4/CD15 on 
SEBTA-001 and NCI-H1299 cells transendothelial migration. Graphs show that 
transendothelial migration was increased by overexpression of FUT4/CD15 but 
inhibited by FUT4/CD15 knockdown. hCMEC/D3 were grown on transwell  filters with 
8µm pore size. Resistance values were manually measured using EVOM. Cancer cells 
were added at 1x10
4 
/well. The green line shows the control well where no cancer cells 
were added, red line refers to cell lines overexpressing  CD15, blue line represents 
adding cell lines with CD15s knockdown, yellow line refers to the addition of the wild 
type and the black line represents the blank control. (EC): hCMEC/D3 cells ,N=3. 
 
Figure 36 A page 1. Effect of overexpression and knockdown of FUT4/CD15 
on SEBTA-001 and NCI-H1299 cells transendothelial migration by EVOM. 
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Figure 36 A page 2. Effect of overexpression and knockdown of FUT4/CD15 on cancer 
cell (COR-L105 and UP-007) transendothelial migration. Graphs show that 
transendothelial migration was increased by overexpression of FUT4/CD15 but inhibited 
by FUT4/CD15 knockdown. hCMEC/D3 were grown on transwell  filters with 8µm pore 
size. Resistance values were manually measured using EVOM. Cancer cells were added 
at 1x10
4 
/well. The green line shows the control well where no cancer cells were added, 
red line refers to cell lines overexpressing  CD15, blue line represents adding cell lines 
with CD15s knockdown, yellow line refers to the addition of the wild type and the black 
line represents the blank control. (EC): hCMEC/D3 cells, N=3. 
 
Figure 36 A page 2. Effect of overexpression and knockdown of FUT4/CD15 on 
cancer cell (COR-L105 and UP-007) transendothelial migration by EVOM 
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Figure 36 B page 1. Effect of overexpression and knockdown of FUT4/CD15 on 
SEBTA-001 cells transendothelial migration by ECIS. Results show that transendothelial 
migration was increased by overexpression of FUT4/CD15 but inhibited by FUT4/CD15 
knockdown. Resistance of hCMEC/D3 barrier was measured and recorded in real time. 
Brain endothelial cells (hCMEC/D3) were grown on gold electrodes. Cancer cells were 
added at 1x10
4 
/well. Green line indicates where no cancer cells were added, red: cancer 
cells overexpressed CD15, blue: cancer cells with CD15 knocked down, yellow: wild 
type cells and black line: blank. The lower panel shows representative images of the 
endothelial monolayer after 24 hours post-addition of cancer cells. The image was 
obtained using a X4 objectives via a phase contrast microscope. (*P<0.01),N=3. 
 
Figure 36 B page 1. Effect of overexpression and knockdown of FUT4/CD15 on 
SEBTA-001 cells transendothelial migration by ECIS 
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Figure 36 B page 2. Effect of overexpression and knockdown of FUT4/CD15 on NCI-H1299 
cells transendothelial migration by ECIS. The graph show that transendothelial migration 
was increased by overexpression of FUT4/CD15 but inhibited by FUT4/CD15 
knockdown. Resistance of hCMEC/D3 barrier was measured and recorded in real time. 
Brain endothelial cells (EC)(hCMEC/D3) were grown on gold electrodes. Cancer cells 
were added at 1x10
4 
/well. Green line indicates where no cancer cells were added, red: 
cancer cells overexpressed CD15, blue: cancer cells with CD15 knocked down, yellow: 
wild type cells and black line: blank. The lower panel shows representative images of the 
endothelial monolayer after 24 hours post-addition of cancer cells. The image was 
obtained using a X4 objectives via a phase contrast microscope. (*P<0.01), N=3. 
Figure 36 B page 2. Effect of overexpression and knockdown of FUT4/CD15 on 
NCI-H1299 cells transendothelial migration by ECIS 
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Figure 36 B page 3. Effect of overexpression and knockdown of FUT4/CD15 on COR-
L105 cells transendothelial migration by ECIS 
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Figure 36 B page 3. Effect of overexpression and knockdown of FUT4/CD15 on COR-L105 
cells transendothelial migration by ECIS. The graph show that transendothelial migration 
was increased by overexpression of FUT4/CD15 but inhibited by FUT4/CD15 
knockdown. Resistance of hCMEC/D3 barrier was measured and recorded in real time. 
Brain endothelial cells (EC) (hCMEC/D3) were grown on gold electrodes. Cancer cells 
were added at 1x10
4 
/well. Green line indicates where no cancer cells were added, red: 
cancer cells overexpressed CD15, blue: cancer cells with CD15 knocked down, yellow: 
wild type cells and black line: blank. The lower panel shows representative images of the 
endothelial monolayer after 24 hours post-addition of cancer cells. The image was 
obtained using a X4 objectives via a phase contrast microscope. (*P<0.01), N=3. 
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Figure 36 B page 4. Effect of overexpression and knockdown of FUT4/CD15 on UP-007 
cells transendothelial migration by ECIS. 
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Figure 36 B page 4. Effect of overexpression and knockdown of FUT4/CD15 on UP-007 
cells transendothelial migration by ECIS. The graph show that transendothelial migration 
was increased by overexpression of FUT4/CD15 but inhibited by FUT4/CD15 
knockdown. Resistance of hCMEC/D3 barrier was measured and recorded in real time. 
Brain endothelial cells (EC)(hCMEC/D3) were grown on gold electrodes. Cancer cells 
were added at 1x10
4 
/well. Green line indicates where no cancer cells were added, red: 
cancer cells overexpressed CD15, blue: cancer cells with CD15 knocked down, yellow: 
wild type cells and black line: blank. The lower panel shows representative images of the 
endothelial monolayer after 24 hours post-addition of cancer cells. The image was 
obtained using a X4 objectives via a phase contrast microscope. (*P<0.01), N=3. 
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EC alone 
EC+SEBTA-001 (FUT4/CD15 knockdown) 
Blank(no cells)  
EC+SEBTA-001 (Wild type) 
EC+SEBTA-001 (FUT4/CD15 overexpression) 
Figure 36C page 1: Effect of FUT4/CD15 genetic manipulation on SEBAT-001 
cells transendothelial migration by CellZscope. Histogram shows the changes in 
TEER value using CellZscope automated system, pre and post addition of 
SEBTA-001 cells, the green represents control well where no cancer cells were 
added, red line: cell were overexpressing CD15, blue: cells with CD15 
knockdown, yellow: the wild type and black represents the blank control. (EC): 
hCMEC/D3 cells, (*P<0.01), N=3. 
 
Figure 36 C page 1: Effect of FUT4/CD15 genetic manipulation on SEBAT-
001 cells transendothelial migration by CellZscope. 
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EC alone 
EC+NCI-H1299(FUT4/CD15 knockdown) 
Blank(no cells)  
EC+NCI-H1299 (Wild type) 
EC+NCI-H1299(FUT4/CD15 overexpression) 
NCI-H1299 
Figure 36 C page 2: Effect of FUT4/CD15 genetic manipulation on NCI-H1299 cells 
transendothelial migration by CellZscope. Histogram shows the changes in TEER value 
using CellZscope automated system, pre and post addition of SEBTA-001 cells, the green 
represents control well where no cancer cells were added, red line: cell were overexpressing 
CD15, blue: cells with CD15 knockdown, yellow: the wild type and black represents the 
blank control. (EC): hCMEC/D3 cells, (*P<0.01), N=3. 
 
Figure 36 C page 2: Effect of FUT4/CD15 genetic manipulation on NCI-H1299 cells 
transendothelial migration by CellZscope. 
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EC alone 
EC+COR-L105 (FUT4/CD15 knockdown) 
Blank(no cells)  
EC+COR-L105 (Wild type) 
EC+COR-L105 (FUT4/CD15 overexpression) 
COR-L105 
Figure 36C page 3: Effect of FUT4/CD15 genetic manipulation on COR-L105 
cells transendothelial migration by CellZscope. Histogram shows the changes in 
TEER value using CellZscope automated system, pre and post addition of 
SEBTA-001 cells, the green represents control well where no cancer cells were 
added, red line: cell were overexpressing CD15, blue: cells with CD15 
knockdown, yellow: the wild type and black represents the blank control(EC): 
hCMEC/D3 cells, (*P<0.01), N=3. 
 
Cancer cells added  
Figure 36C page 3: Effect of FUT4/CD15 genetic manipulation on COR-L105 
cells transendothelial migration by CellZscope. 
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EC alone 
EC+UP-007(FUT4/ CD15 knockdown) 
Blank(no cells)  
EC+UP-007 (Wild type) 
EC+UP-007(FUT4/CD15 overexpression) 
UP-007 
Cancer cells added  
Figure 36 C page 4: Effect of FUT4/CD15 genetic manipulation on UP-007 cells 
transendothelial migration by CellZscope. Histogram shows the changes in TEER 
value using CellZscope automated system, pre and post addition of SEBTA-001 cells, 
the green represents control well where no cancer cells were added, red line: cell were 
overexpressing CD15, blue: cells with CD15 knockdown, yellow: the wild type and 
black represents the blank control. hCMEC/D3 cells (EC), (*P<0.01), N=3. 
 
Figure 36 C page 4: Effect of FUT4/CD15 genetic manipulation on UP-007 
cells transendothelial migration by CellZscope 
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4.8 Increase in transendothelial migration of cancer cells was induced by 
overexpression of FUT7/CD15s and blocked by FUT7/CD15s knockdown.  
To investigate the effect of overexpression or knockdown of FUT7/CD15s may play a role 
in transendothelial migration of cancer cells during seeding into the brain, the changes in 
transendothelial electric resistance (TEER) of the brain endothelial monolayer was 
assessed using three approaches: EVOM, ECIS™ and CellZscope®. Knockdown and 
overexpression of FUT7/CD15s were induced in the following cell lines: SEBTA-001, 
NCI-H1299, COR-L105 and UP-007. Cancer cells were added on top of the hCMEC/D3 
monolayer and then the changes in TEER values of brain endothelial cells monolayer was 
measured. EVOM results showed a significant and accelerated decrease in TEER value of 
brain endothelial monolayer post addition of the wild type of metastatic lung cancer cells  
(SEBTA-001) as it decreased the TEER to 16.9 Ω.cm2 comparing to control (24.5 Ω.cm2) 
and NCI-H1299 reduced the resistance to 19.0 Ω.cm2 compared to control 24.5 Ω.cm2 . A 
similar decline was observed when FUT7/CD15s-overexpressing cells were added where 
SEBTA-001 decreased the TEER to 14.9 Ω.cm2 and NCI-H1299 to 19.0 Ω.cm2 compared 
to the control (24.5 Ω.cm2). Whereas, no decrease was detected after addition of  
FUT7/CD15s knockdowns: SEBTA-001 (25.0 Ω.cm2) and NCI-H1299 (25.1 Ω.cm2 ). No 
decrease was observed in TEER value even after 24 hours post addition of the wild type of 
both, COR-L105 (22.0 Ω.cm2) and UP-007 (25.3 Ω.cm2), the same behaviour was 
observed in their clones that were treated with shRNA for  FUT7/CD15s. No significant 
decrease in TEER values COR-L105: (22.0 Ω.cm2) and (UP-007: 24.9 Ω.cm2). 
Interestingly, overexpression of FUT7/CD15s in COR-L105 and UP-007 significantly 
decreased TEER values as COR-L105: 17.0 Ω.cm2 compared to the control: 24.5 Ω.cm2 
and UP-007: 18.4 Ω.cm2 compared to control: 24.5 Ω.cm2 (Figure 37A). ECIS analysis 
findings (Figure 37B) showed that a prominent decrease in the electric resistance of the 
brain endothelial barrier was correlated with FUT7/CD15s overexpression in all the cell 
lines: a 69% decrease was caused by addition of  SEBTA-001 and a 56% decrease in 
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resistance caused by the wild type compared to control where no cancer cells were added, a 
61% decrease caused by NCI-H1299 and 43% decrease induced by its wild type compared 
to control, a 60.8% decrease was induced by COR-L107 compared to non-significant 
decreased caused by its wild type and finally, UP-007 overexpressing FUT7/CD15s cells 
were seen to decrease the resistance with 54% compared to the control and knockdown of 
FUT7/CD15s was correlated with high and constant resistance of the hCMEC/D3 
monolayer which suggested a decrease in transendothelial migration of cancer cells. 
CellZscope
® 
results were consistent with the results of EVOM and ECIS, a noticeable and 
fast decrease in TEER value was recorded post addition of SEBTA-001 within 5 hours and 
7 hours (53%) decreased in resistance compared to control where no cancer cells were 
added, NCI-H1299 caused a 54.6% decrease comparing to control. An even faster and 
sharper decrease was caused by SEBTA-001(58% decrease compared to control) and NCI-
H1299 (55.4% decrease compared to control) cells treated for FUT7/CD15s 
overexpression. However, the brain endothelial barrier was seen to maintain its integrity 
and high TEER value even after adding the highly metastatic lung cancer cells SEBTA-
001 (3% decrease) and NCI-H1299 cells (1% decrease) that were treated to knockdown 
FUT7/CD15s. No significant decrease was recorded after adding COR-L105 and UP-007 
(6% increase comparing to control) cells similar to the behaviour of its FUT7/CD15s 
knockdown clones, whereas a significant decrease was caused by overexpression of 
FUT7/CD15s in the same cells as a 60% decrease in TEET followed addition of COR-
L105 and a 66% decrease in TEER caused by UP-007 (Figure 37C).        
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Figure 37 A page 1. Effect of overexpression and knockdown of FUT7/CD15s on 
cancer cell (SEBTA-001 and NCI-H1299) transendothelial migration. Graphs show 
that transendothelial migration was increased by overexpression of FUT7/CD15s but 
inhibited by FUT7/CD15s knockdown. hCMEC/D3 (EC) were grown on transwell  
filters with 8µm pore size. Resistance values were manually measured using EVOM. 
Cancer cells were added at 1x10
4 
/well. The green line shows the control well where 
no cancer cells were added, red line refers to cell lines overexpressing  CD15s, blue 
line represents adding cell lines with CD15s knockdown, yellow line refers to the 
addition of the wild type and the black line represents the blank control. N=3. 
 
Figure 37 A page 1. Effect of overexpression and knockdown of FUT7/CD15s 
on cancer cell (SEBTA-001 and NCI-H1299) transendothelial migration 
measured by EVOM. 
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Figure 37A page 2. Effect of overexpression and knockdown of FUT7/CD15s on 
cancer cell (COR-L105 and UP-007) transendothelial migration 
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Figure 37A page 2. Effect of overexpression and knockdown of FUT7/CD15s on cancer 
cell (COR-L105 and UP-007) transendothelial migration. Graphs show that 
transendothelial migration was increased by overexpression of FUT7/CD15s but inhibited 
by FUT7/CD15s knockdown. hCMEC/D3 (EC) were grown on transwell  filters with 
8µm pore size. Resistance values were manually measured using EVOM. Cancer cells 
were added at 1x10
4 
/well. The green line shows the control well where no cancer cells 
were added, red line refers to cell lines overexpressing  CD15s, blue line represents 
adding cell lines with CD15s knockdown, yellow line refers to the addition of the wild 
type and the black line represents the blank control. N=3. 
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EC alone 
EC+SEBTA-001 (FUT7/CD15s 
 knockdown) 
Blank(no cells)  
EC+SEBTA-001 (Wild type) 
EC+SEBTA-001 (FUT7/CD15s  
over-expression) 
SEBTA-001 
No cancer  Knockdown 
Blank 
Wild type Overexpression 
Figure 37 B page 1. Effect of overexpression and knockdown of FUT7/CD15s on 
SEBTA-001 cells transendothelial migration by ECIS. Results show that transendothelial 
migration was increased by overexpression of FUT7/CD15s but inhibited by 
FUT7/CD15s  knockdown. Resistance of hCMEC/D3 barrier was measured and recorded 
in real time. Brain endothelial cells (hCMEC/D3) (EC) were grown on gold electrodes. 
Cancer cells were added at 1x10
4 
/well. Green line indicates where no cancer cells were 
added, red: cancer cells overexpressed CD15s, blue: cancer cells with CD15s knocked 
down, yellow: wild type cells and black line: blank. The lower panel shows 
representative images of the endothelial monolayer after 24 hours post-addition of cancer 
cells. The image was obtained using a X4 objectives via a phase contrast microscope. 
hCMEC/D3 cells (EC), (*P<0.01), N=3. 
 
Figure 37 B page 1. Effect of overexpression and knockdown of FUT7/CD15s 
on SEBTA-001 cells transendothelial migration by ECIS. 
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Blank(no cells)  
EC+NCI-H1299 (Wild type) 
EC+NCI-H1299(FUT7/over-expression) 
NCI-H1299 
No cancer cell  Knockdown 
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Figure 37 page 2. Effect of overexpression and knockdown of FUT7/CD15s on NCI-
H1299 cells transendothelial migration by ECIS. Results show that transendothelial 
migration was increased by overexpression of FUT7/CD15s but inhibited by FUT7/CD15s 
knockdown. Resistance of hCMEC/D3 barrier was measured and recorded in real time. 
Brain endothelial cells (EC) (hCMEC/D3) were grown on gold electrodes. Cancer cells 
were added at 1x10
4 
/well. Green line indicates where no cancer cells were added, red: 
cancer cells overexpressed CD15s, blue: cancer cells with CD15s knocked down, yellow: 
wild type cells and black line: blank. The lower panel shows representative images of the 
endothelial monolayer after 24 hours post-addition of cancer cells. The image was 
obtained using a X4 objectives via a phase contrast microscope. hCMEC/D3 cells (EC), 
(*P<0.01),  N=3. 
 
Figure 37 page 2. Effect of overexpression and knockdown of FUT7/CD15s on NCI-
H1299 cells transendothelial migration by ECIS. 
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EC alone  
EC+COR-L105(FUT7/knockdown) 
Blank(no cells)  
EC+COR-L105 (Wild type) 
EC+COR-L105(FUT7/over-expression) 
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Figure 37 B page 3. Effect of overexpression and knockdown of FUT7/CD15s on 
COR-L105 cells transendothelial migration by ECIS. Results show that transendothelial 
migration was increased by overexpression of FUT7/CD15s but inhibited by 
FUT7/CD15s knockdown. Resistance of hCMEC/D3 barrier was measured and 
recorded in real time. Brain endothelial cells (EC)(hCMEC/D3) were grown on gold 
electrodes. Cancer cells were added at 1x10
4 
/well. Green line indicates where no 
cancer cells were added, red: cancer cells overexpressed CD15s, blue: cancer cells with 
CD15s knocked down, yellow: wild type cells and black line: blank. The lower panel 
shows representative images of the endothelial monolayer after 24 hours post-addition 
of cancer cells. The image was obtained using a X4 objectives via a phase contrast 
microscope. hCMEC/D3 cells (EC), (*P<0.01), N=3. 
 
Figure 37 B page 3. Effect of overexpression and knockdown of FUT7/CD15s on 
COR-L105 cells transendothelial migration by ECIS. 
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UP-007(FUT7/over-expression) 
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No cancer cells  Knockdown Blank Wild type Overexpression 
Figure 37 B page 4. Effect of overexpression and knockdown of FUT7/CD15s on 
UP-007 cells transendothelial migration by ECIS. Results show that 
transendothelial migration was increased by overexpression of FUT7/CD15s but 
inhibited by FUT7/CD15s knockdown. Resistance of hCMEC/D3 (EC) barrier 
was measured and recorded in real time. Brain endothelial cells (hCMEC/D3) 
were grown on gold electrodes. Cancer cells were added at 1x10
4 
/well. Green line 
indicates where no cancer cells were added, red: cancer cells overexpressed 
CD15s, blue: cancer cells with CD15s knocked down, yellow: wild type cells and 
black line: blank. The lower panel shows representative images of the endothelial 
monolayer after 24 hours post-addition of cancer cells. The image was obtained 
using a X4 objectives via a phase contrast microscope. hCMEC/D3 cells (EC), 
(*P<0.01),  N=3. 
 
Figure 37 B page 4. Effect of overexpression and knockdown of FUT7/CD15s 
on UP-007 cells transendothelial migration by ECIS. 
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Figure 37 C page 1: Effect of FUT7/CD15s genetic manipulation on SEBTA-001 
cells transendothelial migration by CellZscope. 
EC alone  
EC+SEBTA-001 (FUT7/knockdown) 
Blank(no cells)  
EC+SEBTA-001 (Wild type) 
EC+SEBTA-001 (FUT7/over-expression) 
SEBTA-001 
Figure 37 C page 1: Effect of FUT7/CD15s genetic manipulation on SEBTA-001 
cells transendothelial migration by CellZscope. Histogram shows the changes in 
TEER value using CellZscope automated system, pre and post addition of SEBTA-
001 cells, the green represents control well where no cancer cells were added, red 
line: cell were overexpressing CD15s, blue: cells with CD15s knockdown, yellow: 
the wild type and black represents the blank control. hCMEC/D3 cells (EC), 
(*P<0.01), N=3. 
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EC alone 
EC+NCI-H1299(FUT7/knockdown) 
Blank(no cells)  
EC+NCI-H1299 (Wild type) 
EC+NCI-H1299(FUT7/over-expression) 
NCI-H1299 
Figure 37 C page 2: Effect of FUT7/CD15s genetic manipulation on NCI-H1299 cells 
transendothelial migration by CellZscope. Histogram shows the changes in TEER value 
using CellZscope automated system, pre and post addition of NCI-H1299 cells, the green 
represents control well where no cancer cells were added, red line: cell were 
overexpressing CD15s, blue: cells with CD15s knockdown, yellow: the wild type and 
black represents the blank control. hCMEC/D3 cells (EC), (*P<0.01),  N=3. 
 
Cancer cells added  
Figure 37 C page 2: Effect of FUT7/CD15s genetic manipulation on NCI-H1299 
cells transendothelial migration by CellZscope 
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EC alone 
EC+COR-L105(FUT7/knockdown) 
Blank(no cells)  
EC+COR-L105 (Wild type) 
EC+COR-L105(FUT7/over-expression) 
COR-L105 
Figure 37 C page 3: Effect of FUT7/CD15s genetic manipulation on COR-L105 
cells transendothelial migration by CellZscope. Histogram shows the changes in 
TEER value using CellZscope automated system, pre and post addition of COR-105 
cells, the green represents control well where no cancer cells were added, red line: 
cell were overexpressing CD15s, blue: cells with CD15s knockdown, yellow: the 
wild type and black represents the blank control. hCMEC/D3 cells (EC), 
(*P<0.01), N=3. 
 
Cancer cells added  
Figure 37 C page 3: Effect of FUT7/CD15s genetic manipulation on COR-
L105 cells transendothelial migration by CellZscope. 
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EC alone  
EC+UP-007(FUT7/knockdown) 
Blank(no cells)  
EC+UP-007 (Wild type) 
EC+UP-007(FUT7/over-expression) 
Figure 37 C page 4: Effect of FUT7/CD15s genetic manipulation on UP-007 cells 
transendothelial migration by CellZscope. Histogram shows the changes in TEER 
value using CellZscope automated system, pre and post addition of UP-007 cells, the 
green represents control well where no cancer cells were added, red line: cell were 
overexpressing CD15s, blue: cells with CD15s knockdown, yellow: the wild type 
and black represents the blank control. hCMEC/D3 cells (EC), (*P<0.01), N=3. 
 
UP-007 
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Figure 37 C page 4: Effect of FUT7/CD15s genetic manipulation on UP-007 
cells transendothelial migration by CellZscope 
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4.9 Discussion  
 
The brain is known to be a key target for metastasis cancers from the lung. 20%-40% of 
patients with NSCLC cancer have been reported to develop secondary brain tumours (Ali 
et al., 2013). Brain metastasis is correlates with poor prognosis. The mechanisms 
underlining brain metastasis are not fully elucidated. The metastatic process includes a 
complex interaction between metastatic cancer cell and host environment. There are five 
key elements in the process of metastasis to the brain: (a) intravasation from within the 
primary cancer (b) travelling within the blood circulation (c) adhesion to the target organ 
(brain) vascular endothelium (d) extravasation into brain tissue and (e) colonisation and 
growth within the brain. Cancer cells generally metastasise to the brain via the capillaries 
which constitute a compartment of the BBB vascular network. The importance of brain 
endothelial cells in brain metastasis has recently been highlighted; particularly in the early 
stages of cancer cell seeding (Soto et al., 2014). CD15 and CD15s are important adhesion 
molecules and both involved in the homing process of leukocytes (Strell and Entschladen, 
2008) 
23
. Their overexpression has been correlated with cancer progression and metastasis 
in non-CNS cancers CD15 (Gout et al., 2006) and CD15s (Desiderio et al., 2015) were 
seen to accumulate at the invading edges of tumours. Little is known about these molecules 
within the CNS and even less is known about their role in brain metastasis. In a previous 
study, we showed that CD15 plays a key role in adhesion of cancer cells to brain 
endothelium via CD15-CD62E interaction and adhesion of cancer cells was significantly 
reduced by immune-blocking of CD15 (Jassam et al., 2015). Here, we investigated the role 
of knockdown and overexpression of CD15 and CD15s in adhesion on brain endothelium 
as well as their role in transmigration across a brain endothelial monolayer. A human 
microvascular endothelial cell line (hCMEC/D3) was used to represent the first line in 
within an in vitro BBB model to circumvent the use of experimental animals and gain 
important information within the metastatic process. In vivo models have been shown to be 
flawed for the study of human cerebral metastasis due to the species differences in BBB 
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(Syvanen et al., 2009). Human brain endothelial monolayers in vitro models have 
previously been used to study mechanism involved in transendothelial migration of 
melanoma cells (Fazakas et al., 2011)
 
and transmigration of lymphocytes (Kugler et al., 
2007 and Man et al., 2008)
 
. In vitro BBB models are used to study, one side of metastasis 
such as cell-cell interactions. However, there are many limitations and challenges face 
those models. Such as lack of desirable shear stress, use of non-transformed cells, and the 
accurate and functional co-cultures representing the accurate BBB designed. The 
hCMEC/D3 cell line has been widely used in in vitro human BBB model lines (Forster et 
al., 2008 
 
and Carl et al., 2010). CD15 and CD15s biosynthesis is widely known to be 
regulated by fucosyltransferase enzymes (α1,3 FUTs); FUT3,-4,-5,-6,-7 and -9. One or 
more of FUTs enzymes are involved in CD15 and CD15s biosynthesis depending on tissue 
type (de Vries et al., 2001). It was further shown that FUT4 and FUT7 are predominantly 
expresses in the haematopoietic cells and overexpression of fucosyltransferase IV (FUT4) 
increases the expression of CD15 which correlates with increased metastasis in colorectal 
cancer (Giordano et al., 2015)
 33
. Conversely, FUT4 knockdown reduced the expression of 
CD15 in promyelocytes and monocytes but not in mature granulocytes (Nakayama et al., 
2001). It was also reported that FUT4 and FUT7 knockdown was shown to significantly 
reduce the homing of leukocytes and lymphocytes (Maly et al., 1996  and Homeister et al., 
2001). Our results showed that the highest expression level of FUT4/CD15 and 
FUT7/CD15s was seen in metastatic lung cancer cells (SEBTA-001 and NCI-H1299) 
compared to primary lung cancer and GBM cells. These findings are in concert with 
previous studies where it was shown that fucosyltransferase (FUT) overexpression in 
general was correlated with poor prognosis and metastasis in prostate cancer (Jorgensen et 
al., 1995 and Barthel et al., 2004)
 
as well as lung cancer (Ogawa et al., 1996). It was 
reported that colon carcinoma cells overexpressing CD15s were able to metastasise to the 
liver compared to cells with low levels of CD15s (Izumi et al., 1995)
 
in in vivo models. 
FUTs have also been reported to regulate the homing of metastatic prostate cancer cells in 
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mice (Barthel et al., 2009). Overexpression of the fucosyltransferase VII (FUT7) enzyme 
via upregulation of the FUT7 gene was seen to increase the expression of CD15s in 
prostate cancer cells (Barthel et al., 2009)
 
and FUT7 knockdown downregulated the 
expression of CD15s and led to CD15s deficiency in human promyelocytic leukaemia cells 
(Weston et al., 1999). In our study, FUT4 and FUT7 were chosen to manipulate the 
expression of CD15 and CD15s by overexpressing and silencing respectively. Transfection 
with FUT4 and FUT7 genes were applied in four different cancer cell lines (SEBTA-001, 
NCI-H1299, COR-L105 and UP-007). Results showed that the FUT4 gene directly 
controlled the expression of CD15 and the same scenario was seen during transfection with 
the FUT7 gene which induced the overexpression of CD15s. These findings agreed with 
what those previously reported where CD15 (Lewis x) was mainly controlled by FUT4 and 
FUT9 at the organ buds progressing in mesenchymal of human embryos (Cailleau-Thomas 
et al., 2000). We also found that silencing FUT4 and FUT7 genes led to a downregulation 
of the expression of CD15 and CD15s respectively in all the studied cancer cell lines. The 
same effect was previously reported with FUT7 knockdown on reduced expression of 
CD15s in lymphocyte cells (Buffone et al., 2013). Another study showed that silencing of 
ST3Gal-4 reduced the biosynthesis of CD15s in cells of human myeloid lineage (Mondal 
et al., 2015). There is little known about FUTs enzymes and their functional role in lung 
cancer or GBM cells thus, we decided to start with FUT4 and FUT7. ICC, WB and flow 
cytometry analysis were employed to confirm expression levels of CD15 and CD15s post 
FUT4/CD15 and FUT7/CD15s knockdown and overexpression. The effect of knockdown 
and overexpression of FUT4/CD15 and FUT7/CD15s were investigated on the adhesion 
ability of cancer cells. Overexpression of FUT4/CD15 was seen to increase the adhesion 
ability in all studied cancer cells and FUT4/CD15 knockdown was seen to decrease the 
adhesion of cancer cells. These findings are in agreement with those of Yang et al., 2013 
who highlighted that overexpression of FUT4 correlated with high metastatic potential in 
breast cancer cells and is implicated in both adhesion and invasion of breast cancer cells. 
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Fucosyltransferase (FUT4) protein was seen to be overexpressed on highly invasive cells 
(Yang et al., 2012). Overexpression of FUT4 and FUT7 were also found to be correlated 
with metastasis of lung cancer cells. Similarly, we observed that overexpression of 
FUT7/CD15s increased adhesion of cancer cells and knockdown of FUT7/CD15s 
significantly reduced the adhesion ability of cancer cell to brain endothelial cells. It was 
reported that silencing of FUT7/CD15s reduced the adhesion ability of human leukocytes 
(Buffone et al., 2013). 
 Adhesion of cancer cells is an important step in cancer metastasis but do not mean that all 
adherent cells will be able to cross the BBB into the brain therefore we investigated 
transendothelial migration ability of cancer cells, by measuring the TEER value of 
hCMEC/D3 barrier using three different approaches: the first one was EVOM, which is 
based on applying a non-invasive current (AC), it is useful in providing accurate readings 
and simple to use however, it is not helpful in providing real-time TEER readings that is 
why we decided to use the other two automated devices: ECIS and CellZscope. Both two 
approaches are based on on applying a non-invasive current (AC) to detect the gaps 
between the attached cells; however, ECIS highly sensitive device which, is designed in a 
way that the mobility of the adherent cells may affect the resistance readings and to avoid 
this we validate ECIS results by using another device. CellZscope is perfectly designed to 
measure the resistance and mathematically calculates the data and then displays it as a pure 
TEER values. Our results showed that trans-endothelial migration ability of cancer cells 
was increased following overexpression of FUT4/CD15 and significantly decreased in 
knockdown cells. These results suggested that FUT4/CD15 play a role in transendothelial 
migration of cancer cells during metastasis to the brain. Likewise, FUT7/CD15s silencing 
clearly reduced the ability of cancer cells to transmigrate via the brain endothelial 
monolayer as seen by no decrease in the resistance (TEER) value. These findings highlight 
that FUT7/CD15s may also play a role in NSCLC transendothelial migration. These 
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findings were supported by previous literature which highlighted that knockdown of 
FUT7/CD15s reduced the transendothelial migration of human leukocytes (Buffone et al., 
2013). An in vivo study also showed that decreasing CD15s biosynthesis via a disaccharide 
compound significantly reduced the metastasis of lung carcinoma cells (Brown et al., 
2009). This study demonstrated the key role of CD15 and CD15s in adhesion and 
transendothelial migration.  
In conclusion, our findings showed a strong correlation between FUT4/CD15 and 
FUT7/CD15s in adhesion of lung cancer cells and transendothelial migration potential. 
Knockdown of FUT4/CD15 and FUT7/CD15s significantly reduced the number of 
adherent metastatic and primary lung cancer cells as well as GBM cells to brain 
endothelium. Similarly reduced transendothelial migration ability of primary lung cancer 
and GBM cells were observed following silencing of CD15 and CD15s. Highly metastatic 
lung cancer cells (SEBTA-001 and NCI-H1299) showed similar results. TEER values of 
brain endothelial monolayer did not decrease following knockdown of (–FUT4 or –FUT7) 
cancer cells. In parallel transfection of (+FUT4 or +FUT7) in cancer cells showed high 
adhesive potential and transendothelial migration ability via the brain endothelial 
monolayer.  
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CHAPTER FIVE  
 The expression of CD15 and CD15s during different 
stages of cell cycle in cancer cells 
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5.1 Expression of CD15 and CD15s is correlated with cell cycle arrest at G1 phase in 
primary and metastatic brain tumour cells 
The expression of cell membrane glycoconjugates is reported to be highly influenced by 
cell differentiation status (Hakomori 1981 and Stamatos et al., 2010).
 
Some cancer cells 
express particular glycoconjugates during the transformation process and the 
overexpression of some of these conjugates has been directly correlated with malignancy 
(Schultz et al, 2013). CD15s has been shown to play a key role in cell-cell recognition as 
in sperm-egg fertilisation (Tulsiani and Abou-Haila, 2012) and in extravasation of 
leukocytes (Buffone et al., 2013). Both CD15 and CD15s are expressed in a variety of non-
neoplastic cells such as granulocytes, monocytes (Nakayama et al., 2001), epithelial cells 
(Atsuta et al., 1997) and neurons (Mai and Reifenberger 1988; Chaoyang et al., 2007). A 
considerable number of studies have shown a strong correlation between overexpression of 
CD15, CD15s and malignancy in different cancers such as; Hodgkin’s lymphoma, breast, 
lung (Ohana-Malka et al., 2003, Brooks et al., 1995, Gadhoum et al., 2008 and  renal 
carcinoma (Tozawa et al., 1995), colon (Rho et al., 2005), head and neck squamous 
carcinoma (Fukusumi et al., 2014) and brain metastases from lung (Notle et al., 2013)  and 
breast (Gadhoum et al., 2008). Although CD15 was previously reported to be rarely 
expressed in anaplastic glioma and glioblastoma (Mai and Reifenberger; Martin et al., 
1995) it has recently been suggested that CD15 may serve as a marker for brain cancer 
stem-like cells in human astrocytoma, ependymoma and medulloblastoma (Mao et al., 
2009). The aim of this study was to gain greater understanding of CD15 and CD15s 
expression in CNS malignancies. Herein we demonstrated that expression of CD15 and 
CD15s is cell cycle dependent, which may account for the lack of consistency in previous 
studies.     
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5.2 Expression of CD15 in non-synchronised brain cancer cells 
Under non-synchronised culture conditions, immunocytochemistry and confocal results 
indicate an absence of CD15 expression in non-neoplastic astrocytes (SC-1800), while in 
glioblastoma cells (SNB-19 and UP-007), expression of CD15 was noted on the cell 
surface of individual cells (Figure 38 A).  Semi-quantitative analysis revealed a 5 fold 
higher number in CD15 fluorescence intensity in UP-007 cells and a 4 fold higher in SNB-
19 cells compared to SC-1800 and isotype control (Figure 38 A, B; p< 0.05). CD15 
expression in secondary lung to brain metastatic tumour cell lines demonstrated a 15 fold 
higher in SEBTA-001 and 12 fold higher in SEBTA-005 compared to SC-1800 and isotype 
control (Figure 38 A, B; p<0.01). Western blot analysis of CD15 expression in SC-1800 
cells confirmed the confocal data showing no detectable level of CD15 (Figure 38 C).  A 
CD15 immunoreactive protein at molecular weight 95-118 kDa was detected in both GBM 
cell lines (UP-007 and SNB-19) and lung to brain metastatic cells (SEBTA-001 and 
SEBTA-005). ABCE-1 with a molecular weight 68 kDa was used to ensure equal loading 
of samples (Figure 38 C). The level of CD15 expression in SEBTA 001 and SEBTA-005 is 
higher compared to the glioma cell lines which is in agreement with the ICC results. Flow 
cytometry analysis indicated that only 3% of SC-1800 expressed CD15 and this was not 
significantly different from isotype controls (Figure 38 E). CD15 was expressed at a lower 
level in SNB-19 (9.5%) and UP-007 (13.4%) compared to isotype control (p<0.05 and 
p<0.01) and to SEBTA-001(44%) and SEBTA-005 (36%) cells respectively (Figure 38 D 
and E). Both the lung to brain metastatic cell lines were significantly higher in terms of 
their CD15 positive cells compared to isotype controls (p<0.001) and the glioma cell lines 
(p<0.01).  
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Figure 38. Expression and localization of CD15 in non-synchronised cells. A: 
Immunocytochemistry images showing no CD15 expression (green) in non-neoplastic 
astrocytes (SC-1800) but low positivity in primary GBM cells (UP-007 and SNB-19) and 
secondary brain cancer cells (SEBTA-001 and SEBTA-005). Hoechst blue was used as a 
nuclear counterstain. Scale bar =20μm. B: Semi-quantitative analysis of CD15 from 
confocal microscopy images using Zeiss Zen image software. C: Western blot analysis 
shows no CD15 expression in human astrocytes, weak expression in GBMs (UP-007 and 
SNB-19) and highest expression in brain secondary metastatic cancer cells (SEBTA-001 
and SEBTA-005). D: Representative flow cytometric histograms and E: Quantitative flow 
cytometric analysis of CD15 expression in SC-1800, UP-007, SNB-19, SEBTA-001 and 
SEBTA-005. CD15 was highly expressed in SEBTA-001 and SEBTA-005 and least 
expressed in SC-1800.  *(P≤0.05), ** (P<0.01) and *** (P<0.001) difference compared to 
the IgM isotype control. Results are representative of three independent experiments 
carried out in triplicate (n=3).  
Figure 38. Expression and localization of CD15 in non-synchronised 
cells. 
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5.3 Expression of CD15s in non-synchronised brain cancer cells 
CD15s was not detected on the surface of SC-1800 whereas a faint expression was 
detected in primary glioma cell lines with the highest expression seen in the lung to brain 
metastatic cell lines (Figure 39A).  As with CD15, CD15s was localised to the outer edges 
of cell surface. Semi-quantitative analysis there was a 2.9 fold increase in CD15s 
expression in UP-007 and a 5.1 fold increase in SNB-19 cells compared to the isotype 
controls (Figure 39 A, B p<0.05). SEBTA-001 is 7 fold and SEBTA-005 is 6 fold higher in 
CD15s intensity compared to the expression of CD15s in SC-1800 and isotype control 
(Figure 39 A, B p<0.001). Western blot analysis (Figure 39 C) failed to detect CD15s 
protein in SC-1800 whereas a CD15s-immunoreactive proteins at molecular weight 95-118 
kDa was detected in both GBM cell lines (UP-007 and SNB-19) and lung to brain 
metastatic cells (SEBTA-001 and SEBTA-005) (Figure 39 C). The level of CD15 
expression was higher in SEBTA 001 and SEBTA-005 which agree with the ICC results. 
Flow cytometry analysis indicated 2% of SC-1800 cells were positive for CD15s compared 
to isotype controls. 8% of SNB-19 cells and 16% of UP-007 were CD15s positive in non-
synchronised glioma cells whereas in lung to brain metastatic cell lines expressed 34% 
(SEBTA-005) and 47% (SEBTA-001) (Figure 39 D and E). Both the lung to brain 
metastatic cell lines were significantly higher in terms of their CD15s positive cells 
compared to isotype controls (p<0.001) and the glioma cell lines (p<0.01).  
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Figure 39. Expression and localisation of CD15s in non-synchronised cells. A: 
Immunocytochemistry images showing no CD15s expression (green) in non-neoplastic 
astrocytes (SC-1800) but positivity in in primary GBM cells (UP-007 and SNB-19) and 
secondary brain cancer cells (SEBTA-001 and SEBTA-005). Hoechst blue was used as a 
nuclear counterstain. Scale bar =20μm. B: Semi-quantification analysis of CD15s from 
confocal microscopy images using Zeiss Zen image software. C: Western blot analysis 
showing no CD15s expression in human astrocytes, weak expression in GBMs (UP-007 
and SNB-19) and highest expression in brain secondary metastatic cancer cells (SEBTA-
001 and SEBTA-005). D: Representative flow cytometric histograms and E: Quantitative 
flow cytometric analysis of CD15s expression in SC-1800, UP-007, SNB-19, SEBTA-001 
and SEBTA-005. CD15s was highly expressed in SEBTA-001 and SEBTA-005 and least 
expressed in SC-1800.  *(P≤0.05), ** (P<0.01) and *** (P<0.001) difference compared to 
the IgM isotype control. Results are representative of three independent experiments 
carried out in triplicate (n=3).  
Figure 39. Expression and localization of CD15s in non-
synchronised cells. 
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5.4 Synchronisation of cell cultures  
All of the cell cultures were synchronised to G1, S and G2/M phase of the cell cycle using 
serum depletion, hydroxyurea and Nocodazole respectively. Efficiency of synchronisation 
was determined in each in cell line using DNA analysis via flow cytometry (Figure 40). 
Results of flow cytometry analysis of propidium iodide stained cells from serum depletion 
showed most cells were arrested at G1 phase at 94% in SC-1800, 91% in UP-007, 92% in 
SNB-19, 92% in SEBTA-001 and 90% in SEBTA-005 (Figure 40). Hydroxyurea blocks 
the de novo synthesis of DNA through inhibiting the activity of ribonucleotide reductase 
25
. 
Results showed that where cell cultures were incubated at 1mM/mL of Hydroxyurea, 55% 
of SC-1800 cells, 42% of UP-007, 48% of SNB-19, 64% of SEBTA-001 and 53% of 
SEBTA-005 were synchronised in S phase; the slight discrepancy in synchronisation of 
astrocytes is considered acceptable due to the unbalanced cell growth caused by the 
treatment with hydroxyurea which is an anti-cancer drug as well as the high heterogeneity 
of cancer cell cultures which caused a different response to hydroxyurea among individual 
cells. The short period of transition from G phase to G2/M phase also made it unlikely that 
there would be a high number of cells arrested at S phase (Figure 40). The third arrest point 
was G2/M phase. Cells were induced to enter G1 phase then treated with 2μg/mL 
Nocodazole as a mitotic inhibitor for 24 hours. Results showed that 61% of SC-1800 cells, 
82% of UP-007, 53% of SNB-19, 68% of SEBTA-001 and 61% of SEBTA-005 were 
arrested at G2/M phase (Figure 40).     
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Figure 40. Synchronisation of cell cultures. Cell cultures were synchronised at different 
cell cycle stages using serum depletion to arrest cells at G1 phase, 1mM/L hydroxyurea 
for S phase and 2μg/mL Nocodazole for G2/M phase. Flow cytometry analysis was 
used to assess the efficiency of cell synchronisation and the distribution of arrested cells 
in each phase. 91% of SC-1800, 91% of UP-007, 92% of SNB-19, 92% of SEBTA-001 
and 90% of SEBTA-005 were arrested in G0/G1 phase after 48 hours of serum 
depletion treatment. 55% of SC-1800, 42% of UP-007, 48% of SNB-19, 64% of 
SEBTA-001 and 53% of SEBTA-005 cells were synchronised in S phase by incubation 
in 1mM/L for 24 hours in full growth medium. 61% of SC-1800, 82% of UP-007, 92% 
of SNB-19, 92% of SEBTA-001 and 90% of SEBTA-005 of cells were arrested in 
G2/M phase after treatment with 2µg/mL Nocodazole for 24 hours.  
 
Figure 40. Synchronisation of cell cultures 
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5.6 Expression of CD15 at different cell cycle stages 
Two methods were used to determine if CD15 is expressed in a cell cycle dependant 
manner with one synchronised as described above and a qualitative method using a 
Premo™ (FUCCI) cell cycle sensor. In synchronised cells, flow cytometry analysis 
revealed that CD15 was expressed at low levels in SC-1800 with no observable difference 
in expression in G1 (1.8%), S (1.18%) or G2/M (1%) whilst in GBM cells, CD15 
expression was significantly higher in cells arrested at G1 phase: 14.7% and 21.4% in UP-
007 (p<0.05) and SNB-19 (p<0.01) respectively compared to non-synchronised 
counterparts (Figure 5 A and B). In addition, in each of the GBM cell lines there was 
significantly higher CD15 expression in G1 compared to S (p<0.01) G2/M (p<0.01). 
Similarly CD15 was significantly elevated in secondary brain tumour cells synchronised in 
G1 phase (p<0.01) with positivity of 66% in SEBTA-001 and 38% in SEBTA-005 
compared to non-synchronised cells (Figure 41 A and B). These data were supported by 
qualitative results obtained from transfected cells using the Premo™ (FUCCI) cell cycle 
sensor to differentiate specific cell cycle stages, visualised using a LSM 510 Axioskop2 
confocal microscope. G1, S and G2/M phases were detected by red, yellow and green 
nuclei respectively. In these non-synchronised studies, CD15 cell surface expression 
(green) was mostly co-localised with red nuclei indicative of G1 (Figure 41C) supporting 
that higher levels of CD15 expression can be detected in cells at G1 phase of the cell cycle.   
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Figure 41. Expression and localisation of CD15 during different stages of the cell 
cycle. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 41. Expression and localisation of CD15 during different stages of the cell 
cycle. A:  Flow cytometric histograms representing CD15 expression in synchronised 
cells SC-1800 (1), UP-007 (2), SNB-19 (3), SEBTA-001(4) and SEBTA-005(5) cells. 
CD15 positive expression is represented by a shift to the right. B: Statistical analysis 
of flow cytometry results showing that the highest level of CD15 expression was 
detected in G0/G1 synchronised cells followed by non-synchronised cells and G2/M 
phase. Cells are arrested at S phase showed that the least CD15 expression level. 
*(P≤0.05), ** (P<0.01) and *** (P<0.001) difference compared to the IgM isotype 
control. C: Immunocytochemistry results of CD15 extracellular expression (green). 
Cells were treated with FUCCI™ system to differentiate specific cell cycle stages 
depending on the colour of the nuclei (red: G1; yellow: S and green: G2/M phase). 
Results show CD15 expression was detected at low levels on SC-1800 cell with red 
nuclei (G1 phase). In GBM cells (UP-007 & SNB-19) and metastatic lung-brain 
cancer cells (SEBTA-001 & SEBTA-005), CD15 was expressed and well distributed 
on cell surfaces with red or yellowish-red nuclei (arrow) indicating G1 phase. Scale 
bar is 20μm. Results are representative of three independent experiments carried out 
in triplicate (n=3).  
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5.7 Expression of CD15s at different cell cycle stages 
CD15s expression also appears to be cell-cycle dependent. As with CD15, CD15s 
expression in the astrocyte cell line was low and did not significantly change with 
synchronisation. In GBM cells, CD15s expression was significantly higher in cells arrested 
at G1 phase: 39% and 48% in UP-007 (p<0.001) and SNB-19 (p<0.001) respectively 
compared to non-synchronised counterparts (Figure 42 A and B). In addition, in each of 
the GBM cell lines there was significantly higher CD15s expression in G1 compared to S 
(p<0.001) G2/M (p<0.001). Similarly CD15s were elevated in secondary brain tumour 
cells synchronised in G1 phase (p<0.05) with positivity of 44% in SEBTA-001 and 27% in 
SEBTA-005 compared to non-synchronised cells (Figure 42 A and B). In non-
synchronised co-localisation studies, CD15s expression (green) was also co-localised with 
red nuclei indicative of G1 (Figure 42 C). These results suggest that over-expression of 
CD15s correlates with G1 phase.   
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Figure 42:Expression and localisation of CD15s during different stages of the cell 
cycle. A: Immunocytochemistry results of CD15s extracellular expression (green). 
Cells were treated with the FUCCI™ system to differentiate specific cell cycle stages 
depending on the colour of the nuclei (red: G1; yellow: S and green: G2/M phase). 
Results showed that CD15s expression was detected at low level on SC-1800 cells 
with red nuclei (G1 phase). In GBM cells (UP-007 & SNB-19) and metastatic lung-
brain cancer cells (SEBTA-001 & SEBTA-005), CD15s was expressed and well 
distributed on cell surfaces with red or yellowish-red nuclei (arrow) indicating G1 
phase. Scale bar=20μm. B: Flow cytometric histograms representing CD15s 
expression in synchronised cells: SC-1800 (1), UP-007 (2), SNB-19 (3), SEBTA-
001(4) and SEBTA-005(5) cells. CD15s positive expression is represented by a shift 
to the right. C: Statistical analysis of flow cytometry results show that the highest 
level of CD15s expression was detected in G0/G1 synchronised cells followed by 
non-synchronised cells and G2/M phase. Cells which arrested at S phase showed 
lowest CD15s expression levels. *(P≤0.05), ** (P<0.01) and *** (P<0.001) 
difference compared to the IgM isotype control. Results are representative of three 
independent experiments carried out in triplicate (n=3). 
Figure 42. Expression and localisation of CD15s during different stages 
of the cell cycle 
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5.8 Discussion  
CD15 and CD15s are fucosylated polysaccharide epitopes and tumour-associated cell 
adhesion molecules. Overexpression of both epitopes has been correlated with malignancy 
of many non-CNS cancers (Ohana-Malka et al., 2003). Early studies in CNS cancers 
reported the absence or low expression in GBM cells (Mai JK, Reifenberger 1988; Martin 
et al., 1995). However more recently, overexpression of CD15 in high grade malignant 
CNS tumours has been reported (Mao et al., 2009 and Kahlert et al., 2012). In addition, 
CD15 has been documented as a marker of self-renewing stem-like cells in GBM (Kahlert 
et al., 2012). In contrast, Kenney-Herbert et al, (2015) reported that were no phenotypic or 
genetic differences between CD15- and CD15+ GBM cells and CD15 expression was not 
enough to distinguish a discrete population of GBM cells. Few studies have however, 
considered the possibility of cell-cycle dependent CD15 expression which may explain the 
inconsistencies reported in the literature. CD15s has also been associated in malignancy of 
many non-CNS cancers (Ogawa et al., 1994 and Sozzani et al., 2008). CD15s has 
frequently been reported to correlate with invasiveness of cancer cells, for example in head 
and neck carcinoma where it was also proposed as a cancer stem cell marker (Czerwinski 
et al., 2013). In GBM, CD15s expression has also been shown to be highly heterogeneous 
within different non-synchronised cell lines of GBM with positivity roughly from 4.8%-
32.8% (Lou et al., 2015) which is in agreement with our findings that show the variability 
in expression in non-synchronised GBM cell lines (UP-007 and SNB-19). In non-
neoplastic astrocytes, CD15 and CD15s expression was low and this did not change when 
cell lines were synchronised to G1, S, or G2/M consistent with reports showing low CD15 
expression in astrocytes (Martin et al., 1995). In the GBM cell lines tested the expression 
of CD15 and CD15s was significantly higher when cells are synchronised in G1 phase. In 
secondary lung-brain tumour cells, higher levels of CD15 were seen in non-synchronised 
cells which perhaps relates to the fact that CD15 is well known to be elevated in lung 
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carcinomas (Kadota et al., 1999). These findings suggest that overexpression of both CD15 
and CD15s in GBM cells and secondary lung-brain tumour cell correlate with G1 phase. 
Our overall findings suggest that in GBM cell lines, CD15 and CD15s expression is 
correlated with specific stages of the cell cycle, in particular G1. This may help explain the 
opposing reports in the literature concerning CD15 expression in glioma cells and ‘glioma 
stem-like cells’ as it could be that due to ‘stem-like cells’ spending more time in the S 
phase where CD15 and CD15s expression would be low. Whether this is the case remains 
to be determined and requires additional research. An additional interesting question is do 
CD15 and CD15s play a role during cell cycle progression, particularly while cells are in 
G1. It has been suggested since the late 1980’s that cells in G1 were more susceptible to 
initiate differentiation in response to growth factors (Mummery CL  et al). The concept of 
connecting the cell cycle phase and cell fate as well as the time spent in each phase has 
gained supportive experimental evidence over the years (reviewed in Dalton, S Trends in 
cell biology 2015; Hardwick and Philpott Trends in genetics 2014)
 
Recently Singh (2015)
 
proposed a hypothetical model of the relationship between cell cycle, pluripotent cells and 
heterogeneity and that G1 could serve as a ‘differentiation induction point’ (Singh, AM 
2015 Stem cells international). Could, as proposed by Hardwick and Philpott (2014), the 
length of time ‘glioma stem-like cells’ are in G1 be targeted to enhance differentiation and 
slow tumour progression? How does the glioma ‘cancer stem cell niche’ contribute to the 
cell cycle length? In an interesting proteomic study using a breast cancer cell line in G1, 
bioinformatic tools and databases, Tenga and Lazar (2014 – BMC) reported from their 
study that three major clusters of interacting networks emerged and included oxidative 
phosphorylation, DNA repair and signalling. Instead of relying on ‘glioma stem-like cell’ 
markers the idea of using molecular regulatory components that act within a network may 
prove promising in terms of understanding and identification of therapeutic targets for 
GBM and ‘stem-like cells’.  
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Expression of CD15 and CD15s in lung to brain metastatic cell lines is also correlated with 
the G1 phase. We have recently shown that CD15 in lung to brain metastasis plays a role in 
binding to brain endothelial cells 
17
 and our current data helps direct future investigations 
to address the question of how circulating lung cancer cells and their cell cycle stage 
influence adherence to endothelial cells of blood capillaries during brain metastasis. This 
may be critical in terms of determining preventative therapeutics for brain metastasis as 
many drugs arrest cells in specific cell cycle phases. For example, a drug causing cell cycle 
arrest at G1 may not be recommended if CD15 and CD15s are highly expressed in this 
phase as it would result in an increase in adhesion to brain endothelial cells. Although 
highly speculative, this points for the need for further research into this area.  
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CHAPTER SIX 
CONCLUSIONS  
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CD15 and CD15s are overexpressed in metastatic lung cancer cells. CD62E is 
expressed on brain endothelium stimulated with TNF-α and interaction between 
CD15/CD15s and CD62E plays an important role in lung cancer cell adhesion to 
brain endothelium cells.   
CD15 and CD15s are important cell-cell adhesion molecules and are both implicated in 
metastasis in many non-CNS malignancies (Kadota et al., 1999 and Giordano et al., 2015). 
The exact functional role of these molecules in metastasis to the CNS is not known. In this 
project, expression of CD15 was characterised in a range of primary and metastatic human 
NSCLC cells. ICC images showed a prominent and condensed expression of CD15 on the 
outer edges of cell surface of metastatic lung cancer cells compared to less expression on 
the primary lung cancer cells. These results were confirmed by Western blotting and flow 
cytometry analysis (Figure 19). CD62E is an important ligand of CD15 and CD15s. 
Adhesion of lymphocytes to endothelial cells has been shown to be regulated by the 
heterophilic interaction between these two molecules (Homeister et al., 2001). We 
hypothesised that metastatic lung cancer cells may mimic lymphocyte behaviour and 
investigated CD62E expression in brain endothelial cells after 18 hours stimulation with 
TNF-α (25pg/mL). Results demonstrated that CD62E was highly expressed in human brain 
endothelial cells. Stimulation with TNF-β was also used to confirm the specificity of TNF-
α (Figures 22 and 23). We then investigated the role of CD62E and CD15 in adhesion of 
lung cancer to brain endothelial cells. Results of qualitative and quantitative adhesion 
assays revealed that CD62E play a key role in the adhesion process of cancer cells and its 
absence significantly reduced the number of adherent cells (Figure 24). Findings also 
showed that metastatic lung cancer cells were more adherent than primary lung cancer 
cells and immunoblocking of CD15 significantly reduced the adhesion of cancer cells 
(Figure 24). These results suggested a strong correlation between CD15 and the adhesion 
of lung cancer cells on brain endothelium. Similarly, immunoblocking of CD15 reduced 
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the adhesion of highly metastatic lung to brain cancer cells in a dynamic flow experiment 
which was conducted under shear stress at perfusion rate of 2.5 dyn/cm
2
 (Figure 24). 
CD15-CD15 homophilic interactions were localised between adjacent cancer cells (Figure 
25). In addition, the heterophilic binding between CD15 and CD62E was localised at the 
site of adhesion of metastatic lung cancer cells adhering on brain endothelial monolayer 
(Figure 25C) and this co-localisation was confirmed by 3-dimantional confocal imaging 
generated by Z-stacks (Figure 25D).             
CD15s was seen to be expressed at low levels on the cell surface of brain endothelium and 
primary NSCLC and a higher level on metastatic lung cancer cells. It was found also to be 
expressed in human tissue sections of brain tumour metastasised from lung while no 
CD15s was seen in tissue sections of normal brain (Figure 27). A qualitative adhesion 
assay showed that immunoblocking with CD15s monoclonal antibodies significantly 
reduced the number of adherent cancer cells on activated monolayer of brain endothelial 
cells. These findings were assessed by quantitative adhesion assay which showed a 
noticeable decrease in adhesion ability of cancer cells following immunoblocking with 
CD15s antibodies under static conditions (Figure 28 and 29). We then examined whether 
CD15s may play a role in cancer cell adhesion to brain endothelial monolayer under shear 
stress with flow rate of 2.5 dyn/cm
2
. Findings showed that blocking with CD15s 
monoclonal antibodies reduced the adhesion ability of highly metastatic and adherent lung-
brain metastatic cells (SEBTA-001) (Figure 30). CD15s expression was also seen to be 
localised on the surface of adherent cancer cells with prominent staining on the edges of 
the cancer cells boundary at the site of the adhesion (Figure 31). Both CD15 and CD15s 
were seen to be expressed in human tissue section of brain metastatic brain tumour 
originated from lung, however, CD15 and CD15s were not seen in normal brain tissue as 
in figure (26 and 32).      
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 Knockdown of FUT4/CD15 and FUT7/CD15s reduced the transmigration potential 
of cancer cells and overexpression of FUT4/CD15 and FUT7/CD15s accelerated the 
transmigration of cancer cells through a brain endothelial monolayer. 
The haematogenous pathway is the major route in brain metastasis and circulating cancer 
cells usually reach the brain through transmigration across BBB capillaries. Recently, the 
substantial role of brain endothelial in brain metastasis was highlighted. Overexpression of 
CD62E on brain endothelium was detected at the early stages of tumour seeding (Soto et 
al., 2014). We investigated the role of CD15 and CD15s in adhesion of cancer cells to 
brain microvaacular endothelial cells (hCMEC/D3) as well as their role in transendothelial 
migration across the endothelial monolayer where a previous study showed that CD15 and 
CD15s played a role in the leukocytes homing process (Strell and Entschladen, 2008). The 
functional role of these molecules in metastasis to the CNS is still not fully explained. 
Here, we investigated the effect of knockdown and overexpression of FUT4/CD15 and 
FUT7/CD15s in adhesion of NSCLC to brain endothelium as well as their role in 
transmigration across a brain endothelial monolayer. Our findings showed that knockdown 
of fucosyltransferase IV (FUT4) reduced the expression of CD15 whereas its upregulation 
led to CD15 overexpression in GBM, lung primary and metastatic cancer cells (Figure 32). 
FUT7 knockdown significantly reduced the expression of CD15s while upregulation of 
FUT7 induced the overexpression of CD15s (Figure 33). We then examined the effect of 
FUT4/CD15 and FUT7/CD15s genetic manipulation on the adhesion of transfected cells 
and findings showed that FUT4/CD15 knockdown decreased the adhesion ability of cancer 
cells while FUT4/CD15 increased adhesion in all studied cancer cells (Figure 34A). 
Similarly, we found that adhesion was significantly reduced by knockdown of 
FUT7/CD15s and notable increase in cancer cell adhesion was induced by upregulating 
FUT7/CD15s (Figure 34B). We also investigated the transendothelial migration potential 
of above mentioned cancer cells using three different approaches (EVOM, ECIS and 
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CellZscope). This was to validate our results and show consistency in our findings 
irrespective of equipment used. Results revealed that the highest transendothelial migration 
was seen in metastatic lung cancer cells: SEBTA-001 and NCI-H1299. Both cell lines 
caused a significant and accelerated decrease in TEER value in the brain endothelial 
monolayer unlike the primary lung cancer cells COR-L105 which caused a small and non-
significant decrease in TEER value and GBM cells hardly caused any decrease in TEER in 
the endothelial monolayer (Figure 35 A,B and C). In transfected cells, results showed that 
silencing FUT4/CD15 decreased transendothelial migration of highly metastatic as seen by 
a decrease in TEER values. Overexpression of FUT4/CD15 increased cancer cells 
transmigration across the endothelial monolayer suggesting that FUT4/CD15 plays a role 
in transendothelial migration of cancer cells during metastasis to the brain (Figure 36 A,B 
and C). FUT7/CD15s silencing clearly reduced cancer cell to transmigrate via the brain 
endothelial monolayer as demonstrated by no decrease in the resistance of the endothelial 
monolayer (TEER) value. These findings suggest that FUT4/CD15 and FUT7/CD15s play 
a major role in transendothelial migration during NSCLC seeding to the brain.  
 
CD15 and CD15s expression was correlated with cell arrest at G1 phase in primary 
and metastatic brain cancer cells.   
CD15 and CD15s have both been reported to be correlated with malignancy and 
progression to the metastatic stage in many non-CNS neoplasms (Gadhoum et al., 2008, 
Rho et al., 2014, Fukusumi et al., 2014 and Desiderio et al., 2015). Knowledge regarding 
CD15 expression in CNS malignancies however is limited and even less is known about 
the expression of CD15s. In order to understand the discrepancy in literature regarding 
CD15 and CD15s expression and distribution in CNS neoplasms, we characterised CD15 
and CD15s in non-neoplastic adult astrocytes, a range of human primary brain tumour 
(GBM) cells and secondary brain tumour cells that had metastasised from lung during 
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different stages of cell cycle for CD15 and CD15s expression. Our findings showed that in 
non-synchronised cells, CD15 was hardly seen in adult astrocytes and only expressed at 
low levels in GBM cells (5%-15%) whereas a prominent expression of CD15 was seen in 
metastatic brain tumour cells (28%-36%) (Figure 38). CD15s was expressed in 2% of non-
neoplastic astrocytes while 8%-26% of primary brain cancer cells expressed CD15s and 
higher levels of expression were seen in secondary brain tumours with positivity of 34%-
47% (Figure 39). Synchronisation of cultures was done: G0/G1 phase by serum starvation, 
S phase by hydroxyurea (1mM) via inhibition of ribonucleotide reductase activity (Maurer-
Schultze et al., 1988) and G2/M phase by Nocodazole (2μg/mL). It inhibits the 
polymerisation of microtubule (Matsui et al., 2012 and Rosner et al., 2013) (Figure 40). 
Flow cytometry was used to assess the synchronisation in treated cells followed by CD15 
and CD15s expression localised and measured using a fluorescent cell cycle indicator 
system (FUCCI) and flow cytometry analysis respectively. In synchronised cells, FUCCI 
results showed that CD15 was seen to be expressed in cells with red and red-yellowish 
nuclei in non-neoplastic astrocytes, primary and secondary brain tumour cells. These 
findings indicated that CD15 was mostly expressed on cells arrested at G1 phase. Flow 
cytometry results validated FUCCI findings and highest level of CD15 expression was 
seen in cells which were synchronised at G1 phase (Figure 41). CD15s was expressed on 
the surface of cells at G1 phase in non-neoplastic astrocytes, primary brain tumour cells 
and secondary brain tumour cells. Faint expression of CD15s was also seen on cells at S 
and G2/M phase. Flow cytometry analysis showed that the highest levels of CD15s 
expression was detected in cells synchronised at G1 phase in non-neoplastic astrocytes, 
primary and secondary brain tumour cells (Figure 42).            
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Appendix 1: DNA profiling of studied cells (cell authentication) 
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B- STR genotypes of the cell lines 
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hCMEC/D3 X,Y 11,10 17,18 6,7.8 11,11  10,11 11,9 10,12 12,9 
SC-1800 X, Y 9, 10 17, 17 7, 9.3 11, 11 28, 29 11, 13 8, 11 9, 12 11,11 
SNB-19 X, Y 11, 12 16, 18 9.3, 9.3 10, 11 28, 29 10, 12 8, 8 12, 12 11,12 
UP-007 X, Y 12, 12 19, 19 7, 9 10, 11 28, 28 9, 10 8, 8 10, 13 9, 11 
A549 X, Y 11, 11 14, 14 8, 9.3 11, 11  8, 11 8, 11 11, 12 10, 12 
COR-L105 X, Y 11, 12 16, 17 8, 9.3 10, 11  8, 11 8, 11 11, 12 9, 11 
SEBTA-001 X, X 12, 12 18, 18 9,9 11, 11  9, 9 9, 9 11, 11 10, 11 
SEBTA-005 X, X 11, 12 14, 16 9, 9.3 11, 12 28, 29 10, 10 8, 11  11, 12 
NCI-H1299 X,Y 10,9 16,18 6,7 10,11  10,9 8,8 10,10 10,11 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 1: DNA profiling of studied cells conducted by microfluidic system (Agilent 
2100 Bioanalyzer). A: Representative single electropherograms of short tandem repeat 
(STR) profiles of the cell lines: hCMEC/D3, SC-1800, SNB-19, UP-007, 549, A549, 
COR-L105, SEBTA-001, SEBTA-005 and NCI-H1299. Samples were analysed based 
on the molecular size as recorded above each peak B: A unique DNA profile of each cell 
line shown by fragment sizing.  The electropherograms were illustrated via Agilent 2100 
Expert software and experiments were conducted in triplicates for three independent 
times. (Acknowledgement: Mrs. Katie Loveson). 
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Appendix 2: Cellular growth curves of cell lines used throughout the project. Cell 
count was determined using a VICELL
XR
 machine. Measurements were conducted 
in triplicate in three independent experiments.    
Appendix 2: Growth curves of the cell lines 
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Appendix 3A: plasmid map of FUT4- human pCMV6-AC-GFP retroviral GFP 
vector 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 3B: plasmid map of FUT7- human pCMV6-AC-GFP retroviral GFP 
vector 
 
 
 
 
 
 
 
 
 
 
 
Appendix 3A:  Cloning scheme for RG223829. FUT4- human cDNA ORF clone pCMV6-
AC-GFP retroviral GFP vector ready-cloned, contains unique construct of alpha (1,3) 
fucosyltransferase, myeloid-specific protein (FUT4), CMV promoter, T7 promoter, G418 
resistance gene, C-terminal TurboGFP tag (Obtained from Origen). 
 
Appendix 3B: Cloning scheme for RG223829. FUT7- human cDNA ORF clone : pCMV6-
AC-GFP retroviral GFP vector ready-cloned, contains unique construct of alpha (1,3) 
fucosyltransferase (FUT7) protein, CMV promoter,T7 promoter, G418 resistance gene, C-
terminal TurboGFP tag (Obtained from Origen). 
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